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Abstract 
 
Background: Surgical aortic valve replacement (SAVR) remains first-line treatment for 
symptomatic severe aortic stenosis, whereas transcatheter aortic valve implantation (TAVI) is 
indicated in patients who are inoperable or considered too high-risk for surgery. Current focus is 
centred on differences in the impact of valve replacement upon cardiovascular function to guide 
patient selection and the development of novel prosthetic valves to improve outcomes. 
Cardiovascular Magnetic Resonance (CMR) imaging is the investigative modality of choice for 
such a purpose. 
 
Objectives:  
To compare the impact of SAVR and TAVI upon aortic stiffness, right ventricular function and 
myocardial strain, and to compare two vendor designs in the quantity of post-TAVI aortic 
regurgitation and reverse remodelling.  
 
Methods: A prospective study of patients with severe aortic stenosis under surveillance and 
subsequently requiring SAVR or TAVI, recruited between September 2009 and December 
2015. A 1.5 Tesla CMR study was performed pre and 6 months post SAVR, and pre, 
immediately and 6 months post implantation of Medtronic CoreValve and Boston Lotus TAVI. 
Aortic distensibility (AD), pulse wave velocity (PWV), right ventricular (RV) volumes, myocardial 
strain and aortic regurgitation (AR) were quantified.  
 
Results: At 6 months, SAVR was associated with a significant worsening in PWV (6.38±4.47 
vs. 11.01±5.75ms-1, p=0.001) and ascending AD (1.95±1.15 vs. 1.57±0.68x10-3mmHg-1, 
p=0.044), whereas no change was seen following TAVI. A significant reduction in RV ejection 
fraction (58±8 vs. 53±8%, p=0.005) was seen flowing SAVR, with no change following TAVI. A 
significant and comparable decline in LV torsion and twist was observed. Baseline 
circumferential strain was significantly associated with all-cause mortality (hazard ratio, 1.03; 
1.01–1.05; p=0.009). Significantly less AR was seen immediately following Lotus than 
CoreValve TAVI (4.3±3.4 vs.11.7±8.4%, p=0.001) with equivalent degrees of reverse 
remodelling observed at 6 months. 
 
Conclusion: Compared with TAVI, SAVR is more detrimental upon aortic stiffness and right 
ventricular function at 6 months. CMR derived circumferential strain is associated with survival 
following SAVR and TAVI. 
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Chapter 1 General Introduction 
1.1 Aortic Stenosis  
Aortic valve stenosis (AS) is the sequela of active valve remodelling which can readily be 
diagnosed but at present is beyond prevention. At the macroscopic level there is focal 
subendothelial thickening, inflammatory cell infiltration and subsequent calcification 
(Rajamannan et al., 2011). There is therefore progressive narrowing of the aortic valve orifice 
leading to obstruction of left ventricular (LV) outflow with consequential myocardial hypertrophy 
to preserve wall stress and cardiac performance (Clayton et al., 2014). Decompensation is 
driven by progressive myocyte death and myocardial fibrosis (Chin et al., 2014b). Increased LV 
filling pressures and reduced cardiac output lead to exertional dyspnoea. Angina is also 
frequent from subendocardial ischaemia as a result of an increased LV mass and reduced 
coronary flow reserve (Julius et al., 1997). Severe aortic stenosis also carries an increased risk 
of sudden cardiac death (Iung and Vahanian, 2014).  
 
Degenerative aortic valvular stenosis is the most common valve disease in the western world 
(Nkomo et al., 2006). The largest population-based study to date originates from the National 
Health, Lung and Blood Institute of 11,911 adults across the United States of America. 
Systematic echocardiographic examination indicated a prevalence ≤ 0.2% before 65 years of 
age, rising to 2.8% after 75 years (Nkomo et al., 2006). In 2010, there were an estimated 1.2 
million people in the USA with at least moderate AS, including 520,000 aged over 75 years 
(Iung and Vahanian, 2012). The European Tromso study included 3,273 patients and reported 
higher prevalence in the elderly, affecting 9.8% of adults between 80 and 89 years of age. The 
annual incidence rate (derived from the study period 1974-2008) was 4.9 per 1000 (Eveborn et 
al., 2013). Aging populations and the absence of any validated prevention method mean that 
the burden of aortic stenosis is expected to double within the next 50 years (Iung and Vahanian, 
2012). 
 
The onset of symptoms is a major predictor of mortality; a concept first described by Ross and 
Braunwald in 1968 (Ross and Braunwald, 1968). The prognosis is particularly poor in the 
elderly (Leon et al., 2010) in whom there are other significant co-morbidities in more than one-
third of cases (Iung et al., 2007). In octogenarians with comorbidities, mortality rates between 
40% and 50% at 1 year have been reported (Iung and Vahanian, 2014). Five-year mortality has 
recently been reported at 60% after a first hospitalization with a diagnosis of AS (Berry et al., 
2013). Two year follow-up data from the PARTNER cohort B study (Kodali et al., 2012) 
indicated standard medical treatment was associated with a cardiovascular mortality of 62.4% 
and repeat hospitalisation of 72.5%. Given the lack of effective medical treatment, management 
21 
 
is centred on optimal timing of aortic valve intervention, to reverse hypertrophy, restore systolic 
and diastolic function, relieve symptoms and ultimately restore prognosis (Thaden et al., 2014).  
 
1.2 Aortic Valve Surgery 
Surgical aortic valve replacement (SAVR) is a routine procedure that has been practised for 
over 50 years and its evidence base places it first-line in the treatment of symptomatic severe 
aortic stenosis (Walther et al., 2012). The first-in-human heterotopic aortic valve replacement 
was performed in 1952 by Hufnagel and Harvey, palliating severe aortic regurgitation by 
implanting an artificial ball prosthesis in the descending aorta (Hufnagel and Harvey, 1953). In 
1955, Gordon Murray placed a homograft in the same position (Murray, 1956).  The advent of 
cardiopulmonary bypass facilitated maintenance of procedural haemodynamics and heralded 
the first sub-coronary mechanical AVR, performed by Starr and Harken in 1960. Two years 
later, Donald Ross implanted a sub-coronary homograft (Ross, 1962).  As a result, surgical 
AVR emerged as the gold standard for the management of AS. Crucial to the procedure is 
complete excision of calcified degenerated aortic cusps followed by precise implantation under 
direct vision of a modern xenograft or mechanical prosthesis using standard suturing 
techniques. Due to its ability to cure aortic stenosis completely, conventional AVR has long 
since been considered the gold standard intervention (Walther et al., 2012). 
 
Indeed, despite the intrusive nature, even elderly patients do favourably post SAVR. In a cohort 
of over 1000 octagenarians, survival rates of 89% and 69% after 1 and 5 years, respectively, 
were seen (Asimakopoulos et al., 1997). Guidelines from Europe (Joint Task Force on the 
Management of Valvular Heart Disease of the European Society of et al., 2012) and the USA 
(Nishimura et al., 2014b) list a Class I recommendation for SAVR in those with symptoms or 
reduced ejection fraction. However, surgery does carry an associated morbidity and mortality 
that may be considered prohibitive in elderly patients with multiple comorbidities and frailty. 
Indeed, in the Euro Heart Survey, one third of 216 patients with symptomatic severe AS aged 
over 75 years were not referred on for surgery (Iung et al., 2005). 
 
1.3 Transcatheter Aortic Valve Implantation  
The concept of a permanent “stent valve”, catheter-mounted, balloon-deployable valve 
prosthesis dates back over thirty years to animal experimental models (Binder and Webb, 
2012). In 2002, the first-in-human transcatheter aortic valve implantation (TAVI) was performed 
via an antegrade, transvenous approach (Cribier et al., 2002). Later, the retrograde approach, 
with access via the femoral artery, gained favour and became a reproducible, fully 
percutaneous procedure (Webb et al., 2006). Since then, the rate of TAVI has risen 
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enormously, with over 200,000 having been performed worldwide, the vast majority in Europe 
(Newton et al., 2015). 
The early UK experience has been well charted through the construction of the UK TAVI 
registry (Moat et al., 2011). Data were collected prospectively on 870 patients until 31 
December 2009. TAVI was performed with the use of the Medtronic CoreValve (Medtronic, 
Minneapolis, Minnesota, USA) (52%) or the Edwards-SAPIEN THV (Edwards Lifesciences, 
Irvine, California, USA) (48%). The majority of the TAVI implants (69%) were performed via the 
transfemoral approach according to the widespread ‘transfemoral first’ policy. Outcomes of 
TAVI patients in the UK TAVI Registry at 30 days, 1 year and 2 years were encouraging with 
mortality rates of 7.1%, 21.4% and 26.3%, respectively.  
 
Health related quality of life measures are an important clinical outcome and are significantly 
improved following TAVI, with scores maintained out to 1 year (Fairbairn et al., 2012); this is 
despite silent cerebral microinfarctions which are more frequently seen following TAVI than 
SAVR (Uddin et al., 2015). In a cost-utility analysis, TAVI was demonstrated to be a cost-
effective option in high-risk but operable elderly patients when compared with SAVR (Fairbairn 
et al., 2013a). TAVI improves survival and functional capacity when compared with standard 
medical therapy (Leon et al., 2010, Kapadia et al., 2015), and recently data suggests 2 year 
survival is superior to SAVR in high surgical risk patients (Reardon et al., 2015) and similar at 5 
years (Mack et al., 2015). Furthermore, the TAVI procedure is less restricted by patient frailty or 
confounding surgical considerations such as a “porcelain” aorta or mediastinal adhesions 
(Rodes-Cabau et al., 2010). Given its transformative benefits, TAVI is now an established 
intervention in symptomatic patients deemed inoperable or with too high a predicted 
postoperative mortality (Sorajja and Pedersen, 2014). 
 
1.4 Cardiovascular MR and pre-procedure assessment 
Cardiovascular Magnetic Resonance (CMR) imaging is a commonly used technique and 
determines both morphological and functional information that is crucial to the assessment of 
valvular heart disease. CMR permits high resolution imaging in any plane and can quantify the 
severity of the valvular lesions, determine aetiology, assess global and regional cardiac function 
as well as the anatomy of associated great vessels (Myerson, 2012). Furthermore, myocardial 
perfusion, myocardial viability, tissue characterisation and proximal coronary anatomy can all be 
examined within a single study without any ionising radiation (Ripley et al., 2014).  
 
A typical CMR study for evaluating valvular heart disease comprises left ventricular long-axis (2-
, 3- and 4-chamber views) and a complete stack of sequential short-axis (every 8-10mm from 
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base to apex) cine images using a steady-state free precession (SSFP) pulse sequence (Figure 
1.1).  
 
 
Figure 1.1 CMR cine imaging demonstrating anatomical and functional 
information.  
A. Short-axis of left ventricle at basal level in diastole indicating mild concentric hypertrophy 
(white arrow, 14mm)  
B. Coronal left ventricular outflow tract (LVOT) view acquired through plane of aortic valve 
leaflet tips indicating restricted leaflet motility and resultant high velocity jet (white arrow).  
C. Cine imaging of a bicuspid aortic valve orifice in systole with A-P closure line. This view 
permits direct planimetry of valve area in addition to morphological assessment.  
D. 4-chamber view allowing visual assessment of ventricular, mitral and tricuspid function and 
atrial size.  
E. Sagittal-Oblique view of aorta throughout its entire thoracic course. F. Cine imaging of 
heavily stenosed trileaflet aortic valve. 
 
This generates images with an excellent signal-to-noise ratio and high blood-to-myocardium 
contrast, with a typical in-plane spatial resolution of (1.5-2.0mm) comparable to 
transoesophageal echocardiography for aortic valve planimetry and assessment of cusp 
anatomy (Lopez-Mattei and Shah, 2013, Paelinck et al., 2011). CMR facilitates clear 
visualisation of sub-valvular and supra-valvular aortic stenosis, and also permits assessment of 
prosthetic valvular function (Figure 1.2). 
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Figure 1.2 CMR (coronal LVOT) imaging following aortic valve intervention 
A. Medtronic CoreValve.  
B. Boston Lotus valve.  
C. Bioprosthetic Sorin MitroFlow valve.  
D. Mechanical 30mm Carbomedics Carbo-Seal Valsalva with 27mm ascending aortic 
prosthesis. 
 
CMR is the most accurate technique for assessing both left and right ventricular volumes and 
mass (Bellenger et al., 2000a, Myerson et al., 2002a, Koch et al., 2000). It has been validated 
against post-mortem studies of animal and human hearts (Childs et al., 2011) and is highly 
reproducible (Grothues et al., 2002). By providing 3-dimensional datasets, it is also more 
sensitive and reproducible to changes than one or two-dimensional echocardiographic 
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measures (Myerson et al., 2002b) and it is independent of geometric assumptions of ventricular 
morphology. This can be crucial for the surveillance of asymptomatic patients to determine 
deterioration in ventricular function (Myerson, 2012). 
 
CMR permits direct flow quantification using through-plane phase contrast velocity mapping 
(Gatehouse et al., 2005). This is a unique advantage of CMR which unlike echocardiography 
and invasive catheterisation, does not depend upon derivation from complex calculations 
(Myerson, 2012). The technique measures phase shift of moving protons inside a magnetic 
field, exploiting their difference to stationary protons. A bipolar gradient pulse pair is applied;  
the second gradient re-phases  the de-phasing caused by the first gradient. Flowing blood has 
a different phase of transverse magnetization to that of stationary tissue and this  difference is 
proportional to the velocity of the blood in the direction of the applied gradient. VENC refers to 
the maximum measurable velocity range and is operator defined. Aliasing occurs when the 
velocity of blood flow exceeds the VENC set, with positive velocities being displayed as 
negative velocities and vice versa. Modulus and phase images are reconstructed from a 
gradient-echo flow sequence and post-processing of this data allows an accurate measurement 
of forward and backward flow across the valve (Figure 1.3) (Gatehouse et al., 2005). 
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Figure 1.3 Velocity encoded Phase Contrast (PC) imaging to quantify aortic 
stenosis 
A. Short-axis view indicating a bicuspid valve with double-barrelled orifice.  
B. Transverse LVOT views obtained using steady state free precession.  
C. Coronal LVOT view used to plan imaging planes for PC acquisition.  
D. Phase velocity map.  
E. Magnitude image 
F. Time-velocity curve of aortic flow rate (in this patient peak gradient 53mmHg, RF 14%) 
 
However, the temporal resolution of CMR is typically 25-45ms which is considerably lower than 
continuous wave Doppler echocardiography (which can be ~2ms) (Myerson, 2012). This in 
conjunction with turbulent flow artefacts and partial volume effects mean CMR peak velocity 
measurements may be underestimated compared to echocardiography especially when peak 
velocities surpass 3.5-4.0 m/s (O'Brien et al., 2008). Indeed, a number of validation studies 
referencing CMR against echocardiography have indicated good correlation but a trend towards 
this underestimation by CMR, and clinically the velocity definitions of valvular severity remain 
echo derived (Cawley et al., 2009). 
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Accurate measurements of the aortic root and ascending thoracic aorta can be ascertained 
(Myerson, 2012) which may be dilated, particularly in context of bicuspid aortic valve disease, 
with important repercussions for subsequent surgical management. Furthermore, in patients 
with severe LV systolic dysfunction, a dobutamine-stress protocol may be employed to 
differentiate pseudo from true aortic stenosis and determine contractile reserve (Lopez-Mattei 
and Shah, 2013).  
 
The European Society of Cardiology guidelines for management of aortic stenosis advocate 
CMR in particular for more detailed assessment in patients with paradoxical low-flow low-
gradient aortic stenosis, assessment of the ascending aorta when enlarged, and for the 
detection and quantification of myocardial fibrosis. This is in addition to assessment of 
ventricular volumes and systolic function (Joint Task Force on the Management of Valvular 
Heart Disease of the European Society of et al., 2012). US guidelines similarly indicate CMR 
may be required to determine optimal treatment for a patient as an ancillary investigation to 
transthoracic echocardiography (Nishimura et al., 2014b). 
 
1.4.1 CMR detection of fibrosis and predicting prognosis  
Aortic stenosis increases LV afterload and triggers an initial compensatory hypertrophic 
response. Women develop a concentrically hypertrophied, small cavity LV, whereas men are 
more prone to the development of eccentric hypertrophy (Dobson et al., 2015). However, left 
untreated, there is progressive myocyte necrosis and subsequent replacement myocardial 
fibrosis (Hein et al., 2003). This is associated with abnormal cardiac remodelling and increased 
ventricular stiffness in both animal and human studies (Mewton et al., 2011) and ultimately 
culminates in heart failure and a worse prognosis (Chin et al., 2015). Myocardial fibrosis has 
thus been targeted extensively as a potentially objective marker of LV decompensation that 
may hold promise in guiding appropriately timed valve intervention. 
 
Historically, the gold standard for validating myocardial fibrosis has been myocardial biopsy but 
this is invasive, susceptible to sampling errors and does not assess the whole heart (Mewton et 
al., 2011). There have been varying degrees of interstitial fibrosis reported on histological 
assessment in patients with severe AS, ranging from 4% to 39% (Krayenbuehl et al., 1989, Flett 
et al., 2010). 
 
A pivotal and unique strength of CMR is in vivo tissue characterisation, offering a direct 
visualization, whole-heart assessment of myocardial fibrosis (Ambale-Venkatesh and Lima, 
2015) (Figure 1.4). The technique probes the retention of gadolinium-based contrast agents 
within myocardial tissue, with dead or scarred myocardium appearing bright in contrast to 
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normal black myocardium on late inversion recovery T1-weighted imaging (Singh et al., 2014). 
The use of late gadolinium enhancement (LGE) imaging has been validated against surgical 
biopsy studies in AS (Azevedo et al., 2010), with focal mid-wall enhancement reportedly present 
in 19-62% of patients (Chin et al., 2015) and with increasing quantities increasing with 
increasing hypertrophy (Debl et al., 2006). 
 
 
Figure 1.4 Late Gadolinium Enhancement CMR imaging 
A. Absence of any hyperenhancement.  
B. Typical subendocardial infarction pattern (affecting the inferior interventricular septum and 
inferior walls, black arrow).  
C. Focal (non-infarct) myocardial fibrosis affecting the inferolateral wall (white arrow). 
 
The degree of myocardial fibrosis at histology correlates with worsening NYHA class and 
impaired longitudinal systolic function, and is inversely associated with the degree of functional 
improvement following SAVR (Weidemann et al., 2009). In another histology study, fibrosis 
quantity was strongly associated with increased LV cavity diameters, and reduced LV ejection 
fraction, a finding also demonstrated from CMR imaging (Nigri et al., 2009). Furthermore, pre-
operative fibrosis grade was the strongest independent predictor of mortality post AVR (Milano 
et al., 2012). 
 
Following on from biopsy observations, LGE imaging has been used to assess the clinical 
significance of fibrosis in patients with severe AS, both prior to and after valve intervention. The 
presence of mid-wall fibrosis in this context is associated with raised plasma troponin 
concentrations (Chin et al., 2014a) and a hypertrophic strain pattern on electrocardiogram 
tracing (Shah et al., 2014), both of which can provide incremental prognostic information in 
asymptomatic patients. In a small cohort of patients (n=52, including 24 with aortic 
regurgitation) the quantity of fibrosis was a multivariate predictor of all-cause mortality and, in a 
29 
 
subset of these patients, predicted lack of improvement of ejection fraction after SAVR 
(Azevedo et al., 2010). Another study reported that the absence of fibrosis was associated with 
good prognosis after SAVR for AS and that the extent of LGE did not change after SAVR 
(Weidemann et al., 2009).  
 
In a larger study of 143 medically treated patients (40% moderate, 60% severe AS), presence 
of mid-wall hyperenhancement was associated with an 8-fold increase in all-cause mortality in 
comparison to patients without fibrosis, despite comparable valvular haemodynamics. Half the 
study population eventually underwent SAVR, and in this group the mortality rate was 53.8 per 
1000 patient years in those with mid-wall fibrosis, compared with 13.7 in those without focal 
fibrosis (Dweck et al., 2011). In a subsequent publication, the incidence of major adverse 
cardiac events (MACE), stroke and heart block following SAVR were significantly higher in 
those with mid-wall fibrosis compared to those without. There were no 30-day MACE events, 
nor patient deaths at 2 year follow-up in those without fibrosis, highlighting the potential use of 
CMR in predicting risk / outcome prior to AVR for AS (Quarto et al., 2012).  
 
The largest study to date investigating the prognostic importance of CMR defined focal fibrosis 
involved 194 consecutive patients, all with severe AS undergoing SAVR (n=154) and TAVI 
(n=40) (Barone-Rochette et al., 2014). This study demonstrated that the presence and extent of 
myocardial fibrosis detected by CMR imaging predicted increased perioperative risk and worse 
all-cause mortality in those undergoing SAVR, and increased cardiovascular related mortality in 
those undergoing SAVR or TAVI. Furthermore, the authors observed a high incidence of 
sudden cardiac death in those with fibrosis raising the possibility that prophylactic implantable 
cardioverter-defibrillators may improve long-term survival. 
 
The evidence thus far indicates fibrosis detection using CMR heralds LV decompensation and 
there are on-going prospective studies to confirm whether this technique holds prognostic 
importance and could potentially improve patient selection for intervention 
(https://ClinicalTrials.gov: PRIMID-AS, RELIEF-AS, and NCT01755936). 
 
1.4.2 Myocardial Perfusion Reserve 
The myocardial perfusion reserve (MPR) is derived as the ratio of myocardial blood flow during 
maximal hyperaemia compared to resting conditions (Garcia et al., 2009). In the absence of 
epicardial disease, it therefore indicates the presence of coronary microvascular dysfunction 
(Rajappan et al., 2003). Defining this ratio of maximal myocardial flow to baseline has been 
used to evaluate severity of coronary disease, as well as defects in the myocardial 
microcirculation associated with other conditions such as diabetes mellitus, hypertension and 
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hypertrophic cardiomyopathy (Parkka et al., 2006). MPR can be measured using CMR and has 
been shown in one study to independently predict aerobic exercise capacity in 46 patients with 
severe AS; with a strong inverse relationship to symptom status (Steadman et al., 2012). 
However, CMR quantification of MPR is complicated and lacks consensus (Singh et al., 2014). 
The recently completed PRIMID-AS trial was designed to compare CMR with exercise testing in 
identifying patients likely to benefit from SAVR, and thus will help clarify the role of CMR MPR in 
aortic stenosis (Singh et al., 2013). 
 
1.4.3 Assessment of Aortic Stiffness 
Aortic function regulates the entire cardiovascular system and changes in aortic wall 
composition and elasticity are important to the development of cardiovascular disease. 
Increased arterial stiffness is an independent predictor of adverse outcomes in patients with 
hypertension, renal failure, diabetes and the elderly (Ripley et al., 2015) and is thus increasingly 
a clinical focus. CMR permits the measurement of both aortic distensibility (reflecting the 
systolic expansion of the aorta) and pulse wave velocity (the propagation speed of the pressure 
wave along the length of the aorta). CMR holds several advantages over conventional 
ultrasound, but most notably can reproducibly detect more subtle changes in regional stiffness 
at any operator chosen location (Cavalcante et al., 2011). CMR has been used to study patients 
with bicuspid aortic valve disease, in whom significantly reduced elasticity of the entire thoracic 
aorta is observed, even without significant stenosis (Grotenhuis et al., 2007).  
 
1.5 CMR and post-intervention assessment 
1.5.1 Detection of myocardial injury 
CMR is the gold standard imaging technique for the non-invasive detection and quantification of 
myocardial infarction (Gibbons et al., 2004), and has been used to investigate myocardial injury 
following treatment for severe AS (Fairbairn et al., 2013b, Kim et al., 2014). Using LGE CMR, 
focal fibrosis due to prior myocardial infarction is typically subendocardial in distribution, 
extending transmurally towards the epicardium the larger the infarct, and confined to a specific 
epicardial coronary artery territory; a pattern entirely distinct from that of mid-wall myocardial 
fibrosis (Mahrholdt et al., 2005). In a CMR study of 50 patients (25 SAVR, 25 TAVI), new 
postoperative sub-endocardial infarction was evident in six individuals (5 SAVR, 1 TAVI, 
p=0.11). Despite the small numbers, the study was the first to suggest TAVI expansion was not 
detrimental to the patency of coronary ostia, and that perioperative myocardial protection in 
severely hypertrophied ventricles could, on occasion, be suboptimal during SAVR (Fairbairn et 
al., 2013b). 
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In a larger study of patients undergoing TAVI for severe AS (n=61), new myocardial late 
enhancement with an ischaemic pattern occurred in 18%; averaging 1.8% of the LV mass in 
quantity. This was assumed to be embolic in origin, but importantly, did not correlate with 
cardiac biomarkers of injury, which were ubiquitously elevated in all patients.  Furthermore, 
patients with injury detectable by CMR imaging featured a significant reduction in LV function at 
discharge (Kim et al., 2014). Further work is needed to evaluate the prognostic significance of 
new, CMR detected infarction following TAVI, as has been done with elevated serum 
biomarkers (Sanz and Dangas, 2014).  
 
1.5.2 Reverse Ventricular Remodelling  
Aortic valve stenosis increases the afterload of the LV which compensates through alteration in 
wall geometry to preserve wall stress. Left ventricular hypertrophy is part of this 
pathophysiological adaptation and a remodelling process is well recognised comprising 
myocyte degeneration, replacement fibrosis and reduced ventricular performance. SAVR 
restores valvular function and removes the aorto-valvular impedance and afterload mismatch 
seen with aortic stenosis. This subsequently drives a “reverse remodelling” defined by mass 
regression, volumetric reduction and improved function. Indeed, this reverse remodelling 
underscores the improvement of symptoms and prognosis conferred by SAVR (Fairbairn et al., 
2013b). 
 
CMR affords greater precision to 2D echocardiography in the three-dimensional analysis of LV 
volumes and mass without the requirement for geometric assumptions, and has been used to 
characterise reverse ventricular remodelling in detail following both SAVR (Fairbairn et al., 
2013b) and TAVI (La Manna et al., 2013, Fairbairn et al., 2013b). 
 
In a study of 50 patients (25 SAVR, 25 TAVI) CMR was used to directly compare changes 
between baseline and 6 months following intervention (Fairbairn et al., 2013b). Both TAVI and 
SAVR were associated with significant and comparable reduction in the LV end systolic volume 
and LV mass index, with a greater reduction in LV end diastolic volume seen following SAVR 
compared to post-TAVI. Myocardial fibrosis reduced post-TAVI (10.9±6% vs 8.5±5%, p=0.03) 
but not post-SAVR (4.2±2% vs 4.1±2%, p=0.98). It remains undetermined as to whether this 
reduction in mass reflects an actual change in myocyte size and further work using pre- and 
post-contrast T1 mapping to determine extracellular volume and estimate cardiomyocyte size is 
warranted. Overall, adjusting for baseline characteristics, the authors felt global geometric 
reverse remodelling was unlikely to differ between the two procedures. Interestingly, right 
ventricular reverse remodelling seemed more favourable following TAVI with a reduction in 
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volumes and improved function observed. This was in contrast to SAVR, where a decline in RV 
function was reported, likely reflecting adverse effects of cardiopulmonary bypass during 
cardiac surgery. In this study, the presence of myocardial scar due to infarction, and not focal 
myocardial fibrosis, was associated with worse right ventricular function and volumes at 6 
months. Statistically, worse baseline measures of LV volumes and mass were independent 
predictors of reduced reverse remodelling (defined as the LV mass:EDV ratio). These findings 
again highlight the potential importance of CMR in predicting patient outcomes and those likely 
to benefit from closer clinical observation. 
 
1.5.3 Quantification of Aortic Regurgitation following TAVI 
The TAVI procedure involves destruction of the native aortic valve leaflets, which are crushed 
by a superimposed bioprosthesis as it is expanded within the aortic annulus. Extensive native 
valve leaflet calcification, patient/prosthesis mismatch, under expansion of TAVI prosthesis and 
malposition can preclude a complete sealing of the paravalvular space with resultant 
paravalvular aortic regurgitation (PAR) (Lerakis et al., 2013). Furthermore, the two frequently 
used TAVI designs, namely the Medtronic CoreValve and the Edwards SAPIEN, comprise a 
skirt that covers only the lower part of the TAVI frame, leaving the upper part exposed. The term 
“supra-skirtal regurgitation” describes leakage through the uncovered part of the prosthesis 
above the skirt that may occur if the prosthesis is implanted too low in the aortic position (Stahli 
et al., 2013).  
 
A number of trials and multicentre registries have published data on PAR with an overall 
incidence ranging between 50 and 85% (Lerakis et al., 2013). A recent meta-analysis including 
12,926 TAVI patients reported a pooled estimate incidence of moderate or severe PAR of 
11.7% (Athappan et al., 2013). 
 
The significance of PAR post TAVI is in prognostication. Moderate to severe AR is an 
independent predictor of mortality in the postoperative period to 30 days, at 1 year, and at 2 
years (Lerakis et al., 2013). In a recent study of 2,434 patients, the largest single study 
published, 1 year all-cause mortality, cardiac related mortality and rehospitalisation were 
significantly increased with worsening PAR. The presence of both mild (hazard ratio 1.27) and 
moderate-severe PAR (hazard ratio 2.18) were independently associated with higher late 
mortality on multivariate analysis (Kodali et al., 2015). 
 
The difference in rates of PAR reported after TAVI undoubtedly arises from the variety of 
imaging methods, time points and grading scales applied to the particular cohort. In clinical 
practise, 2D transthoracic echocardiography is the most frequently used modality to evaluate 
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PAR severity given its low cost and availability. However, 2D echocardiography is by its nature 
largely qualitative and suited to central regurgitation; with image quality susceptible to habitus, 
prior cardiac surgery or airway disease impeding acoustic windows (Crouch et al., 2015b).  
 
A semi-quantitative assessment is possible but has considerable limitations when applied to 
eccentric and multiple jets arising from a crescentic irregular orifice, typically seen in the TAVI 
patient. The Valve Academic Research Consortium (VARC) has defined quantification criteria to 
improve uniformity in assessment of PAR post TAVI. However, the use of the grading scheme 
for native valve regurgitation in this post TAVI setting has not been validated (Lerakis et al., 
2013).  
 
CMR affords a number of advantages over echocardiography for the assessment of PAR. It 
permits full quantitation of regurgitant volumes irrespective of valve type, jet number or 
eccentricity and is unaffected by calcification or prosthesis artefact (Pibarot et al., 2015). 
Furthermore, a comprehensive evaluation of the consequences of PAR upon LV volumes and 
function can be determined concomitantly. Indeed the use of CMR to assess both valvular and 
ventricular function in the post-TAVI setting has been validated (Crouch et al., 2015b).  
 
CMR is susceptible to arrhythmia or poor quality ECG triggering as this generates motion 
artefact during cine acquisition reflecting variations in the R-R interval. Uncontrolled AF in 
particular can diminish the accuracy of flow data and is best addressed prior to imaging. 
Furthermore, for AR the measured regurgitant volume assessment will include diastolic 
coronary flow (Pibarot et al., 2015). There is also an inherent potential for underestimation of 
AR as the gap between the image plane of flow mapping and the valve expands in systole; 
reflecting elastic expansion of the aortic root and sinuses and the movement of the aortic valve 
towards the LV apex. This can be exacerbated when there is dilatation of aortic sinuses and 
vigorous longitudinal LV contraction; both of which are associated with AR. 
 
Nonetheless, a recent comparison applying VARC-2 recommendations of 2D, 3D 
echocardiography and CMR in 71 patients, the intra- and inter-observer variability in 
determining regurgitant volume was found to be lowest with CMR (2.2±2.0% and 1.5±1.5% 
respectively) (Altiok et al., 2014). In another recent comparison of quantitative CMR with 2D 
echocardiography, 27 of 56 (48%) TAVI patients had AR which was at least one grade more 
severe on CMR than echo indicating echo underestimates the degree of PAR (Crouch et al., 
2015b). This may in part explain why even patients with reportedly “mild” PAR from PARTNER 
exhibited increased mortality (Kodali et al., 2012). Further work is required to determine whether 
CMR is indeed of superior prognostic value in patients following TAVI. 
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1.5.4 Assessment of Myocardial Deformation and Strain Imaging 
Quantification of myocardial strain and strain rate permits a distinct functional assessment of 
the radial, longitudinal and circumferential fibres of the LV and can detect contractile 
dysfunction prior to an overall decline in ejection fraction. Strain imaging has demonstrated 
prognostic importance in a number of cardiac conditions (Singh et al., 2015). Myocardial tissue 
tagging using CMR was first introduced in 1988 and remains the current gold standard CMR 
method to assess strain with proven reproducibility (Swoboda et al., 2014). This technique has 
been used in patients with symptomatic severe AS in whom pressure overload induces 
increased systolic wringing motion (thought to be compensatory) that progressively declines as 
hypertrophy and dilatation worsens. Following SAVR, there is normalisation of LV torsion 
(Sandstede et al., 2002), but interestingly, this disproportionately favours those without coronary 
disease (Biederman et al., 2005). 
 
Feature tracking is a novel technique involving more rapid semi-automatic analysis of standard 
CMR cine images. It has been compared to tissue tagging in patients with AS and consistently 
produces higher values with excellent reproducibility (Singh et al., 2015). It can detect subtle LV 
impairment not visible in standard echocardiography and has been used to assess LV 
performance in patients undergoing TAVI, in whom a trans-apical approach results in significant 
apical LV dysfunction when compared to a trans-femoral TAVI (Meyer et al., 2014). 
 
1.6 Future applications 
1.6.1 CMR Spectroscopy 
Myocardial triglyceride content can be quantified using 1H CMR spectroscopy, and a number of 
studies have reported an independent correlation between degree of myocardial steatosis and 
both systolic and diastolic dysfunction (McGavock et al., 2006, Ng et al., 2010). This technique 
has been used to demonstrate the presence of myocardial steatosis in patients with severe AS, 
both with and without symptoms. Myocardial triglyceride content, validated against histological 
quantification, was independently associated with degree of LV systolic strain impairment, 
despite a normal ejection fraction. Furthermore, steatosis and strain impairment were reversible 
following SAVR (Mahmod et al., 2013). Excessive fatty acids are precursors to toxic 
intermediates that promote apoptosis and ultimately change myocardial architecture (Goldberg 
et al., 2012). Myocardial lipotoxicity is thus a potentially treatable target which could offset LV 
dysfunction in aortic stenosis and signal a role for CMR spectroscopy in risk stratification. 
 
1.6.2 4D flow imaging 
Two-dimensional phase-contrast CMR imaging has been used for over three decades to 
evaluate pulsatile blood flow of the heart and great vessels (Stankovic et al., 2014). Further 
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advances in technology have heralded phase-contrast with flow-encoding in all three spatial 
directions that is resolved relative to all three dimensions of space, and to the dimension of time 
along the cardiac cycle (3D + time = 4D); referred to as “4D flow CMR” (Dyverfeldt et al., 2015).  
4D flow MRI thus encodes the velocity magnitude and direction of each voxel within the defined 
volume by acquiring data over multiple cardiac cycles. The 3D velocity dataset obtained 
therefore reflects an average cardiac cycle and is insensitive to beat-to-beat variations(van der 
Geest and Garg, 2016). The technique provides full volumetric coverage of any cardiac or 
vascular region of interest, with subsequent off-line analysis used to quantify total flow, peak 
velocity or regurgitant fraction amongst other parameters (Figure 1.5) (Markl et al., 2003). 
Furthermore, deriving advanced haemodynamics such as wall shear stress (Markl et al., 2011), 
pressure difference (Bock et al., 2011) and turbulent kinetic energy (Dyverfeldt et al., 2009) may 
facilitate unprecedented assessment of cardiovascular disease beyond simple flow measures 
(Stankovic et al., 2014). 
 
Figure 1.5 4D flow acquisition 
Path lines of velocity vectors using 4D flow aortic imaging, segmented on a 2D aortic cine 
image (sagittal oblique orientation). Flow acceleration in early systole at peak LV ejection (red 
area) is seen in the ascending aorta in this healthy subject. AAo; ascending aorta, MPA; main 
pulmonary artery, DAo; descending aorta 
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Bicuspid aortic valve disease is associated with an aortopathy and carries a risk of aortic 
dissection. Aortic dimensions are the principal measurement to guide intervention currently, 
given no measures of aortic stenosis have proven useful in risk stratification (Nishimura et al., 
2014b). 4D flow CMR has offered unique insights into this aortopathy which is an area of 
significant clinical interest (Stankovic et al., 2014). In an assessment of 30 patients with 
bicuspid aortic valve (n=15 Right-Left phenotype (BAV-RL), n=15, Right-Non phenotype (BAV-
RN)), 4D CMR flow indicated differences in aortopathy expression (Mahadevia et al., 2014). In 
comparison to controls, the BAV-RL valve phenotype had elevated wall shear stress at the 
right-anterior wall with aortic enlargement predominantly affecting the tubular portion of the 
ascending aorta; in contrast to the BAV-RN valve which affected the right-posterior wall with 
dilatation affecting either the root only or the entire ascending aorta and arch. This unique 
assessment of haemodynamics with 4D flow CMR indicates a physiological mechanism through 
which bicuspid AV morphology may impact on aortopathy phenotype. 
 
4D flow CMR has also been used to assess aortic flow following intervention for AS. Rather 
than physiologic central flow, all stented, stentless and mechanical SAVR prostheses showed 
eccentric flow jets mainly directed towards the right-anterior aortic wall, with significantly 
increased local wall shear stress where the flow jet impinged on the aorta (von Knobelsdorff-
Brenkenhoff et al., 2014). Furthermore, aortic blood flow following SAVR and TAVI have been 
directly compared, with both interventions producing similar asymmetric distributions of wall 
shear stress, but SAVR triggering more extensive vertical and helical (turbulent) flow patterns 
(Trauzeddel et al., 2015). 
 
1.7 Conclusions 
CMR is a well-established imaging technique that is non-invasive and devoid of ionising 
radiation, offering incremental value in the assessment of patients with aortic stenosis, both 
prior to and after valve intervention. In a single imaging session, CMR can provide detailed 
information on cardiac and aortic anatomy, ventricular volumes and mass, myocardial tissue 
characterisation and valvular morphology and function, both native and prosthetic. There is a 
growing body of evidence that CMR can predict clinical outcomes in patients undergoing 
therapy for severe AS and ongoing clinical trials are likely to underscore the importance of CMR 
in managing this common and high-risk cardiac condition. 
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1.8 Aims of the Thesis 
The emergence of TAVI into clinical practise over the last decade has signalled a dramatic 
change in the management of patients with symptomatic severe aortic stenosis. Both US and 
European Society guidelines advocate its use in patients deemed unsuitable by a dedicated 
heart team for conventional SAVR (Hamm et al., 2016). Short and mid-term data continue to 
support the durability, economical viability and survival advantage of this revolutionary 
intervention in patients, in whom previously the options of balloon valvuloplasty or conservative 
medical management meant a limited survival. TAVI is favoured not only in those inoperable, 
but also in those with both high- and intermediate-risk, operable symptomatic severe aortic 
stenosis(Leon et al., 2016). Indeed, the international focus has centred on comparative 
investigation of TAVI and the gold standard technique of surgical aortic valve replacement 
(SAVR), with the objective of improving risk stratification and inform patient selection. 
 
This thesis is centred on the use of CMR to investigate accurately and in detail the impact of 
native severe aortic stenosis, SAVR and TAVI upon cardiac function. In addition, TAVI 
prosthesis design and technology is continually being updated and the reduction of paravalvular 
aortic regurgitation post-TAVI is a principal design brief and outcome measure. The assessment 
of regurgitation post-TAVI is complex but one that CMR is uniquely suited for, given its 
versatility and direct flow quantification method. 
 
The aims of this thesis are outlined below: 
 
1) To comprehensively evaluate the difference in impact of SAVR and TAVI upon thoracic aortic 
stiffness through the measurement of two indices; the local ascending and descending thoracic 
aortic distensibility, and the regional aortic arch pulse-wave velocity (chapter 3).  
 
2) To accurately quantify and contrast the impact of SAVR and TAVI upon right ventricular 
volumes and function; and determine whether any particular procedural factors where of 
significance (chapter 4). 
 
3) To characterise circumferential strain using myocardial tagging CMR prior to and following 
SAVR and TAVI, and determine whether abnormalities in strain were associated with outcome 
(chapter 5). 
 
4) To compare, using serial CMR, the quantity of aortic regurgitation, following TAVI with two 
different designs: the established extensively trialled self-expanding CoreValve (Medtronic, 
Minneapolis, Minnesota) and the novel mechanically expanded Lotus valve (Boston Scientific, 
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Natick Massachusetts). A correlation between non-invasive (CMR derived) and invasive (during 
TAVI implantation) measures of regurgitation was also investigated as was the impact of 
regurgitation and valve design upon LV reverse remodelling at mid-term follow-up (chapter 6). 
 
The fundamental approach to these aims was the CMR imaging of patients with severe aortic 
stenosis at baseline and at 6 months following SAVR and TAVI. In addition, in Chapter 6, 
patients were also scanned immediately post-TAVI prior to hospital discharge to facilitate early 
assessment of TAVI prosthetic function and profile the time-course of any changes. 
 
CMR imaging was based on a comprehensively designed protocol including SSFP cine imaging 
to permit full LV and RV volume and mass quantification and feature tracking analysis, velocity 
encoded phase contrast imaging of native and prosthetic aortic valves (TAVI and SAVR; both 
bioprosthetic and mechanical) for flow analysis and quantification of regurgitation, LGE imaging 
analysis for presence of fibrosis, CSPAMM for circumferential strain quantification, and 
measures of aortic stiffness (PWV and AD). 
 
Chapter 2 (Standard Methods) details methods common to all five results chapters. Each 
results chapter includes a dedicated in depth introduction, specific methods (for techniques 
specific to that particular body of work), results, discussion and conclusion sections with an 
appreciation of important limitations where appropriate.   
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Chapter 2. Standard Methods 
2.1 Patient recruitment 
Patients with severe symptomatic aortic stenosis referred for TAVI and SAVR were 
prospectively recruited from cardiology and cardiac surgery outpatient departments (performed 
by myself and other members of the TAVI research team) between January 2009 and April 
2015 at two surgical tertiary centres: the Leeds General Infirmary, Leeds, UK and Glenfield 
Hospital, Leicester, UK (except for the purpose of chapter 6 where patients were undergoing 
TAVI and exclusively recruited from the Leeds General Infirmary). Severe aortic stenosis was 
defined on the basis of echocardiography as a peak aortic velocity of >4m/s, a mean pressure 
gradient >40mmHg, or an aortic valve area ≤1.0cm2 in line with standard published criteria 
(Baumgartner et al., 2009). Baseline echocardiographic data including peak and mean aortic 
pressure gradients, aortic valve area, left ventricular ejection fraction and estimated pulmonary 
artery systolic pressures were recorded, as were baseline clinical and  demographic data from 
which the EuroSCORE II (http://www.euroscore.org/calc.html) and Society of Thoracic 
Surgeons’ risk score for mortality and morbidity were calculated 
(http://riskcalc.sts.org/stswebriskcalc/#/calculate). Decision for aortic valve replacement was 
made by a dedicated Heart Team comprising interventional and imaging cardiologists and 
cardiac surgeons in line with current guidance (Vahanian et al., 2012). 
 
Inclusion criteria for entry into the study included patients with severe aortic stenosis, aged over 
18 years with the willingness and capacity to provide informed consent. Exclusion criteria were 
essentially any contraindication to CMR, including non-MR conditional permanent pacemaker, 
prior cerebral aneurysm clips, intra-ocular metal, claustrophobia, and those pregnant. In the 
case of patients with impaired renal function (defined as an estimated glomerular filtration rate 
of <30ml/min/1.73m2), gadolinium based contrast was not administered.  
 
The patient invitation and information sheets can be viewed in the Appendix (sections 9.4 and 
9.5 respectively). The study was funded by a British Heart Foundation research project grant 
(PG/11/126/29321), approved by a national research ethics committee (Appendix 9.1, 9.2 and 
9.3) and complied with the Declaration of Helsinki, with all patients providing written informed 
consent (Appendix section 9.6). 
 
2.2 Transcatheter Aortic Valve Implantation 
TAVI was performed under general anaesthesia, or conscious sedation and local anaesthesia 
with X-ray fluoroscopy and echocardiographic (transoesophageal or transthoracic as 
appropriate) guidance by two experienced high volume operators. The balloon expandable 
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Edwards Sapien 3, the self-expanding Medtronic CoreValve, Engager and Evolut-R and the 
mechanically expanded Boston Scientific Lotus TAVI devices were studied, selected primarily 
on the basis of anatomical considerations. Multi detector computed tomography or 3D 
transoesophageal echocardiography were used to derive annulus measurements and thus 
appropriate device sizing. Wherever possible, the femoral artery route was used as a default 
approach, but in cases of femoral artery stenosis, calcification or tortuosity other routes were 
adopted (subclavian, carotid, direct aortic and apical LV).  
 
Balloon aortic valvuloplasty, for pre- and post-dilatation and rapid right ventricular pacing were 
performed during the implant procedure when deemed appropriate. All patients received 
intravenous heparin via a standardised regimen to maintain an activated clotting time of 150-
250s. Dual antiplatelet therapy (typically aspirin 75mg and clopidogrel 75mg) was prescribed for 
up to 6 months following TAVI with aspirin monotherapy thereafter, or in the need for full formal 
anticoagulation (atrial fibrillation, previous venous thromboembolism), warfarin monotherapy 
was administered. 
 
TAVI procedural details, including invasive aortic valve gradient, pre and post TAVI systolic, 
diastolic and left ventricular end diastolic pressures, TAVI type and size, procedure time, 
fluoroscopy screening time and contrast dose were recorded for all patients. 
 
2.3 Surgical Aortic Valve Replacement 
SAVR was performed by experienced cardiothoracic surgeons using the standard approach of 
a midline sternotomy incision. Systemic heparinisation with standard aorto-right atrial 
cannulation was used to establish cardiopulmonary bypass and a mild systemic hypothermia 
(30-34°C). Cold blood cardioplegic arrest of the heart and pericardial carbon dioxide was used 
in all cases. The aorta was cross-clamped and aortotomy performed with the size and type of 
prosthesis being selected according to annulus size, patient characteristics, surgical and patient 
preference. Concomitant CABG was performed using a combination of left internal mammary 
artery (LIMA) and saphenous vein grafting (SVG) to significantly diseased major vessels with 
the aim of complete revascularisation in all patients, where technically possible. Procedural 
details including valve type and size, cross-clamp and cardiopulmonary bypass time, length of 
intensive care stay and need for blood transfusion were collected. Aspirin monotherapy was 
administered for 3 months post-procedure, except in instances of mechanical prosthesis or 
atrial fibrillation where warfarin monotherapy was prescribed. 
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2.4 CMR protocol 
2.4.1 Cine imaging 
Identical CMR scans were obtained on the same imaging platform at baseline and post 
procedure (for timings of follow up scans see individual methods chapters) using the same 1.5T 
scanner (Intera and Ingenia, Philips Healthcare, Best, Netherlands or Avanto, Siemens Medical 
Systems, Erlangen, Germany). Multi-slice, multi-phase cine imaging was performed using a 
SSFP pulse sequence in the short axis (repetition time (TR) 3msec, TE 1.7msec, flip angle 60°, 
SENSE factor 2, 8mm slice thickness, 0mm interslice gap, 30 phases, 192 by 192 matrix, 
typical field of view 340mm) to cover both ventricles. Cine imaging included standard 4 
chamber, 2 chamber and short axis views as well as two left ventricular outflow tract views in 
sagittal-oblique and coronal views (3-5 slices, 6mm slice thickness, 0mm interslice gap, 30 
phases, typical field of view 380mm) to permit planning of aortic valve phase contrast imaging.  
 
2.4.2 Aortic valve phase contrast imaging 
Through-plane velocity encoded (VENC) phase contrast imaging was then performed 
perpendicular to the aortic valve jet at the aortic sinotubular junction (repetition time [TR] 4.3 
msec, echo time [TE] 2.6 msec, flip angle 15°, slice thickness 6mm, 40 phases, FOV 340mm 
typical voxel size 1.2x1.2x8mm3, depending on patient size). Aortic flow data were acquired 
using a free breathing (for regurgitation) and breath-hold (for forward flow) retrospectively gated 
technique with a VENC limit typically set at 400-500cm/sec on the baseline scan and 
250cm/sec post-procedure (individually adjusted/repeated if there was evidence of aliasing). 
The region of interest was planned at the sinotubular junction (with care taken not to include 
aortic valve leaflets) or just above the aortic prosthesis post-replacement, orthogonal to the 
aortic valve jet. For flow measurements following TAVI, through-plane phase contrast imaging 
was performed perpendicular to the aorta at the sinotubular junction, or at the upper margin of 
the stent holding the TAVI prosthesis. This position for imaging has been previously described 
and validated (Salaun et al., 2015). Similarly, if significant turbulence or aliasing was seen in the 
velocity mapped images, the acquisition was repeated a few millimetres further from the valve, 
and/or with a higher VENC. In patients with arrhythmia (e.g. atrial fibrillation), the use of multiple 
acquisitions and averaging of values, and the application of arrhythmia rejection (in which data 
points acquired from excessively long or short heart beats are rejected and reacquired) were 
employed where feasible. 
 
2.4.3 Measures of aortic stiffness 
A sagittal-oblique aortic (‘candy cane’) image was acquired (SSFP pulse sequence; repetition 
time [TR] 3 msec, echo time [TE] 1.7 msec, flip angle 60°, reduction factor 2, 5 slices, 6mm 
slice thickness, 0 mm interslice gap) to enable the planning of an axial SSFP slice, 
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perpendicular to the ascending and descending aorta at the level of the pulmonary artery 
bifurcation. For aortic distensibility, brachial artery blood pressure was recorded by Dinamap 
(Critikon, Tampa, USA) immediately prior to high temporal resolution multi-phase SSFP cine 
imaging (retrospective gating, slice thickness 8mm, acquired spatial resolution 1.07x1.8x8mm, 
acquired temporal resolution 50 phases, TR 3ms, TE 1.5ms, flip angle 60°, breath-held, which 
for a heart rate of 60 beats per minute was equivalent to 12 seconds) acquired transverse to the 
ascending and descending thoracic aorta at the level of the pulmonary artery bifurcation. Aortic 
pulse wave velocity was assessed using identical geometric planning, in order to acquire 
ascending and descending thoracic aortic blood flow velocity with retrospectively gated, 
through-plane, phase-contrast velocity encoded images (single slice, 8mm thick, acquired 
spatial resolution 2.5x2.67x8mm, TR 4.6ms, TE 2.7ms, flip angle 40°, slice thickness 6mm, 
acquired temporal resolution 50 phases, typical FOV 350, and VENC 200-500cm/s, breath-held, 
which for a heart rate of 60 beats per minute was equivalent to 13 seconds). 
 
2.4.4 CMR strain imaging using myocardial tissue tagging 
Complementary spatial modulation of magnetization (CSPAMM) imaging was carried out during 
a single breath hold at end expiration in the short axis orientation, at the apex, mid, and basal 
LV (multishot echo planar imaging, flip angle sweep applied to the radiofrequency excitation 
pulses of subsequent cardiac phases, two orthogonal line tags acquired per slice, field of view: 
300mm, matrix 128x128, slice thickness 10mm, tag separation 8mm, typically 18 phases, TR 
30ms, TE 6ms, flip angle 25°). The “3 of 5 technique” was used to minimize variation in slice 
positioning between visits and has been demonstrated to be highly reproducible (Swoboda et 
al., 2014). 
 
2.4.5 Tissue characterisation: late gadolinium enhancement imaging 
LGE imaging using an inversion recovery-prepared T1-weighted gradient echo pulse sequence 
(TE 1.79msec; TR 4.8msec; flip-angle 15°, spatial resolution 1.46x1.46x10mm) was performed 
with inversion time (TI) individually adjusted according to TI scout (Look-Locker pulse 
sequence). This was planned to cover the entire left ventricle in short axis (10-12 short axis 
slices, 10mm thickness, no interslice gap, matrix 240x240, typical field of view 350mm), 10 
minutes after 0.2mmol/kg of Gadoteric acid (godoterate meglumine, Dotarem, Guerbet, SA, 
Villepinte) or Gadolinium-DTPA (magnevist, Schering, Germany) administered by hand 
injection. An identical contrast agent was used at both study time-points. Four chamber, two 
chamber and left ventricular outflow tract (LVOT) views were also obtained. Cross cuts and 
switching of phase encoding direction were used where necessary to further clarify presence or 
absence of LGE. 
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Figure 2.1 depicts the full CMR protocol and a typical time line of its components. 
 
Figure 2.1 Imaging Protocol 
 
2.5 CMR image analysis 
2.5.1 Ventricular volume quantification from SSFP cine images 
Analyses were performed either using QMass 7.5, Medis Medical Imaging Systems, Leiden, 
The Netherlands (chapters 3,4 and 5) and CVI42, Circle Cardiovascular Imaging, Calgary, 
Alberta (chapter 6). Standard criteria were employed to delineate ventricular endocardial and 
epicardial borders at end-diastole and end-systole in short-axis to allow the calculation of 
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ventricular volumes (using the summation of discs methodology) and mass. Papillary muscles 
were excluded from the LV cavity and included within the LV mass for the purpose of analysis 
(Figure 2.2).  
 
Figure 2.2 Ventricular chamber quantification in (A) end-diastole and (B) end-
systole 
 
LV mass was calculated using Equation 2-1: 
 
LV mass = (epicardial volume – endocardial volume) * 1.05 
Equation 2-1 Calculation of LV mass 
 
All values were indexed to BSA. Structural LV remodelling was defined by LV mass : end 
diastolic volume ratio as previously described (Gaasch and Zile, 2011).  
 
2.5.2 Quantification of Valvular function 
Through-plane phase contrast images were examined to ensure the quality was sufficient and 
that the VENC chosen was appropriate. Aortic flow was quantified in the Flow module of CVI42 
software with contouring of the aortic lumen in both phase and magnitude images (Figure 2.3) 
to provide a peak forward flow velocity (m/s), forward flow volume (ml), backward flow volume 
(ml) and regurgitant fraction (%).  
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Figure 2.3 Quantification of aortic valve function using CVI42 software 
 
Mitral regurgitant fraction (%) was calculated according to Equation 2-2.  
 
Mitral regurgitation fraction = [(LV stroke volume–aortic stroke volume) / LV stroke volume] * 
100. 
Equation 2-2 Calculation of mitral regurgitation fraction 
 
2.5.3 Quantification of Late Gadolinium Enhancement  
All analyses were performed using CVI42, Circle Cardiovascular Imaging, Calgary, Alberta, 
Canada by two experienced observers (TAM and LED) blinded to procedural and clinical 
details. LGE images derived from different geometries (VLA, 4 chamber), cross cut and 
switching of phase encoding direction were used to assist interpretation. Focal myocardial 
fibrosis and scarring (secondary to myocardial infarction) were differentiated then reported 
qualitatively as either present or absent. In only those slices deemed to have LGE present, epi 
and endocardial contours were manually drawn, with care take to exclude artefact, blood pool, 
fat and pericardium. The auto-identification tool was then applied and an area of normal remote 
myocardium defined alongside identification of areas with increased signal intensity. Any hyper 
intense regions felt to be related to artefact were manually excluded and the full-width half max 
technique was applied to quantify LGE mass (Flett et al., 2011). 
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2.6 Reproducibility measurements 
For the assessment of inter-observer variability, two independent investigators analysed a 
random selection of 10 patients both pre- and post- valve replacement. For intra-observer 
variability a similar dataset from 10 patients was analysed twice by the author six months apart. 
For reproducibility, an intra-class correlation was used and the results can be seen in Table 2.1. 
 
Table 2.1 Observer variability of measurements 
Parameter INTRA – observer variability INTER – observer variability 
LV EDV 0.984 0.989 
LV Mass 0.978 0.985 
LVEF 0.982 0.970 
RV EDV 0.995 0.947 
RV ESV 0.996 0.911 
TAPSE 0.939 0.917 
Peak aortic gradient 1.000 0.963 
Aortic Regurgitant Fraction 0.987 0.986 
LGE quantification (%) 0.995 0.979 
2.7 Sample Size and Statistical Analysis 
CMR is accurate and reproducible and permits hypothesis testing from a considerably reduced 
number of patients. For this work, sample sizes were based on published data indicating 20 
patients per group permit the detection of a 10ml change in LVEDV or 10g difference in LV 
mass regression between two treatments (90% power and an alpha error of 0.05) (Bellenger et 
al., 2000b); 30 per group would be sufficient to detect a clinically meaningful 10% absolute 
difference in aortic peak forward flow velocity or regurgitant fraction (85% power and an alpha 
error of 0.05)(Fairbairn et al., 2013b). Continuous variables are presented as mean±SD or 
number (%). Normality was determined by the Shapiro–Wilk test. For normally distributed data, 
two-tailed unpaired Student’s t tests were used for comparisons between groups, and paired 
Students t tests were used for intragroup comparisons. For non-normally distributed data, the 
Related-Samples Wilcoxon Signed Rank Test and independent samples Mann-Whitney U test 
were used. Changes over time were assessed for differences between the treatment groups 
and clinical variables by two-way repeated measures analysis of variance (ANOVA). Predictors 
of functional change were evaluated by a stepwise linear regression model with baseline 
measurements entered as covariate factors. All statistical analyses were performed using 
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PASW software (V.21.0 SPSS, IBM, Chicago, USA); two-sided p<0.05 considered statistically 
significant. 
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Chapter 3. Assessment of Aortic Stiffness by CMR following the 
treatment of Severe Aortic Stenosis by TAVI and SAVR 
3.1 Abstract  
Background: Aortic stiffness is increasingly used as an independent predictor of adverse 
cardiovascular outcomes. We sought to compare the impact of transcatheter aortic valve 
implantation (TAVI) and surgical aortic valve replacement (SAVR) upon aortic vascular function 
using cardiovascular magnetic resonance (CMR) measurements of aortic distensibility and 
pulse wave velocity (PWV). 
 
Methods and Results: A 1.5T CMR scan was performed pre-operatively and at 6m post-
intervention in 72 patients (32 TAVI, 40 SAVR; age 76±8yrs) with high-risk symptomatic severe 
aortic stenosis. Distensibility of the ascending and descending thoracic aorta and aortic pulse 
wave velocity were determined at both time points. TAVI and SAVR patients were comparable 
for gender, blood pressure and left ventricular ejection fraction. The TAVI group were older 
(81±6.3 vs. 72.8±7.0yrs, p<0.05) with a higher EuroSCORE II (5.7±5.6 vs. 1.5±1.0%, p<0.05). 
At 6m, SAVR was associated with a significant decrease in distensibility of the ascending aorta 
(1.95±1.15 vs. 1.57±0.68x10-3mmHg-1, p=0.044) and of the descending thoracic aorta 
(3.05±1.12 vs. 2.66±1.00x10-3mmHg-1, p=0.018), with a significant increase in PWV (6.38±4.47 
vs. 11.01±5.75ms-1, p=0.001). Following TAVI, there was no change in distensibility of the 
ascending aorta (1.96±1.51 vs. 1.72±0.78x10-3mmHg-1, p=0.380), descending thoracic aorta 
(2.69±1.79 vs. 2.21±0.79x10-3mmHg-1, p=0.181) nor in PWV (8.69±6.76 vs. 10.23±7.88ms-1, 
p=0.301) at 6m.  
 
Conclusions: Treatment of symptomatic severe aortic stenosis by SAVR but not TAVI was 
associated with an increase in aortic stiffness at 6m. Future work should focus on the 
prognostic implication of these findings to determine whether improved patient selection and 
outcomes can be achieved.  
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3.2 Introduction 
Degenerative aortic stenosis can be viewed as part of a continuum that comprises not only 
valvular dysfunction but also a reduction in aortic compliance (Hachicha et al., 2009) which 
independently contributes to increased afterload (Briand et al., 2005) and decreased left 
ventricular function. Increased aortic stiffening is detrimental to arterio-ventricular coupling and 
coronary perfusion and is an independent predictor of future cardiovascular events and 
mortality in the general population, essential hypertension, diabetes mellitus, end stage renal 
failure  and in the elderly (Ripley et al., 2015). Measurement of aortic stiffness is therefore 
increasingly used in clinical practice as a prognostic indicator. 
 
CMR offers a robust, reproducible, non-invasive method of assessing both local and regional 
properties of the aortic wall (Metafratzi et al., 2002). Two standard indices of aortic stiffness can 
be expressed; aortic distensibility and pulse wave velocity, and there is a strong inverse linear 
relationship reported between these two measurements (Dogui et al., 2011, Nelson et al., 
2009). 
 
The elastic property of the aorta is in part dependent upon the perfusion of the aortic wall via 
vasa vasorum flow. We hypothesised, based upon the difference in techniques, that more 
favourable measures of aortic stiffness would be observed following TAVI rather than SAVR. 
Ultimately, this may herald prognostic implications and guide future patient selection.  
 
The primary aim of this study was to use CMR to serially compare the effects of TAVI and 
SAVR on aortic stiffness, before and 6m after treatment for severe symptomatic aortic stenosis. 
 
3.3 Methods specific chapter 3 
3.3.1 Study population 
A total of 127 patients were prospectively recruited with severe AS after being referred for either 
TAVI (n=77) or SAVR (n=50) at the University Hospitals of Leeds and Leicester, UK, between 
July 2008 and December 2013. Severe AS was classified according to the criteria in section 
2.1. Decision for TAVI was taken by a multidisciplinary heart team in accordance with 
international guidance. Older, higher-risk (higher EuroSCORE) SAVR patients were 
preferentially recruited wherever possible to facilitate comparable baseline demographics.  
 
3.3.2 Transcatheter Aortic Valve Implantation 
TAVI was performed under general anaesthesia by high-volume operators with >5 years’ 
experience. Either an 18F CoreValve Revalving system (CVR, Medtronic, Minneapolis, 
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Minnesota, USA) or an 18F or 20F Lotus™ Aortic Valve system (Boston Scientific Corporation, 
Natick, USA) were deployed as previously described (Piazza et al., 2008, Meredith et al., 2014). 
 
3.3.3 Surgical Aortic Valve Replacement 
SAVR was performed by standard midline sternotomy with cardiopulmonary bypass and mild 
hypothermia. Biological or mechanical prostheses of varying sizes were used according to 
surgical preference; concomitant coronary artery bypass grafting (CABG) was performed as 
indicated. No patient underwent aortic root or ascending aortic reconstruction. 
 
3.3.4 CMR Protocol 
For each individual patient, identical baseline pre-operative and 6-month post-operative scans 
were performed on the same 1.5T MR system (Phillips Intera, Best, The Netherlands or 
Siemens Avanto Erlangen, Germany). Details of the CMR pulse sequence acquisition protocol 
are outlined in the Standard Methods chapter (sections 2.4.1, 2.4.2 and 2.4.3).  
 
3.3.5 CMR Image Analysis 
Image analysis was performed in line with international guidance (Schulz-Menger et al., 2013), 
blinded to patient details, using off-line commercially available software (QMass V7.5 and 
QFlow V7.2, Medis, Leiden, The Netherlands). Aortic valve flow indices were quantified using 
cross-sectional phase contrast images with contouring of the aortic lumen to derive peak 
forward flow velocity(m/s), and forward and backward flow volumes (ml), for the calculation of 
trans-valvular pressure gradient and regurgitant fraction(%).  
 
To derive the aortic distensibility of the ascending and descending thoracic aorta, cross 
sectional measurements were made by manual planimetry of the endovascular-blood pool 
interface for each phase to determine the maximal and minimal aortic dimensions (Figure 3.1A). 
Aortic distensibility (mmHg-1) was calculated using Equation 3-1:  
 
Distensibility = (Aortic max lumen area - Aortic min lumen area) / (Aortic min lumen area x 
[Systolic BP – Diastolic BP]) 
Equation 3-1 Calculation of aortic distensibility 
 
Aortic PWV (m/s) was calculated by dividing the distance separating two locations and the 
transit time needed to cover this distance (Oliver and Webb, 2003). Analysis was performed 
using validated software (PMI v0.4, https://github.com/plaresmedima/PMI-0.4-Runtime-
CMRLeeds) based on IDL 6.4 (ITT Visual Information Systems, Boulder, USA) (Huber et al., 
2012). The distance between the ascending and descending aorta was measured manually 
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from the sagittal/oblique cines of the aortic arch (Figure 3.1B). Transit time was calculated using 
the foot-foot delay method from velocity encoded images of the ascending and descending 
aorta, manually contoured to derive velocity-time curves (Figure 3.1C) (Ibrahim el et al., 2010).  
 
 
Figure 3.1 CMR measurements of aortic stiffness 
A) Ascending aortic cross-sectional measurements made by manual planimetry of the aortic 
endovascular-blood pool interface at minimal and maximal distension.  
B) Sagittal oblique CMR image from which the length of the aortic arch is manually measured. 
The image is subsequently used to determine site of acquisition of phase contrast cines.  
C) Time-Velocity curve derived using PMI software to calculate foot-foot delay (curves are 
automatically adjusted/overlaid to accommodate time delay). 
 
3.4 Results  
3.4.1 Study population 
Seventy-two patients (32 TAVI, 40 SAVR) with paired pre-operative and 6m post-operative 
CMR scans were included for analysis. Reasons for non-completion of the CMR protocol were 
varied and are depicted in Figure 3.2.  
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Figure 3.2 Patient recruitment pathway 
 
Baseline characteristics of the study population are shown in Table 3.1.  
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Table 3.1 Patient characteristics and baseline data 
 
Characteristics SAVR (n=40) TAVI (n=32) p Value* 
Age 72.8 ± 7.0 81 ± 6.3 0.001 
Male gender, n (%) 31 (78) 20 (63) 0.151 
EuroSCORE II (%) 1.53 ± 1.0 5.66 ± 5.6 0.001 
STS Mortality (%) 2.01 ± 0.6 5.68 ± 3.8 0.001 
BMI (kgm-2) 27.9 ± 6.3 26.6 ± 2.8 0.274 
Systolic BP (mmHg) 131 ± 23 127 ± 28 0.696 
Diastolic BP (mmHg) 73 ± 11 65 ± 11 0.003 
Resting Heart Rate (bpm) 64 ± 12 65 ± 11 0.713 
NYHA class 2.5 ± 0.6 3 ± 1.0 0.002 
Previous MI, n (%) 5 (13) 6 (19) 0.560 
Previous PCI, n (%) 1 (3) 10 (31) 0.001 
Previous CABG, n (%) 0 (0) 12 (38) 0.001 
Stroke/TIA, n (%) 7 (18) 4 (13) 0.667 
Peripheral vascular 
disease, n (%) 
1 (3) 6 (19) 0.028 
Diabetes Mellitus, n (%) 4 (10) 8 (25) 0.125 
Hyperlipidaemia, n (%) 24 (60) 20 (63) 0.977 
COPD, n (%) 4 (10) 6 (19) 0.358 
Atrial Fibrillation, n (%) 1 (3) 8 (25) 0.006 
eGFR (ml/min/1.73m2) 71.7 ± 13.3 61.4 ± 17.1 0.006 
AVA (cm2) 0.90 ± 0.5 0.62 ± 0.2 0.002 
Mean PG (mmHg) 43 ± 15.8 51 ± 13.7 0.023 
LVEF (%) 52±12 52±13 0.961 
ValvuloArterial 
Impedance (Zva) 
3.88 ± 0.9 4.06 ± 1.6 0.982 
Median prosthetic 
replacement size (mm) 
23 27 0.001 
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Sinuses of Valsalva 
dimension indexed to 
BSA (mm/m2) 
17.9±2.2 18.1±2.1 0.615 
Proximal ascending 
aortic dimension indexed 
to BSA (mm/m2) 
17.4±2.8 16.9±2.8 0.505 
Values are mean±SD or n (%). *p value for comparison between procedure types. 
 
For both individual groups, key demographic and haemodynamic parameters of the excluded 
patients were not statistically different to those included for analysis (Table 3.2), indicating that 
our study patients were representative of the larger population. For the TAVI group (n=32), 
9(28%) were taking ACE inhibitors or ARB, 18(56%) β-blockers, 3(9%) spironolactone, 5(16%) 
calcium antagonists, 1(3%) α-blockers, 23(72%) statins and 16(50%) diuretics. For the SAVR 
group (n=40), 5(13%) were taking ACE inhibitors or ARB, 5(13%) β-blockers, 1(3%) calcium 
antagonists, 13(33%) statins and 1(3%) diuretics. None were using spironolactone or α-
blockers. 
 
Table 3.2 Comparison of baseline demographics and aortic stiffness between 
included and excluded TAVI and SAVR patients 
 
Parameter SAVR 
Included 
n=40 
SAVR 
Excluded 
n=10 
p Value TAVI 
included 
n=32 
TAVI 
excluded 
n=45 
p Value 
Age (years) 72.8±7.0 70.0±8.4 0.261 81±6.3 80 ± 7.2 0.593 
STS score (%) 2.01±0.6 2.06±0.9 0.900 5.68±3.8 5.34±2.8 0.693 
EuroSCORE II (%) 1.53±1.0 1.35±0.56 0.116 5.66±5.6 5.18±3.4 0.691 
Systolic BP (mmHg) 131±23 127±23 0.557 127 ± 28 132±19 0.524 
Previous MI (n(%)) 5 (13) 1 (10) 0.611 6 (19) 4 (15) 0.844 
Previous PCI (n(%)) 1 (3) 2 (20) 0.250 10 (31) 8 (31) 0.872 
Peripheral Vascular 
Disease (n(%)) 
1 (3) 1 (10) 0.531 6 (19) 6 (23) 0.581 
Diabetes Mellitus (n(%)) 4 (10) 4 (40) 0.163 8 (25) 5 (19) 0.721 
Hyperlipidaemia, n (%) 24 (60) 8 (80) 0.925 20 (63) 15 (58) 0.998 
COPD, n (%) 4 (10) 1 (10) 0.801 6 (19) 5 (19) 0.849 
Atrial Fibrillation, n (%) 1 (3) 3 (10) 0.121 8 (25) 5 (19) 0.721 
AVA (cm2) 0.90±0.5 0.67± 0.2 0.195 0.62±0.2 0.62±0.2 0.941 
AAD (x10-3mmHg-1) 1.95±1.15 2.12±1.07 0.648 1.96±1.51 1.55±0.61 0.338 
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The TAVI group were older with a higher predicted 30d mortality risk. The aortic dimensions 
between the SAVR and TAVI groups were both equivalent and within published normal 
reference ranges (Evangelista et al., 2010) in keeping with our exclusion criteria (Table 3.1). 
 
3.4.2 Procedural data 
For the TAVI group, 25(78%) patients received a Medtronic CoreValve and 7(22%) a Boston 
Scientific Lotus valve. The femoral access route was used for 30(94%) and the subclavian 
artery for the remaining 2(6%) patients. Procedural success was 100% with an average 
catheterisation time of 159±48min, fluoroscopy time of 25±7min and 146±48ml of contrast 
administered. 
 
In the surgical group, five patients received a mechanical prosthesis (either Sorin Carbomedics 
or St Jude’s mechanical) and the remaining 35(88%) a tissue bioprosthesis (Sorin mitroflow, 
Edwards Perimount Magna, Medtronic Hancock, Hancock II and Mosaic, Vascutek Terumo 
Aspire). Eleven (28%) received concomitant coronary bypass grafting, of which 6 involved use 
of the left internal mammary artery. For the group as a whole, the average bypass time was 
108±50min and average cross clamp time 81±43min. The average length of stay in intensive 
care was 3.5±2.8days. 
 
3.4.3 Aortic Valve Haemodynamics and LV reverse remodelling 
Results of the baseline and 6m CMR scans are shown in Table 3.3. No significant change in 
arterial pulse pressure was observed following SAVR (58.8±18.6 vs. 61.4±14.4mmHg, p=0.402) 
or TAVI (63.5±24.0 vs. 69.7±20.3mmHg, p=0.203). There was no significant change in the 
number of antihypertensive medications used, neither following SAVR (1.3±0.8 vs. 1.4±0.8, 
p=0.503) or TAVI (1.2±1.0 vs. 1.3±1.0, p=0.161). Reductions in aortic valve pressure gradient, 
valvuloarterial impedance, LV mass index and end-diastolic volume index were seen 6m 
following both SAVR and TAVI (Table 3.3). 
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Table 3.3 Preoperative baseline and 6 month follow-up measurements: SAVR vs. 
TAVI 
 SAVR (n=40) TAVI (n=32) p Value
† 
 Baseline 6 months Baseline 6 months  
Haemodynamics      
Heart Rate 
(bpm) 
64±12 65±11 65±11 66±15 0.853 
Systolic BP 
(mmHg) 
131±23 133±20 127±28 134±22 0.325 
Pulse pressure 
(mmHg) 
58±19 61±14 62±24 70±20 0.506 
Number of 
Medications†† 
1.3±0.8 1.4±0.8 1.2±1.0 1.3±1.0 0.760 
Systemic 
Arterial 
Compliance††† 
0.88±0.3 0.74±0.2* 0.81±0.3 0.71±0.2 0.698 
 
Aortic Valve    
 Peak gradient 
(mmHg)†††† 
59±20 32±18*** 54±14 25±13*** 0.439 
Zva 3.9±0.9 3.5±0.8* 4.1±1.6 3.0±1.1** 0.060 
 
Left Ventricle    
Mass Index 
(g/m2) 
80±25 65±16*** 82±22 68±18*** 0.687 
EDVI (ml/m2) 95±25 77±14*** 95±25 86±19* 0.060 
EF (%) 52±12 57±8** 52±13 55±11 0.651 
†Independent samples t-test to compare degree of change seen following SAVR with that seen 
following TAVI.  
††defined as any of: ACE inhibitor, angiotensin II receptor antagonist, β blocker, spironolactone, 
doxazosin, hydralazine, amlodipine, felodipine or bendrofluazide. †††Derived as stroke volume 
index / pulse pressure.  
††††Derived from CMR assessment.  
Paired t test to compare baseline and 6 months: *p<0.05, **p<0.01, ***p<0.001. 
 
3.4.4 Aortic Stiffness Indices 
At baseline there was no difference between the groups in respect to PWV (p=0.153) or 
distensibility; neither of the ascending (p=0.838) or descending thoracic aortia (p=0.306). 
Change in indices of aortic stiffness are depicted in Figure 3.3.  
57 
 
 
 
Figure 3.3 Bar charts depicting change in indices of aortic stiffness seen pre- and post-SAVR and TAVI 
A: pulse wave velocity, B: ascending aortic distensibility, C: descending aortic distensibility. Column height = mean, Bars = standard error. 
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At 6m, SAVR was associated with a decrease in distensibility of the ascending aorta (1.95±1.15 
vs. 1.57±0.68x10-3mmHg-1, p=0.044) and of the descending thoracic aorta (3.05±1.12 vs. 
2.66±1.00x10-3mmHg-1, p=0.018). There was a concomitant increase in PWV observed at 6m 
(6.38±4.47 vs. 11.01±5.75ms-1, p=0.001) (Table 3.4). These changes were independent of 
whether or not bypass grafting occurred at the time of valve replacement.  
 
Table 3.4 Change in mean measurements pre- and post-SAVR and TAVI 
 SAVR (n=40) TAVI (n=32) 
 Pre Post p Value* Pre Post p Value* 
Ascending AD (x10-3mmHg-1) 1.95±1.15 1.57±0.68 0.044 1.96±1.51 1.72±0.78 0.380 
Descending AD (x10-3mmHg-1) 3.05±1.12 2.66±1.00 0.018 2.69±1.79 2.21±0.79 0.181 
Aortic Arch PWV (m/s) 6.38±4.47 11.01±5.75 0.001 8.69±6.76 10.23±7.88 0.301 
Change in AA area** (mm2) 99±54 80±42 0.032 85±32 91±38 0.410 
Change in DA area*** (mm2) 87±26 80±27 0.083 73±28 74±25 0.916 
Pulse pressure (mmHg) 58±19 61±14 0.322 63±24 70±20 0.150 
Length of aortic arch (mm) 139±18 134±20 0.129 126±21 122±16 0.223 
*paired samples t-test 
**defined as maximal– baseline cross-sectional ascending aortic area 
***defined as maximal– baseline cross-sectional descending aortic area 
 
There was no significant change observed in either the distensibility of the ascending aorta 
(1.96±1.51 vs. 1.72±0.78x10-3mmHg-1, p=0.380) or of the descending thoracic aorta 
(2.69±1.79 vs. 2.21±0.79x10-3mmHg-1, p=0.181) following TAVI. Similarly, TAVI was not 
associated with any significant change in PWV at 6m (8.69±6.76 vs. 10.23±7.88ms-1, p=0.301).  
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3.4.5 Demographic and procedural factors associated with change in aortic stiffness 
In linear regression analysis, no baseline characteristic (including age, gender, eGFR, surgical 
risk score or Zva) or procedural variable (including surgical times, CABG and valve type or size) 
was found to be associated with any index of increased aortic stiffness after SAVR (Table 3.5).  
 
Table 3.5 Linear regression analysis for the prediction of increased aortic 
stiffness observed following SAVR 
 
 Univariate Analysis 
Risk Factor PWV AA Distensibility Proximal DA 
Distensibility 
 R p 
Value 
R p 
Value 
R p Value 
Age (years) 0.051 0.767 0.157 0.353 0.229 0.172 
Male gender 0.145 0.392 0.181 0.285 0.103 0.544 
NYHA class 0.061 0.721 0.105 0.538 0.026 0.880 
BMI (kg/m2) 0.164 0.331 0.018 0.917 0.221 0.189 
eGFR (ml/min/1.73m2) 0.175 0.299 0.013 0.940 0.079 0.642 
Hyperlipidaemia 0.111 0.513 0.205 0.223 0.058 0.734 
EuroSCORE II (%) 0.356 0.068 0.361 0.064 0.261 0.188 
AVA (cm2) 0.080 0.639 0.037 0.827 0.043 0.801 
Mean PG (mmHg) 0.055 0.747 0.085 0.618 0.052 0.761 
ValvuloArterial Impedance 
(Zva) 
0.137 0.420 0.211 0.211 0.043 0.799 
Indexed LV mass 0.007 0.965 0.055 0.747 0.046 0.785 
LV mass:volume ratio 0.020 0.907 0.024 0.890 0.170 0.314 
LVEF (%) 0.183 0.279 0.286 0.087 0.252 0.132 
Bypass time (min) 0.131 0.438 0.012 0.943 0.183 0.279 
Cross Clamp time (min) 0.142 0.400 0.040 0.815 0.164 0.332 
Valve size (mm) 0.078 0.645 0.132 0.436 0.203 0.229 
CABG at surgery 0.136 0.422 0.067 0.692 0.078 0.647 
Valve type at surgery 0.164 0.333 0.143 0.400 0.037 0.827 
 
60 
 
3.5 Discussion 
Aortic physiology is central to governing the entire cardiovascular network, serving as a conduit 
and also regulating coronary perfusion and LV performance. Only a limited number of studies 
have evaluated aortic vascular function following intervention for severe aortic stenosis 
(Vavuranakis et al., 2012, Nemes et al., 2007, Nemes et al., 2009, Barbetseas et al., 2006, 
Melina et al., 2002, Schmidtke et al., 2000). The use of M-mode transthoracic echocardiography 
to determine proximal aortic distensibility has been the exclusive method of investigation; none 
have measured local and regional indices simultaneously and none have sought to compare 
SAVR directly with TAVI. 
 
Using CMR we have been able to demonstrate that treatment of severe aortic stenosis with 
SAVR, compared to TAVI, is associated with an increase in aortic stiffness at 6 months 
independent of baseline characteristics. This was consistently defined by non-invasive 
measurement of both local indices (ascending and descending thoracic aortic distensibility) and 
a regional index (aortic arch pulse wave velocity).  
 
The elastic properties of the aorta relate to its inherent histological structure, the influence of the 
autonomic nervous system and the perfusion of the aortic wall via vasa vasorum flow 
(Vavuranakis et al., 2012). In this regard, the fundamental difference in the techniques of SAVR 
and TAVI could explain our observations. 
 
SAVR involves aortotomy and traumatises aortic wall integrity with destruction of the vasa 
vasorum. The removal the periaortic fat (containing the vasa vasorum) from the ascending aorta 
in animal studies has been shown to worsen aortic distensibility acutely due to ischemic medial 
necrosis and altered fibre composition (Stefanadis et al., 1995). In a porcine model, histological 
analysis of avascular aorta following surgical manipulation revealed abnormal straightening of 
the elastin and collagen fibers of the outer media, resulting in increased aortic stiffness under a 
wide range of stresses (Angouras et al., 2000) . 
 
A previous study of 31 patients (mean age 67.2 years) found a significant reduction in 
ascending aortic distensibility at seven days following mechanical AVR (from 2.21 to 1.01), with 
a recovery towards pre-operative levels at six months (1.79) (Barbetseas et al., 2006). The 
authors suggested that the aetiology was due to “aortic root stunning” implicating surgical 
trauma to the aortic wall via cannulation, cooling, clamping, incising and then suturing, all of 
which disrupts the aortic wall continuity. None of this occurs during a conventional TAVI 
procedure and this may underscore the findings of our study. 
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Our study may have missed the early period of aortic root stunning as we did not examine aortic 
stiffness acutely and thus cannot comment on temporal trends post SAVR. However our study 
does suggest that the significant increase in aortic stiffness persists for at least at six months. A 
decrease in distensibility of the descending thoracic aorta has not previously been reported. 
This finding suggests the surgical insult affects the aorta more globally, extending beyond the 
point of local clamp contact. 
 
Interestingly, we found that bypass time, cross clamp time, valve size, valve type and 
concomitant coronary bypass grafting were not associated with a decline in any of the 
parameters of aortic stiffness. This suggests the deterioration in aortic stiffness seen at the 6m 
time point is insensitive to modifiable surgical technique.  
 
Progressive fragmentation of aortic elastin occurs throughout adulthood and underlies a 
reduction in the Windkessel effect of the aorta, elevating pulse pressures for a given stroke 
volume (Cavalcante et al., 2011). A recent CMR study measuring both AD and PWV study in 
healthy subjects reported that aortic segments stiffen with age, but that after the age of 57 
years, the ascending aorta is stiffer than the descending thoracic aorta (Devos et al., 2015). We 
also observed greater distensibility in the descending thoracic aorta compared to the ascending 
aorta in both groups at baseline which reflects this physiological process.  
 
Measures of aortic stiffness, and PWV in particular, exhibit a strong dependence upon age 
(2010) which must be factored into the interpretation of our findings. We have studied two 
groups with an age difference of approximately 9 years; a reflection of current TAVI implantation 
criteria. Despite this age discrepancy, both baseline PWV and distensibility were statistically 
comparable between the two groups, at least at the sample sizes we have studied. The 
ascending AD of the SAVR group and TAVI group were indeed very similar (1.95 vs. 1.96) yet 
at 6 months, a statistically significant decline from this baseline is seen to a value of 1.57 in the 
SAVR group; but not following TAVI (to a mean value of 1.72).  
 
It is noteworthy the deleterious effect seen following SAVR was independent of age when 
entered as a statistical covariate, challenging its potential use in patient selection pre-
operatively. Whilst an ascending AD and PWV of 1.72x10-3mmHg-1 and 10.23m/s may be 
acceptable and expected in patients aged 80 (post-TAVI), worse values of 1.57x10-3mmHg-1 
and 11.01m/s may not necessarily be acceptable in patients 9 years younger (post-SAVR), 
undergoing an intervention for prognostic reasons who inherently have a lower surgical risk 
score. 
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We and others have shown that lowering of blood pressure can improve aortic stiffness (Ripley 
et al., 2015, Asmar et al., 1995, Asmar et al., 1988). However in this study, blood pressure and 
pharmacotherapy were unchanged pre- and post-procedure, suggesting that this was unlikely to 
account for the difference in impact upon aortic stiffness between TAVI and SAVR. The normal 
systemic arterial compliance in both groups indicates that baseline haemodynamics were 
governed predominantly by aortic valve disease without any associated aortic or LV pathology 
(Briand et al., 2005). Following intervention, SAVR was associated with a limited decrease in 
Zva as opposed to TAVI. Given a comparable and important reduction in aortic valve gradient 
(valvular load), the dampened Zva response to SAVR likely reflects an increase in arterial load 
reflecting a mechanical deterioration in aortic function. 
 
The effect of TAVI upon proximal aortic distensibility has been assessed once previously in 30 
patients (mean age 79.9 years) using echocardiography 7 days post-procedure (Vavuranakis et 
al., 2012). No significant change was observed with an AD of 1.89 pre and 2.05 post TAVI. Our 
study supports these findings and additionally demonstrates preservation of local and regional 
aortic stiffness at 6 months post-TAVI. Our study indicates the absence of deterioration in aortic 
stiffness out to 6 months post-TAVI may favour its usage over SAVR in younger patient 
populations.  
 
The motivation for this study was to investigate whether TAVI or SAVR is more favourable upon 
aortic stiffness and thus potentially prognosis. It might be expected that our findings would 
translate into an increased incidence of adverse cardiovascular events in the surgical 
population. From a meta-analysis of 17 longitudinal studies comprising 15,877 subjects, an 
increase in aortic PWV by 1m/s corresponded to an age-, sex-, and risk factor-adjusted risk 
increase of 15% in all-cause mortality (Vlachopoulos et al., 2010). A dramatic increase in PWV 
was seen following SAVR in our study although our follow-up data of the surgical group extends 
to an average of 2.8 years with 95% (n=38) of subjects surviving, such that the numbers are 
insufficient to make any direct inference. 
 
In the US CoreValve High Risk Study, a higher survival rate at one year in patients undergoing 
TAVI compared directly with SAVR was likely due to more rapid recovery coupled with relatively 
lower rates of stroke (Adams et al., 2014). Our findings are noteworthy in this respect as aortic 
stiffness may be a contributory factor to this observation. Indeed, in a study of 310 patients 
aged 50 years or more, lower aortic distensibility was shown to be an independent predictor of 
all-cause mortality in patients presenting with first-ever acute ischemic stroke (Biteker et al., 
2015). Larger studies with longer follow-up post AVR are required to determine the precise 
predictive power of aortic stiffness with respect to mortality and morbidity in this setting. 
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3.5.1 Study Limitations 
The main limitation is the attrition of patients who were unable to complete the CMR protocol at 
6 months. This was predominantly in the TAVI population who are a very challenging group to 
study due to age, frailty and comorbidity. Mortality and pacemaker rates were high, but 
consistent with large international registries. A small number of TAVI patients declined follow up 
because of deteriorating health and transfer into long-term nursing care. This is one of the 
largest studies of its kind and patients not studied at 6m were not statistically different when 
baseline demographics are considered to those that were, as indicated in Table 3.2. 
Nonetheless, the potential for bias cannot be excluded as the sickest patients who withdrew 
may have had higher post-procedural arterial stiffness and worst outcomes. The observed 
difference between the two treatments may also thus be confounded by the repeatability of the 
scans as in absolute terms far fewer SAVR patients were lost than for TAVI. Furthermore, the 
sample size was small, raising the possibility of type 1 and type 2 errors influencing our 
comparison of means. It is possible that our TAVI population, with an average age of 80 years, 
may have reached near maximal aortic stiffness. Thus TAVI itself may be deleterious or even 
beneficial to aortic stiffness, but in our particular population we have not been able to elucidate 
this.  
 
The difference in baseline demographics between the groups was unavoidable due to current 
TAVI implantation criteria. However, our study population can be considered a real life 
reflection, at least of UK national practise (Moat et al., 2011). Finally, this study has not 
assessed patients undergoing isolated on-pump coronary bypass surgery or direct aortic TAVI. 
  
3.6 Conclusion 
In this two centre comparative study using CMR-derived measurements, treatment of 
symptomatic severe aortic stenosis by SAVR but not TAVI was associated with an increase in 
aortic stiffness from baseline to 6m. Given aortic stiffness is a marker of adverse cardiovascular 
events, future work should focus on the potential prognostic benefit of TAVI over SAVR, 
particularly in younger age-matched populations, as TAVI implantation criteria evolve. 
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Chapter 4. Right ventricular function following SAVR and TAVI 
4.1 Abstract 
Background: Right ventricular (RV) function is prognostically important in a variety of 
cardiovascular conditions. The response of the RV following treatment of aortic stenosis is 
poorly defined, reflecting the challenge of accurate RV assessment. Cardiovascular magnetic 
resonance (CMR) is the established reference for imaging of RV volumes, mass and function. 
We sought to define the impact of transcatheter aortic valve implantation (TAVI) and surgical 
aortic valve replacement (SAVR) upon RV function in patients treated for severe aortic stenosis 
using CMR. 
 
Methods and Results: A 1.5T CMR scan was performed pre-operatively and 6 months post 
intervention in 112 patients (56 TAVI, 56 SAVR; 76±8 years) with high-risk severe aortic 
stenosis at two tertiary cardiac centres. TAVI and SAVR patients were comparable for gender 
and valvuloarterial impedance, but the TAVI group were older (80.4±6.7 vs. 72.8±7.2 years, 
p<0.05) with a higher EuroSCORE II (5.8±5.1 vs. 1.6±0.9%, p<0.05). At 6 months, SAVR was 
associated with a significant increase in RV end systolic volume (33±10 vs. 37±10ml/m2, 
p=0.008), and decrease in RV ejection fraction (58±8 vs. 53±8%, p=0.005) and tricuspid 
annular plane systolic excursion (22±5 vs. 14±3mm, p<0.001). Longer surgical cross-clamp 
time was the only predictor of RV end systolic dilatation at 6 months. Post TAVI, there was no 
observed change in RV volumes or function.  
 
Conclusions: SAVR was associated with RV dysfunction in patients with normal baseline 
function; attempts to minimise operative cross-clamp time may reduce adverse remodelling 
seen at 6 months. TAVI had no significant impact upon RV volumes or function. 
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4.2 Introduction 
SAVR was developed in the 1960s and remains first-line therapy for symptomatic patients with 
severe aortic valve stenosis. TAVI has emerged as a clinical and cost-effective treatment for 
patients deemed inoperable or with too high predicted postoperative mortality (Fairbairn et al., 
2013a). Reverse remodelling of the left ventricle observed following both TAVI and SAVR has 
been well documented (Fairbairn et al., 2013b, Clavel et al., 2010). However, much less is 
understood about the response of the right ventricle (RV) in these settings.  
 
RV dysfunction is thought to occur following cardiac surgery for both valvular (Carr-White et al., 
1999) and coronary disease (Pegg et al., 2008) and is an independent predictor of late survival 
and adverse clinical outcomes (Pinzani et al., 1993). The precise mechanism of this dysfunction 
remains to be elucidated but it is thought incising of the pericardium (and resultant impact upon 
ventricular coupling), RV contusion, ischaemia and impairment from cytokine release, and right 
atrial cannulation and subsequent use of an extracorporeal bypass circulation are integral to the 
pathophysiology. Indeed, a number of theories have been proposed based on conflicting 
evidence. The EuroSCORE II and the STS models for calculating operative mortality of cardiac 
surgery do not incorporate preoperative RV dysfunction despite its association with a high 
mortality (Kempny et al., 2012). This in part reflects the challenging nature of reliably evaluating 
RV performance (Wenaweser and O'Sullivan, 2012) with its asymmetric and variable 3D 
geometry, often compounded post-operatively by RV free wall adhesions. 
 
CMR is the established reference modality for imaging of both left and right ventricular volumes 
and function. CMR can image in any plane, has excellent blood-tissue contrast, can detect 
subtle wall motion abnormalities and has good reproducibility (Grothues et al., 2004). 
Furthermore, CMR can be used to quantify tricuspid annular plane systolic excursion (TAPSE). 
This offers invaluable insight into RV performance, which by the nature of its fibre orientation 
contracts predominantly longitudinally. This approach is thus an important tool and can identify 
abnormalities even when overall ejection fraction is normal. Given excellent atrial endocardial 
border definition, CMR has also been used to study atrial volume and function as a reflection of 
the duration and severity of diastolic dysfunction (Gulati et al., 2013). 
 
Studies directly comparing the impact of SAVR with TAVI upon RV function are limited (Kempny 
et al., 2012, Forsberg et al., 2011, Zhao et al., 2011) and have depended upon 2D transthoracic 
echocardiographic (TTE) parameters with relatively short follow-up. The primary aim of this 
study was to use CMR to compare the effect of TAVI and SAVR on RV performance at 6 
months. We hypothesised that SAVR, but not TAVI (which obviates the need of 
cardiopulmonary bypass and pericardiotomy), would be associated with decline in RV function. 
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Furthermore, we sought to elucidate potential mechanisms, by defining the contribution of 
procedural factors and CMR derived parameters to any observed change in RV performance. 
 
4.2 Methods specific to chapter 4 
4.2.1 Study population 
This study prospectively recruited 167 patients with severe AS (TTE valve area ≤1.0cm2 or peak 
velocity >4m/s) who were referred for either TAVI (n=101) or SAVR (n=66) at the University 
Hospitals of Leeds and Leicester, UK, between July 2008 and June 2014. Contemporary TAVI 
implantation criteria precluded a randomised. Higher-risk (higher EuroSCORE) SAVR patients 
were recruited in preference to ensure baseline demographics were more comparable to the 
TAVI group.  
 
4.2.2 Transcatheter Aortic Valve Implantation 
TAVI was performed under general anaesthesia. Either an 18F CoreValve Revalving system 
(CVR, Medtronic, Minneapolis, Minnesota, USA) or an 18F or 20F Lotus™ Aortic Valve system 
(Boston Scientific Corporation, Natick, MA, USA) were deployed as previously described 
(Piazza et al., 2008, Meredith et al., 2014).  
 
4.2.3 Surgical Aortic Valve Replacement 
SAVR was performed by standard midline sternotomy with cardiopulmonary bypass and mild 
hypothermia. Biological or mechanical prostheses of varying sizes were used according to 
surgical preference; CABG was performed as indicated.  
 
4.2.4 CMR Protocol 
For each individual patient, identical baseline preoperative and 6 month postoperative scans 
were performed on the same 1.5T MRI vendor platform (Intera, Phillips Healthcare, Best, 
Netherlands or Avanto, Siemens Medical Systems, Erlangen, Germany). Both sites used the 
identical CMR protocol as previously described (Fairbairn et al., 2013b). Details of the CMR 
pulse sequence acquisition protocol are outlined in the Standard Methods chapter (sections 
2.4.1, 2.4.2 and 2.4.5).   
 
4.2.5 CMR Image Analysis 
Quantification of LV and RV volumes and mass was performed blinded off-line, as detailed in 
section 2.5. Reproducibility was assessed using measurements of intra- and inter-observer 
variability and is detailed in section Table 2.1 of section 2.2.6. For patients in normal sinus 
rhythm, the atrial emptying fraction for both the left and right atrium was measured from a 4 
chamber SSFP cine image, using Equation 4-1.  
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Emptying Fraction = (maximum atrial area – minimum atrial area)*100 / maximum atrial area 
Equation 4-1 Calculation of atrial emptying fraction 
 
LV LGE images were analysed as detailed in the methods. For the purposes of Chapter 4, the 
RV was also assessed qualitatively for the presence or absence of fibrosis from short-axis and 
4-chamber delayed enhancement images. 
 
The tricuspid annular plane systolic excursion (TAPSE) was measured as the maximum apical 
displacement of the lateral tricuspid valve annulus. In the 4 chamber SSFP cine image, 
atrioventricular motion was measured at the lateral junction points between right atrium and 
right ventricle at end systole and end diastole. The perpendicular distance between these two 
points was measured (Figures 4.1A and B).  
 
Figure 4.1 Method for calculation of tricuspid annulus systolic plane excursion 
 
4.2.6 Statistical Analysis 
Based on published data, 45 patients per group were required to detect a 7ml change in 
RVEDV or 2% difference in EF between the two treatments (80% power and an α error of 0.05) 
(Grothues et al., 2004). Continuous variables are presented as mean±SD. Frequencies are 
reported as number (%). Normality was determined by the Shapiro–Wilk test. The Student t-test 
and Wilcoxon signed rank test were used for continuous variables. Changes over time were 
assessed for differences between the treatment groups and clinical variables by two-way 
repeated measures ANOVA. Predictors of functional change were calculated by a stepwise 
multiple linear regression model with baseline measurements entered as covariates. Variables 
with a univariate p<0.05 were deemed significant.  
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4.3 Results 
4.3.1 Patient population 
A total of 112 patients (56 TAVI and 56 SAVR) completed both preoperative and 6 month post-
operative scans. Of these, 100 were from Leeds and 12 from Leicester. Reasons for non-
completion of the CMR protocol were varied (Figure 4.2).  
 
 
 
Figure 4.2 Study profile 
 
Baseline characteristics of the final study population are reported in Table 4.1. For the TAVI 
group (n=56), 19(34%) were taking ACE inhibitors or ARB, 27(48%) β-blockers, 4(7%) 
spironolactone, 12(21%) calcium antagonists, 1(2%) α-blockers, 35(63%) statins and 28(50%) 
diuretics. For the SAVR group (n=56), 13(23%) were taking ACE inhibitors or ARB, 14(25%) β-
blockers, 7(13%) calcium antagonists, 31(55%) statins and 8(14%) diuretics. None were using 
α-blockers and only 1(2%) spironolactone.  
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Table 4.1 Patient characteristics and baseline echocardiographic data 
 
Characteristics SAVR (n=56) TAVI (n=56) p Value* 
Age 72.8 ± 7.2 80.4 ± 6.6 < 0.001 
Male gender, n (%) 38 (72%) 32 (57%) 0.12 
EuroSCORE II (%) 1.51 ± 0.91 5.84 ± 5.10 < 0.001 
STS Mortality (%) 2.13 ± 0.73  5.54 ± 3.41 < 0.001 
BMI (kgm-2) 27.6 ± 4.71 27.6 ± 3.81 0.98 
Previous MI, n (%) 7 (13) 11 (20) 0.31 
Previous PCI, n (%) 2 (4) 14 (25) 0.001 
Previous CABG, n (%) 0 (0) 16 (29) < 0.001 
Stroke/TIA, n (%) 8 (14) 10 (18) 0.61 
Peripheral vascular disease, n (%) 2 (4) 13 (23) 0.002 
Diabetes Mellitus, n (%) 11 (21) 11 (20) 0.89 
Hyperlipidaemia, n (%) 32 (60) 35 (63) 0.82 
COPD, n (%) 4 (8) 13 (23) < 0.001 
Atrial Fibrillation, n (%) 4 (8) 14 (25)  0.018 
eGFR (ml/min/1.73m2) 72.7 ± 13.5 63.7 ± 18.9 0.01 
AVA (cm2) 0.82 ± 0.4 0.60 ± 0.2 0.002 
Mean aortic valve PG (mmHg) 46 ± 13 52 ± 18 0.07 
Pulmonary Hypertension**, n (%) 8 (14) 16 (29) 0.05 
Moderate (31-55 mmHg), n (%) 6 (11) 10 (18)  
Severe (>55 mmHg), n (%) 2 (3) 6 (11)  
ValvuloArterial Impedance (Zva) 3.86 ± 1.0 3.76 ± 1.4 0.70 
Values are mean±SD or n (%). *p Value for comparison between TAVI and SAVR groups. 
Zva, valvuloarterial impedance (systolic arterial pressure + mean transvalvular gradient / stroke 
volume index). **Pulmonary hypertension defined as estimated pulmonary artery systolic 
pressure by transthoracic echocardiography to be >35mmHg 
 
The revascularisation status of the study patients is detailed in Table 4.2.  
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Table 4.2 Revascularisation status of study patients 
 
 SAVR (n=56) TAVI (n=56) 
Baseline    
No coronary disease 40 29 
Previous CABG 0 16 
LIMA to LAD  13 
SVG to LAD  3 
SVG to Cx  15 
SVG to RCA  12 
Previous PCI 2 14 
LMS  2 
LAD 1 4 
Cx 1 4 
RCA  7 
SVG  1 
 
SAVR Procedural CABG: 16 - 
LIMA to LAD 9 - 
SVG to LAD 2 - 
SVG to Cx 7 - 
SVG to RCA 5 - 
   
TAVI Procedural PCI - 1 (Cx) 
RWMA at baseline 8 15 
Anterior 2 6 
Septum 0 1 
Inferior 2 7 
Lateral 7 9 
 
 
TAVI patients were older, with a higher STS score and greater frequency of coronary 
intervention. There was no difference in baseline pulmonary artery systolic pressure, as 
estimated by echocardiography, between the two intervention groups (p=0.159).   
 
71 
 
4.3.2 Procedural data 
For the TAVI group, 46(82%) patients received a Medtronic CoreValve and 10(18%) a Boston 
Scientific Lotus valve. The femoral artery was the route of access for 51(91%) patients. Three 
TAVIs were performed via the subclavian artery, one via the carotid artery and one via a direct 
aortic approach. Procedural success was 100% with an average catheterisation time of 
162±53min, fluoroscopy time 25±7min and 147±50mls of contrast agent. One patient had 
concomitant PCI at the time of TAVI. 
 
For the surgical group, there was heterogeneity in respect of surgical intervention received; the 
prosthesis size and type being selected according to annulus size, patient characteristics, 
surgical and patient preference. Seven patients received a mechanical prosthesis and the 
remaining 49(88%) a tissue bioprosthesis. Sixteen (29%) received concomitant CABG, of which 
9 involved use of the left internal mammary artery. None of the surgical patients received a 
concomitant tricuspid or mitral valve annuloplasty ring and none underwent surgical closure of 
the pericardium. For the group as a whole, the average bypass time was 104±47min and cross 
clamp time 76±40min. The average length of stay in intensive care was 3.1±2.5 days. 
 
4.3.3 Haemodynamics, valvular function and LV reverse remodelling 
 
Baseline and follow-up CMR scan results are shown in Table 4.3.  
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Table 4.3 Preoperative baseline measurements and postoperative changes in the 
two procedural groups  
  SAVR TAVI p Value† 
 Baseline 6 months Baseline 6 months  
Haemodynamics      
Heart Rate (bpm) 64±11 65±12 66±11 67±14 0.950 
Systolic BP (mmHg) 131±22 132±20 127±27 134±25 0.316 
Diastolic BP (mmHg) 73±10 71±11 64±10 65±10 0.257 
 
Valves    
AV peak PG (mmHg)†† 56±19 29±13*** 53±15 23±11*** 0.485 
AR fraction (%) 19±17 10±10** 17±12 8±7*** 0.932 
MR fraction (%) 13±14 6±9** 26±17 16±19** 0.445 
 
Left Ventricle    
EDVI (ml/m2)  90±26 74±13*** 96±23 87±20** 0.09 
ESVI (ml/m2) 43±22 31±9*** 48±24 42±17** 0.06 
LVEF (%)  54±11 58±8** 52±13 53±11 0.098 
Mass Index (g/m2) 77±24 61±16*** 80±20 67±18*** 0.694 
LVM/LVEDV (g/ml) 0.88±0.2 0.85±0.2 0.86±0.2 0.79±0.2** 0.224 
 
Right Ventricle    
EDVI (ml/m2)  78±17 78±16 80±18 77±19 0.334 
ESVI (ml/m2) 33±10 37±10** 40±15 38±14 0.005 
RVEF (%)  58±8 53±9** 52±10 52±10 0.013 
Mass Index (g/m2) 15±4 15±4 15±5 13±4** 0.259 
RVM/RVEDV (g/ml) 0.21±0.07 0.20±0.07 0.20±0.08 0.18±0.06** 0.499 
TAPSE (mm) 22±5 14±3*** 19±6 19±7 0.001 
Paired t test vs baseline: *p<0.05, **p<0.01, ***p<0.001. † Independent samples t-test to 
compare degree of change seen following SAVR with that seen following TAVI.  †† Derived from 
MRI assessment.  
 
Comparable degrees of reduction in aortic valve gradient and LV reverse remodelling were 
seen following TAVI and SAVR.  
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A significant decline in the RA emptying fraction was seen following SAVR (baseline 34.7±8.7% 
vs. 6m 25.5±9.7%, p<0.001) and increase following TAVI (baseline 31.6±10.8% vs. 6m 
35.7±12%, p=0.009). No change in LA emptying fraction was seen following SAVR (baseline 
48.5±12.8% vs. 6m 48.7±9.1%, p=0.945) but a significant improvement occurred following TAVI 
(baseline 36.9±12.6% vs. 6m 43.4±10.4%, p=0.011). 
 
4.3.4 Impact of intervention upon Right Ventricular size and function 
No difference existed between the groups’ preoperative indexed measurements of right 
ventricular EDV (p=0.547) or mass (p=0.462). Although both groups had preserved RV systolic 
function, the baseline RV ejection fraction (p=0.001) and TAPSE (p=0.026) were significantly 
higher in the SAVR group. SAVR, but not TAVI, was associated with a statistically significant 
decrease in RV ejection fraction with a concomitant increase in indexed RVESV at 6 months. 
Similarly post-operative SAVR TAPSE values were significantly lower than the TAVI group 
(p<0.001). The effect of intervention upon RV mass at 6 months was comparable between the 
two groups (p=0.259).  
 
4.3.5 Late Gadolinium Enhancement  
LGE imaging was performed in all but three TAVI patients, in whom renal impairment was 
prohibitive. For the TAVI group, 26(49%) had mid-wall/patchy LV fibrosis and 8(15%) prior 
myocardial infarction prior to intervention. Only 3(6%) patients had RV hyper-enhancement at 
baseline with no new cases seen at 6 months. For the SAVR group, 18(32%) had 
midwall/patchy LV fibrosis and 7(13%) had evidence of previous myocardial infarction. Only two 
SAVR patients had RV fibrosis at baseline and 4 (7%) had new hyper-enhancement at 6 
months. No change in total quantity of scar (% LV myocardium) was seen following SAVR (2.4 
vs 2.3%, p=0.759) or TAVI (3.1 vs 3.6%, p=0.795). In the subgroup of SAVR patients without 
baseline LV scar (n=31(55%)), no significant change was seen in RVEF post-operatively 
(56.9±7.8% vs. 53.0±8.8%, p=0.071). 
 
4.3.6 Demographic and procedural risk factors associated with RV functional decline  
Table 4.4 shows the results of univariate regression analyses of clinical and CMR variables 
associated with change in RV indices. Surgical cross clamp time statistically was the only factor 
significantly associated with an increase in RVESV index in the SAVR group at follow up. 
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Table 4.4 Univariate regression analysis of clinical and CMR variables for the 
identification of factors associated with change in RV volume / function indices 
 Univariate analysis  
Variables B Coefficient±SE R2 95% CI p Value 
RVESVI (ml/m2)  
Concomitant CABG -3.86±2.87 0.035 -9.6 to 1.88 0.185 
Bypass time  0.05±0.03 0.066 -0.01 to 0.11 0.059 
Cross Clamp time 0.07±0.03 0.088 0.01 to 0.13 0.028 
Mechanical SAVR 5.93±3.63 0.048 -1.33 to13.19 0.108 
Pulmonary Hypertension -3.31±3.28 0.019 -9.87 to 3.25 0.318 
COPD 2.80±4.73 0.006 -6.66 to 12.26 0.556 
RVEF (%)  
Concomitant CABG 5.83±3.39 0.056 -0.95 to12.61 0.091 
Bypass time -0.03±0.03 0.014 -0.09 to 0.03 0.387 
Cross Clamp time -0.05±0.04 0.028 -0.13 to 0.04 0.221 
Mechanical SAVR -5.08 ± 4.36 0.025 2.94 to -13.8 0.249 
Pulmonary Hypertension -4.52±3.55 0.030 -11.62 to 2.58 0.209 
COPD -4.08±5.75 0.010 -15.58 to 7.42 0.481 
TAPSE (mm)  
Concomitant CABG 0.61±1.74 0.003 -2.87 to 4.09 0.729 
Bypass time 0.01±0.02 0.007 -0.03 to 0.05 0.610 
Cross Clamp time 0.01±0.02 0.009 -0.03 to 0.05 0.560 
Mechanical SAVR -3.28±2.25 0.054 -7.78 to 1.17 0.154 
Pulmonary Hypertension 0.23±2.37 0.000 -4.51 to 4.97 0.924 
COPD 2.20±2.81 0.017 -3.42 to 7.82 0.438 
Each parameter had a separate regression analysis performed.  
4.3.7 Association between RV indices and outcome 
Over a maximum 6.3y follow up (median 2.8yrs); there were 19 deaths (all-cause mortality) out 
of the 112 patients that completed 6 month follow-up imaging. Of the 56 TAVI patients, 18 
(32%) died compared to only 1 (1.7%) from the SAVR group (p=0.001). For the TAVI group, 
there was a significant association between RV mass index at 6 months and all-cause mortality 
(B 0.306±0.104, p=0.003). This is presumably a reflection of worse outcome in those with right-
sided pressure overload from more significant underlying pulmonary disease, despite having 
received TAVI and restoration of aortic valve haemodynamics. 
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4.4 Discussion  
This prospective two centre study of the right ventricle in aortic stenosis has shown that SAVR 
resulted in deterioration in RV systolic volumes and function, associated with longer surgical 
cross-clamp times. In contrast, RV volumes and systolic function were preserved following 
TAVI. 
The prognostic importance of the right ventricle and its contribution to exercise capacity in a 
number of cardiac conditions is well recognised (Tamborini et al., 2009). Recently it has been 
demonstrated that RV dysfunction is independently associated with reduced late survival after 
left heart valve surgery (Kammerlander et al., 2014). There have been inconsistent findings 
from studies assessing RV function post-TAVI, in part due to the variety of echocardiographic 
definitions for systolic function being used (Forsberg et al., 2011, Zhao et al., 2011, Quick et al., 
2013). This is in contrast to patients receiving SAVR where an early decline in RV ejection 
fraction appears ubiquitous (Kempny et al., 2012). 
 
TAPSE has been the principal measurement studied in this context. However, TAPSE 
assessment maybe insensitive to global RV performance and is confounded by paradoxical 
interventricular septal motion, and particularly following SAVR, thoracic wall pericardial 
adhesions. Furthermore, TAPSE is an insensitive marker of RVEF unless it falls below 35% 
(Nijveldt et al., 2008). Even 3D echo can systematically underestimate RV volumes (Crean et 
al., 2011). CMR is considered the reference investigation for RV morphological and functional 
assessments. It is reproducible and permits unrestricted imaging of the RV that is variable in 
configuration and difficult to define geometrically using ultrasound.  
 
We have demonstrated using CMR that there is no change in RV volumes or ejection fraction at 
6 months following TAVI. SAVR on the other hand is associated with a significant increase in 
RV end systolic volume, preserved end diastolic volume and overall reduction in ejection 
fraction. Consistent with this observation was a significant reduction in TAPSE.   
 
CMR has previously been used to assess RV function in a comparison between off-pump and 
on-pump techniques for CABG (Pegg et al., 2008). CABG was associated with a significant 
reduction in RV function 6 days post-operatively which normalised by 6 months. This was 
independent of surgical technique and thus not compounded by the use of a cross-clamp or 
cardiopulmonary bypass. The early decline was due to a decrease in the RV end diastolic 
volume, with the indexed RV end systolic volume remaining unchanged. Our surgical group was 
on average ten years older than the previously studied CABG cohort with a larger baseline 
RVESVi. Furthermore, there was no change in indexed LV volumes or mass seen in the CABG 
studies (Pegg et al., 2008). This is very different to the reverse remodelling seen post-SAVR 
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(Fairbairn et al., 2013b) and together suggests our SAVR cohort and the CABG group are not 
directly comparable. 
 
Our study has uniquely combined CMR volumetric RV analysis with the measurement of 
TAPSE as part of a comprehensive assessment of systolic function. TAPSE measurement 
disregards RV dimensions and is less sensitive to subtle RV changes (Nijveldt et al., 2008). 
This is an important limitation to relying on TAPSE alone to assess treatment response. Our 
observed combined reduction in both TAPSE and volumetric ejection fraction following SAVR, 
and not TAVI,  implies SAVR confers a genuine functional decline in RV systolic function, and 
not merely a geometric change post-operatively, such as that described following mitral valve 
surgery (Tamborini et al., 2009). 
 
Contrary to our findings, a recent study using CMR reported a significant acute decline (mean 
4.7±4 days) in RV function following TAVI, possibly mediated through paravalvular aortic 
regurgitation, whereas no change in RV function was observed following bioprosthetic SAVR 
(Crouch et al., 2015a). The different timings of the post-procedure CMR scan may account for 
this observed difference, as in our study repeat CMR was performed at 6 months so that we 
could study the effect of reverse remodelling on both ventricles. The preservation of RV systolic 
function in this study early following SAVR is of interest given their surgical operative times 
were notably shorter than ours, which supports our observation that cardiopulmonary bypass 
time may be an important factor that influences post-operative RV function. However their study 
does differ from others, albeit based on echocardiography, that have reported early 
preservation of RV function following TAVI (Zhao et al., 2011, Puentes et al., 2012, Quick et al., 
2013, Ayhan et al., 2014, Keyl et al., 2015) and early deterioration following SAVR (Quick et al., 
2013, Keyl et al., 2015, Forsberg et al., 2011, Okada et al., 2014).  
 
Our findings allow us to consider further the pathophysiology of RV deterioration observed 
following SAVR which remains poorly understood. In our study, LA emptying fraction did not 
change, mitral regurgitation decreased and LV ejection fraction improved 6 months following 
SAVR. These findings strongly suggest the pathophysiology of RV systolic decline post SAVR 
is independent of left heart function.  
 
Our study indicates the increase in RVESV following SAVR is statistically associated with 
longer aortic cross clamp times at surgery. This is a new, previously undescribed observation. 
Prolonged cardiopulmonary bypass time is associated with increased mortality and morbidity 
(Salis et al., 2008). Longer cross-clamp times are associated with a greater risk of myocardial 
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ischaemia (Liakopoulos et al., 2010) and raised biomarkers of myocardial damage (Chalmers et 
al., 2014).  
 
Tissue characterisation is a pivotal and unique strength of CMR. However, the thin RV wall, 
susceptibility to artefact and close association with pericardial fat are all limitations to LGE 
assessment. Nonetheless, we detected new infarction in only 7% of patients. This is, to our 
knowledge, the first study to utilise LGE in the assessment of RV response to surgery. Our 
findings suggest the decline in RV function we observed following SAVR is not fully explicable 
by suboptimal RV protection during cardiopulmonary bypass. The lack of association with 
bypass grafting at the time of surgery is also consistent with a process unrelated to epicardial 
coronary disease.  
 
It is noteworthy that RV dysfunction post operatively is an adverse prognostic marker (Pinzani 
et al., 1993) and in a small study, patients without LV LGE had no 30-day MACCE events and 
no deaths up to 2 years following SAVR (Quarto et al., 2012). In our patients without baseline 
hyperenhancement, SAVR was not associated with a change in RV ejection fraction at 6 
months. Further work is needed to investigate the potential role CMR in risk stratifying patients 
that are potentially most susceptible to RV deterioration following aortic valve surgery. 
 
Incision of the pericardium has been suggested as the principal factor responsible for RV 
deterioration post-cardiac surgery (Unsworth et al., 2013). A significant decline in RV systolic 
tissue Doppler velocity occurs within minutes and is sustained, possibly through alterations in 
pericardial constraint and subsequently RV geometry (Unsworth et al., 2014). Our findings of 
RV preservation following TAVI which obviates any pericardial insult, supports this hypothesis. 
Alternatively, a reduction in myocardial strain of the right atrium may confer a reduction in RV 
inlet long-axis systolic function post-SAVR (Zhao et al., 2011). In experimental canine models, 
selective RA ischemic injury increases RV free wall dyskinesia (Goldstein et al., 1991). The 
significant decline in RA emptying fraction following SAVR, and not TAVI, is likely a sequela to 
traumatic surgical venous cannulation and may contribute to the RV systolic decline observed 
at 6 months. 
 
Previous studies demonstrating an early decline in RV function following cardiac surgery have 
implicated an increase in pulmonary vascular resistance (Pegg et al., 2008). It is conceivable 
that such an increase in afterload could mediate RV dysfunction through end systolic cavity 
dilatation. The use of mechanical ventilation, anaesthesia and pro-inflammatory cytokines have 
all been implicated (Honkonen et al., 1997). However, pulmonary vascular resistance is thought 
to normalize soon after surgery and thus unlikely to fully explain our findings at 6 months (Kwak 
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et al., 2004). Furthermore, cross-clamping of the thoracic aorta significantly increases mean 
pulmonary arterial and pulmonary capillary wedge pressures (Kouchoukos et al., 1979). Canine 
models suggest this is mediated through blood volume redistribution and increased afterload 
(Stokland et al., 1980). Such an afterload mismatch may contribute to the increased RVESV 
observed at 6 months and underscore the influence of aortic cross-clamp time at surgery. 
 
4.4.1 Study Limitations 
Our study is not randomised and baseline differences in demographics between our study 
groups are unavoidable due to current TAVI implantation guidelines.  
 
The higher mortality in the TAVI group may have a confounding effect, potentially excluding 
patients with worse cardiac function from the analysis. There was statistically no difference in 
the STS score between the included 56 TAVI patients and those that withdrew/died (n=18) 
(5.54±3.4% vs. 5.28±3.82%, p=0.791). Furthermore, RV function at baseline as assessed by 
CMR, was also equivalent between these two groups.  
 
Our study did not include patients undergoing trans-apical TAVI. CMR assessment of trans-
apical TAVI and its impact upon RV function is warranted to help clarify whether this approach 
might be less favourable in patients with pre-existing RV dysfunction given the procedural 
interruption of the pericardium. 
 
Image analysis occurred oblivious to patient details which helped to eliminate bias for pre-
operative images. However, post-operative scans inherently appeared different for those with 
and without sternotomy and thus analysis of 6 month images could not truly be blinded. 
Furthermore, the heterogeneity in the surgical group in particular may have affected results 
given that mechanical and bioprosthetic valves with and without concomitant bypass grafting all 
pose different surgical considerations and procedure duration. However this data does reflect 
clinical practice. 
 
The requirement for permanent pacing, particularly post TAVI, is a recognised phenomenon 
likely to result from trauma to degenerative conduction tissue during valvuloplasty. We have not 
been able to address the impact of pacing upon RV function in the post-intervention setting 
which is an important and relevant issue in clinical practice. 
 
This present work has not measured LVEDP pre- and post-SAVR and TAVI and this merits 
attention in future work to determine any contribution of filling pressures towards RV 
performance.  
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We have not assessed the impact of tricuspid regurgitation (TR) quantified by CMR upon the 
changes in RV function seen. The standard method to quantify TR using CMR requires an 
additional acquisition of flow through the pulmonary valve (subsequently deducting forward flow 
being from the RV stroke volume to derive TR volume). For the purposes of this research, 
pulmonary valve assessment was not a component of the protocol. However, in an attempt to 
account for TR, baseline and follow-up echo imaging was assessed. Based on qualitative 
echocardiography (grading TR as none, mild, moderate or severe), no significant change in 
degree of tricuspid regurgitation was seen following TAVI (average interval of 5 months, 
p=0.144) nor SAVR (average interval of 6 months, p=0.819). We can infer from this that 
deterioration in RV systolic function is not likely to have been related to post-operative tricuspid 
regurgitation. The recent suggestion that RV dysfunction, and not significant TR, is 
independently associated with survival late following a left heart valve operation is noteworthy in 
this regard (Kammerlander et al., 2014).  
 
4.5 Conclusion 
SAVR, but not TAVI, resulted in RV dysfunction that was associated with longer aortic cross 
clamp times. Further work is needed to determine whether reduction in cross clamp times can 
preserve RV function following SAVR, and whether TAVI may be the preferable intervention in 
patients with pre-existing RV dysfunction. Assessment of both left and right ventricular function 
by CMR may be clinically important when making treatment decisions for high-risk patients with 
severe aortic stenosis.  
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Chapter 5. CMR evaluation following TAVI and SAVR for symptomatic 
severe aortic stenosis: association of myocardial strain and mortality 
 
5.1 Abstract 
Background: It is unknown whether circumferential strain is associated with prognosis after 
treatment of aortic stenosis (AS). We aimed to characterise strain in severe AS, using 
myocardial tagging cardiovascular magnetic resonance (CMR), prior to and following 
Transcatheter Aortic Valve Implantation (TAVI) and Surgical Aortic Valve Replacement (SAVR), 
and determine whether abnormalities in strain were associated with outcome. 
 
Methods and Results: CMR was performed pre- and 6m post-intervention in 98 patients (52 
TAVI, 46 SAVR; 77±8years) with severe AS. TAVI patients were older (80.9±6.4 vs. 
73.0±7.0years, p<0.01) with a higher STS score (2.06±0.6 vs. 6.03±3.4, p<0.001). Tagged cine 
images were acquired at the basal, mid and apical LV levels with a complementary spatial 
modulation of magnetization (CSPAMM) pulse sequence. Circumferential strain, strain rate and 
rotation were calculated using inTag© software. No significant change in basal or mid LV 
circumferential strain, or of diastolic strain rate, was seen following either intervention. However, 
a significant and comparable decline in LV torsion and twist was observed (SAVR: torsion 
14.08±8.40 vs. 7.81±4.51, p<0.001, twist 16.17±7.01 vs.12.45±4.78, p<0.01; TAVI: torsion 
14.43±4.66 vs. 11.20±4.62, p<0.001, twist 16.08±5.36 vs. 12.36±5.21, p<0.001). Over a 
maximum 6.0y follow up, there were 23 (16%) deaths following valve intervention. On 
multivariable Cox analysis, baseline mid LV circumferential strain was significantly associated 
with all-cause mortality (hazard ratio, 1.03; 1.01 – 1.05; p=0.009) independent of age, LV 
ejection fraction and STS mortality risk score.  ROC analysis indicated a mid LV circumferential 
strain > -18.7% was associated with significantly reduced survival.  
 
Conclusion: TAVI and SAVR procedures are associated with comparable declines in rotational 
LV mechanics at 6m, with largely unchanged strain and strain rates. Pre-operative peak mid LV 
circumferential strain is associated with post-operative mortality. 
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5.2 Introduction 
 
The LV responds to pressure overload from aortic stenosis with hypertrophy to offset increased 
wall stress, in accordance with Laplace’s law (Ozkan et al., 2011). This involves adverse 
remodelling of the extracellular matrix and altered protein composition which initially leads to a 
regional reduction in myocardial deformation, with global impairment in contraction occurring 
later (Kaden et al., 2003).  
  
Myocardial strain, strain rate and twist allow more sensitive characterisation of subtle 
myocardial performance (Wang et al., 2013) and can all be objectively quantified using 
myocardial tagging CMR with proven reproducibility (Swoboda et al., 2014, Singh et al., 2015). 
The myocardium deforms simultaneously in 3 directions and strain measurements can detect 
pathology prior to decline in conventional indices such as ejection fraction (Galli et al., 2014). 
Patients with preserved cardiac output and severe AS reportedly exhibit compensatory high 
circumferential strain with increased apical rotation which are lost with decompensation of LV 
function (Carasso et al., 2011).  
 
Current guidelines recommend aortic valve replacement with the onset of symptoms or cardiac 
dysfunction (LVEF<50%) (Vahanian et al., 2012). However, impaired LVEF is a late change 
indicating significant myocardial damage and poorer outcomes, even after correction of AS 
(Vaquette et al., 2005). It is notable LVEF is normal in most patients with severe AS, even when 
symptoms develop and that valve area and transvalvular gradients do not predict clinical 
outcomes following AVR (Hachicha et al., 2007). The prognostic importance of circumferential 
myocardial strain in particular on outcome after treatment of aortic stenosis is unknown. 
 
The aims of this study were to 1) characterise LV systolic and diastolic function as measured by 
CMR tagging in patients with severe symptomatic aortic stenosis prior to and following TAVI 
and SAVR, and 2) to assess whether CMR measures of strain could hold prognostic importance 
in those undergoing intervention. 
 
5.3 Methods specific to chapter 5 
5.3.1 Study Population 
146 patients were prospectively recruited with severe AS who were referred for either TAVI 
(n=91) or SAVR (n=55) at the University Hospitals of Leeds and Leicester, UK, between July 
2008 and March 2014. The duration of follow-up ranged from the initial CMR to July 2014. 
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Outcomes assessment was based on determining all-cause mortality, confirmed by consulting 
patient summary care records on the NHS Spine Portal.  
 
5.3.2 Transcatheter Aortic Valve Implantation 
TAVI was performed under general anaesthesia. Either an 18F CoreValve Revalving system 
(CVR, Medtronic, Minneapolis, Minnesota, USA) or an 18F or 20F Lotus™ Aortic Valve system 
(Boston Scientific Corporation, Natick, MA, USA) were deployed as previously described 
(Piazza et al., 2008, Meredith et al., 2014). A transfemoral route was used preferentially when 
vascular access was suitable. In the presence of significant peripheral vascular disease, a 
subclavian artery approach was performed. The invasively measured LV end diastolic pressure 
was recorded from procedural details. 
 
5.3.3 Surgical Aortic Valve Replacement 
SAVR was performed by standard midline sternotomy with cardiopulmonary bypass and mild 
hypothermia. Biological or mechanical prostheses of varying sizes were used according to 
surgical preference; concomitant coronary artery bypass grafting was performed as indicated.  
 
5.3.4 CMR Protocol 
For each patient, identical preoperative and 6m postoperative scans were performed on the 
same 1.5T MRI vendor platform (Intera, Phillips Healthcare, Best, Netherlands or Avanto, 
Siemens Medical Systems, Erlangen, Germany). Both sites used the identical CMR protocol as 
previously described (Fairbairn et al., 2013b). Details of the CMR pulse sequence acquisition 
protocol are outlined in the Standard Methods chapter (sections 2.4.1, 2.4.2, 2.4.4 and 2.4.5).  
 
5.3.5 Image Analysis 
CSPAMM analysis was performed for each myocardial slice using a dedicated tagging analysis 
package (inTag© software, Creatis, Lyon, Fr). Endocardial and epicardial contours were drawn 
for each slice, and a mid-myocardial contour was automatically calculated; contours were 
propagated through all cardiac phases. Strain is defined as an index that refers to the amount of 
myocardial deformation in one direction normalised to its initial dimension. Strain rate is the rate 
of deformation within in a time unit (Ozkan et al., 2011, Wang et al., 2013). Circumferential 
Lagrangian strain and strain rates (between epicardial and endocardial contours) and rotation 
were calculated for the three short axis slices. Left ventricular twist was determined as the 
difference between rotation at the apex and rotation at the base. Torsion was calculated as twist 
corrected for by length and radius of the LV cavity (Figure 5.1). 
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Figure 5.1 Directions and quantification of myocardial fibre deformation 
A. Schematic representation of circumferential, radial and longitudinal strain demonstrating their 
directions of motion. 
B. Schematic representation of basal clockwise and apical counter-clockwise rotation during 
systole. The images below show apical, mid LV and basal slices (from left to right) tagged with 
CSPAMM, with endocardial, mid myocardial and epicardial contours drawn, (LV radius and 
length measurements derived from cine imaging). 
 
5.3.6 Statistical Analysis 
Continuous variables are presented as mean±SD. Normality was determined by the Shapiro–
Wilk test. Frequencies are reported as number (%). Changes over time were assessed for 
differences between the treatment groups and clinical variables by two-way repeated measures 
analysis of variance (ANOVA). Cox proportional-hazards ratio regression analyses were 
performed to investigate univariate and multivariate correlates of all-cause mortality. Hazard 
ratios and 95% confidence intervals (CIs) were reported. Variables with univariate p<0.05 were 
entered in the multivariate analysis in a stepwise forward approach. Receiver operating 
characteristic (ROC) curves were constructed to assess the sensitivity and specificity predictor 
variables. The cumulative event rates were calculated on the basis of the Kaplan-Meier method, 
and comparisons between groups were assessed by log-rank test. All statistical analyses were 
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performed using the PASW software package (V.21.0 SPSS, IBM, Chicago, Illinois, USA) with 
the exception of ROC analysis that was performed with MedCalc version 9.3.1 (MedCalc 
Software, Mariakerke, Belgium). A two-sided significance level of p<0.05 was considered 
statistically significant.  
 
5.4 Results  
Ninety-eight patients (52 TAVI, 46 SAVR) with paired pre-operative and 6m post-operative CMR 
scans were included for analysis. Reasons for non-completion of the CMR protocol were varied 
and are depicted in Figure 5.1.  
 
 
Figure 5.2 Study profile 
At baseline, 15 patients did not undergo LGE imaging due to impaired renal function. Baseline 
characteristics of the study population are shown in Table 5.1 and grouped according to 
treatment received. As expected the TAVI group were older with a higher predicted 30 day 
mortality and greater frequency of prior coronary artery intervention.  
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Table 5.1 Patient characteristics and baseline echocardiographic data 
 
Characteristics SAVR (n=46) TAVI (n=52) p Value* 
Age 73.0 ± 7.0 80.9 ± 6.4 < 0.001 
Male gender, n (%) 34 (74) 28 (54) 0.041 
STS Mortality (%) 2.06 ± 0.6 6.03 ± 3.4 < 0.001 
BMI (kgm
-2
) 27.5 ± 4.4 27.0 ± 3.8 0.709 
Previous MI, n (%) 6 (13) 9 (17) 0.560 
Previous PCI, n (%) 1 (2) 14 (27) 0.001 
Previous CABG, n (%) 1 (2) 17 (33) < 0.001 
Stroke/TIA, n (%) 6 (13) 8 (15) 0.742 
Peripheral vascular disease, n (%) 1 (2) 10 (19) 0.008 
Hypertension 32 (70) 25 (48) 0.032 
Diabetes Mellitus, n (%) 7 (15) 10 (19) 0.602 
Hyperlipidaemia, n (%) 23 (50) 31 (60) 0.342 
COPD, n (%) 4 (9) 12 (23) 0.056 
Atrial Fibrillation, n (%) 3 (7) 15 (29) 0.005 
eGFR (ml/min/1.73m
2
) 73.3 ± 13.8 59.8 ± 18.9 < 0.001 
AVA (cm
2
) 0.83 ± 0..46 0.59 ± 0.17 < 0.001 
Mean aortic valve PG (mmHg) 46.9 ± 13.4 53.2 ± 19.2 0.102 
Pulmonary Hypertension**, n (%)
 
7 (15) 15 (29) 0.110 
ValvuloArterial Impedance (Zva) 3.73 ± 0.99 3.71 ± 1.09 0.734 
Values are mean±SD or n(%). *p Value for comparison between TAVI and SAVR groups. 
**Pulmonary hypertension defined as estimated pulmonary artery systolic pressure by 
transthoracic echocardiography to be >35mmHg.  
Zva, valvuloarterial impedance (systolic arterial pressure + mean transvalvular gradient / stroke 
volume index).  
 
For the TAVI group (n=52), 16(31%) were taking ACE inhibitors or ARB, 25(48%) β-blockers, 
4(8%) spironolactone, 11(21%) calcium antagonists, 1(2%) α-blockers, 33(63%) statins and 
25(48%) diuretics. For the SAVR group (n=46), 8(17%) were taking ACE inhibitors or ARB, 
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9(20%) β-blockers, 5(11%) calcium antagonists, 24(52%) statins and 5(11%) diuretics. None 
were using spironolactone and only 1(2%) α-blockers. 
 
5.4.1 Procedural data  
Procedural data are summarised in Table 5.2. For TAVI, 40(77%) patients received a Medtronic 
CoreValve and 12(23%) a Boston Scientific Lotus valve. A 29mm valve was the most frequently 
used size (n=26, 50%). In the surgical group, six patients received a mechanical prosthesis and 
the remaining 40(87%) a tissue bioprosthesis from various manufacturers. The modal valve size 
was 23mm (n=17, 37%). Twelve (26%) patients received concomitant coronary bypass grafting. 
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Table 5.2 Procedural and operative data 
  n (%) 
TAVI   
Medtronic CoreValve size (n=43) 31mm 2 (5) 
 29mm 28 (65) 
 26mm 9 (21) 
 23mm 3 (7) 
Boston Lotus size (n=9) 23mm 
27mm 
3 (33) 
6 (67) 
Vascular access  Femoral 48 (92) 
 Subclavian 4 (8) 
Procedure-time, (min)  15652 
Fluoroscopy-time, (min)  257 
Contrast volume, (ml)  15049 
SAVR   
Biological, n (%)  40 (87) 
Mechanical, n (%)  6 (13) 
Size, (mm)(median, range)  23 (18–30) 
Bypass-time, (mean±SD) 
 
All  
SAVR only 
SAVR and CABG 
10549 
9650 
13238 
Cross-clamp-time, (mean±SD) All  
SAVR only 
SAVR and CABG 
7843 
7346 
9127 
CABG, n (%)                                  All 
LIMA 
12 (26) 
6 (13) 
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5.4.2 Aortic Valve Haemodynamics and LV reverse remodelling 
Results of the baseline and 6m CMR scans are shown in Table 5.3. Significant reductions in 
peak aortic valve pressure gradient resulted in comparable reverse remodelling post-SAVR and 
TAVI; with reductions in both indexed LV EDV and mass. 
 
Table 5.3 Preoperative baseline measurements and postoperative changes in the 
separate procedural groups. 
 SAVR TAVI p Value† 
 Baseline 6 months Baseline 6 months  
Haemodynamics 
Heart Rate (bpm) 63±9 64±12 67±12 68±15 0.952 
Systolic BP (mmHg) 136±21 133±20 133±25 137±23 0.200 
Diastolic BP (mmHg) 75±10 72±11 66±10 65±9 0.265 
 
Valvular Function 
Aortic Peak PG (mmHg)†† 52±18 30±13*** 52±16 22±13*** 0.072 
MR fraction (%) 20±18 8±10** 26±16 16±16** 0.514 
 
Left Ventricle 
EDVI (ml/m2)  94±25 76±13*** 94±21 88±20** 0.023 
LVEF (%)  58±12 61±11* 52±11 54±11 0.403 
Mass Index (g/m2) 76±22 61±16*** 79±21 66±18*** 0.691 
LVM/LVEDV (g/ml) 0.82±0.2 0.81±0.2 0.86±0.2 0.77±0.2*** 0.041 
 
Peak Circumferential strain  
Base (%) 
-19.8 ± 5.2 -18.6 ± 4.9 -17.6 ± 5.8 -18.5 ± 5.8 0.03 
Mid (%) 
-21.1 ± 5.3 -20.0 ± 4.3 -19.3 ± 6.1 -19.8 ± 6.5 0.158 
Apex (%) 
 -20.0 ± 6.4 -17.5 ± 6.8** -18.8 ± 6.7 -18.8 ± 6.0 0.054 
 
Peak mid-ventricular strain rate 
Systolic (S
-1
) 
-0.032 ± 
0.010 
-0.034 ± 0.009 -0.029 ± 0.008 -0.032 ± 0.007** 0.188 
Diastolic (S
-1
) 
0.028 ± 
0.016 
0.028 ± 0.018 0.022 ± 0.015 0.023 ± 0.014 0.653 
 
LV torsion 
14.08 ± 8.40 7.81 ± 4.51*** 14.43 ± 4.66 11.20 ± 4.62*** 0.094 
LV twist (°) 
16.17 ± 7.01 12.45 ± 4.78**  16.08 ± 5.36 12.36 ± 5.21*** 0.999 
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5.4.3 Measures of strain by CMR 
At baseline, both groups undergoing SAVR and TAVI had comparable LV circumferential strain 
of the base (p=0.081) mid (p=0.128) and apex (0.318) with overall preserved LV ejection 
fraction. Similarly LV torsion (p=0.845) and twist (p=0.879) were comparable between groups. 
However, both systolic (p=0.039) and diastolic (p=0.037) strain rates were higher in the SAVR 
group. 
 
At baseline for the TAVI group, there was moderate correlation between increasing LV end 
diastolic pressure (measured invasively during TAVI implantation) and both a deterioration in 
peak basal circumferential strain (r=0.4, n=33, p=0.04, two-sided) and diastolic peak mid-
ventricular strain rate (r=-0.5, n=33, p=0.003, two-sided).  
 
No significant change in basal or mid-LV circumferential strain or of diastolic strain rate was 
seen following intervention, either post-SAVR or TAVI. A significant decline in peak apical 
circumferential strain following SAVR and an increase in circumferential systolic strain rate 
following TAVI were noted. 
 
Both SAVR and TAVI were associated with a significant and comparable decline in LV twist and 
torsion at 6 months following intervention (Figure 6.2). 
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Figure 5.3 Change in twist and mid-LV circumferential strain 
Twist pre and post-SAVR (A) and pre and post-TAVI (B). 
Circumferential strain pre and post-SAVR (C) and pre and post-TAVI (D). 
 
Analysing the total severe AS patient population (n=98), no change in LV strain at any level was 
seen following aortic valve intervention (Base: -0.186±0.056 vs. -0.186±0.054, p=0.961; Mid: -
0.201±0.058 vs. -0.199±0.006, p=0.714; Apex: -0.194±0.065 vs. -0.182±0.064, p=0.05). 
 
5.4.4 Predictors of Mortality following Intervention 
Over a maximum 6.0y follow up (median 2.5yrs); there were 23 deaths (all-cause, of which 14 
had completed follow-up imaging). Stepwise logistic regression identified a number of 
demographics and measures of cardiac function that were associated with mortality. Notably, 
the presence of baseline myocardial fibrosis (detected by LGE imaging), indexed LV mass, 
mean aortic pressure gradient and history of myocardial infarction were not significantly 
associated with prognosis. In multivariate analysis, baseline mid LV circumferential strain 
remained independently associated with all-cause mortality (Table 6.4).  
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Table 5.4 Cox proportional hazard analysis for prediction of all-cause death 
following valve intervention 
 
ROC analysis indicated the optimal threshold for pre-procedure mid LV circumferential strain to 
be -18.7%, from which a Kaplan-Meier graph was derived (Figure 5.4). 
 
 
 
 
 
Variable Univariate analysis                                         
Multivariate analyisis 
 
 Hazard ratio (95% CI) 
 
p-Value Hazard ratio (95% CI) p-Value 
Age (per year) 
 
1.125 (1.043 – 1.215) 0.002 1.084 (0.935 - 1.256) 0.286 
STS score (per %) 
 
1.238 (1.037 – 1.477) 0.018 1.365 (0.943 - 1.976) 0.099 
eGFR (per ml/min/1.73m2) 
 
0.963 (0.936 – 0.991) 0.010 0.988 (0.947 – 1.053) 0.953 
Baseline Mid LV CS (per %) 
 
1.016 (1.007 – 1.024) 0.001 1.029 (1.007 – 1.052) 0.009 
Baseline LVEF (per %) 
 
0.962 (0.926 – 0.999) 0.046 1.031 (0.949 – 1.119) 0.473 
TAVI procedure 
 
3.776 (1.283 – 11.109) 0.016 0.397 ( 0.043 – 3.646) 0.414 
Myocardial Fibrosis (LGE +ve) 
 
1.670 (0.615 – 4.541) 0.315 - - 
Baseline LVMI 
 
1.014 (0.993 – 1.035) 0.189 - - 
History of MI 
 
0.611 (0.148 – 2.516) 0.495 - - 
Mean Aortic PG 
 
1.018 (0.91 – 1.046) 0.182 - - 
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Figure 5.4 Association of circumferential strain with survival 
A) ROC curve for baseline mid LV circumferential strain showing optimal discrimination value (-
18.69%) and an AUC of 0.74.  
B) Kaplan-Meier survival curves for AS patients undergoing valve intervention stratified by mid 
LV circumferential strain more positive than -18.7% (n=67, green) or more negative than -18.7% 
(n=40, blue). 
 
5.5 Discussion 
This prospective multicentre study has demonstrated that in severe symptomatic AS patients 
with abnormal strain and torsion, a reduction in torsion but no recovery in circumferential strain 
is seen post-valve replacement (with either TAVI or SAVR). In addition, reduced baseline mid-
LV circumferential strain was associated with a higher post-operative mortality, independent of 
age, STS predicted mortality and LVEF. 
  
Previous studies in patients with symptomatic severe AS and preserved LV ejection fraction 
have reported uniformly reduced longitudinal strain (Pibarot and Dumesnil, 2010, Attias et al., 
2013, Becker et al., 2007, Iwahashi et al., 2006). Sustained severe AS culminates in 
hypertrophic LV remodelling and an elevation in LVEDP. This predisposes to subendocardial 
ischaemia and impairs longitudinal subendocardial fibre contractility (Lancellotti et al., 2010) 
reducing global systolic function (Ross, 1976). Our study is the first to define an inverse 
relationship between invasively measured LVEDP and CMR derived circumferential strain and 
diastolic strain rate in aortic stenosis. 
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Higher circumferential strain in patients with preserved LVEF, and increased apical rotation in 
patients with mild LV dysfunction are thought to indicate compensatory mechanics serving to 
maintain radial strain. These compensatory mechanisms are reduced as LV performance 
declines (Carasso et al., 2011) and their loss appears to occur at the time of symptom onset 
(Lancellotti et al., 2010) indicating their potential use for surveillance and timing of surgery 
(Carasso et al., 2015). 
 
At baseline, our severe AS population had abnormally low circumferential strain with normal 
twist values compared with echocardiography derived reference ranges (Kaku et al., 2014). 
This is indicative of failing dynamic LV compensation consistent with their symptomatic status, 
despite an overall preserved LVEF. Our findings are thus a novel contribution, distinct from prior 
published work (Biederman et al., 2005, Grabskaya et al., 2011, Carasso et al., 2009, Carasso 
et al., 2011), in reporting the impact of treatment in a study population with more advanced LV 
dysfunction as a consequence of severe AS. 
 
Our study population had particularly severe indices of AS severity and the observed reduced 
baseline strain may reflect diminished coronary flow reserve (Biederman et al., 2005) and 
repetitive ischaemic myocardial injury (Grabskaya et al., 2011). Improved valvular function 
following intervention is thought to confer improved transmural myocardial perfusion and 
subsequent improved LV mechanics (Delgado et al., 2009) but this was not seen in our study; 
neither following TAVI, SAVR, or as a treated AS population in its entirety. It is notable coronary 
heart disease is thought to blunt recovery of myocardial mechanics following SAVR (Meimoun 
et al., 2011). Both the TAVI and SAVR groups were heterogeneous in their degree of coronary 
disease and established infarction, with over a quarter of SAVR patients also receiving 
revascularisation. It is challenging to estimate the impact of revascularisation in comparison to 
valve correction in our study; but in a sub analysis of our entire AS population excluding those 
with diseased epicardial vessels, we still failed to observe any improvement in circumferential 
strain at any LV level following treatment.  
 
Conflicting changes in LV strain rates have been reported, with both improvements (Delgado et 
al., 2009, Rost et al., 2010, Becker et al., 2007)  and a decline (Carasso et al., 2009) following 
SAVR; and either no change (Grabskaya et al., 2011) or an improvement following TAVI (Poulin 
et al., 2014). Our study demonstrates neither SAVR nor TAVI was associated with improvement 
of peak circumferential strain at any level, or of diastolic strain rate. In a sub analysis of our 
entire AS population excluding those with late gadolinium hyperenhancement, we still failed to 
observe any improvement in circumferential strain at any LV level following treatment. This lack 
of improvement indicates a degree of irreversible decompensation at baseline which may have 
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potential future implications for surveillance of systolic function and timing of intervention in 
severe AS. 
 
Our study provides unique insight into the assessment of LV rotational mechanics, which 
remains largely unaddressed by previous studies; both in the context of symptomatic AS and 
following aortic valve intervention. LV torsion and twist are integral components of ventricular 
contractility and diastolic filling (Sengupta et al., 2008). Previous CMR studies have reported 
changes in rotation in the context of AS, but inferences were confounded by very small sample 
sizes (largest n=13) (Nagel et al., 2000, Stuber et al., 1999). An increase in LV twist has been 
described in severe AS with preserved LVEF as compensation for impaired systolic longitudinal 
function (Meimoun et al., 2011). The baseline LV twist in our patients was notably lower than 
those awaiting SAVR from published echo studies (Lindqvist et al., 2011), again suggesting 
failure of compensation and a more advanced stage of disease (Poulin et al., 2014). 
 
Our study indicates that significant and comparable reductions in both torsion and twist, similar 
to that reported by others, occurs following SAVR (Lindqvist et al., 2011) and TAVI (Poulin et 
al., 2014). Twist is an energy saving process reflecting the helical orientation of cardiac fibres 
which offsets afterload mismatch, generating high intra-cavity pressure with minimal fibre 
shortening (Nagel et al., 2000). The reduction observed following intervention likely reflects the 
relief of afterload previously imposed by severe AS. Torsion is dependent on LV shape and falls 
with declining concentric hypertrophy, representing reduced leverage from epicardial fibres 
(Young and Cowan, 2012). In our study, both TAVI and SAVR precipitated comparable reverse 
LV remodelling with significant reductions in both indexed LVEDV and LV mass, consistent with 
the equivalent changes in torsion observed. 
 
Patients with severe aortic stenosis and reduced LV ejection fraction carry a high risk of 
mortality following both SAVR (Monin et al., 2003) and TAVI (Sannino et al., 2014). However, 
deteriorating ejection fraction is a late occurrence and significant interest remains in identifying 
advanced objective predictors of mortality when ejection fraction is above 50%. This study is, to 
our knowledge, the first to demonstrate circumferential strain derived by CMR is independently 
associated with all-cause postoperative mortality in symptomatic patients with severe AS and 
preserved LVEF undergoing intervention. 
 
Previous studies have hypothesised the prognostic value of longitudinal strain in AS may reflect 
the impact of myocardial fibrosis and provide the link to poor outcome (Dahl et al., 2012, 
Kusunose et al., 2014). This study has tested for an association between myocardial fibrosis 
and strain with respect to outcome, and demonstrates the prognostic importance of 
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circumferential strain measurement is unrelated to late gadolinium hyperenhancement. This is 
inconsistent with previous reports; but the follow-up period of 6 years is notably longer than that 
of others (Dweck et al., 2011) and this study assessed all-cause rather than cardiovascular-
specific causes of mortality. In this study, circumferential strain did not improve following SAVR 
/ TAVI which may not have been the case in other studies of younger patients; in whom LGE 
thus may be more influential with respect to outcome. This study is thus noteworthy but cannot 
definitively conclude on the importance of fibrosis, whether it be mid-wall or ischaemic, in this 
context. Lower circumferential strain in severe AS is independently associated with myocardial 
triglyceride accumulation (Mahmod et al., 2013). It is possible this lipotoxicity, which is 
undetectable using conventional LGE imaging, is important to the link between strain and 
outcome. However, our findings are not fully explicable by myocardial steatosis which has been 
shown to regress following SAVR, albeit in younger patients than our study (Mahmod et al., 
2013). 
 
Based on our work, patients with severe AS, even in the context of preserved LVEF, are at high 
risk for mortality when baseline mid-LV circumferential strain is >-18.7%. It is noteworthy this 
association occurs despite the relief of index aortic stenosis with SAVR or TAVI, and thus these 
patients in particular may benefit from greater scrutiny in follow-up. Measurement of 
circumferential strain using CMR is a non-invasive and reproducible modality by which a single, 
breath-held acquisition can potentially provide prognostic information independent of age, LVEF 
and surgical risk score. 
 
5.5.1 Limitations 
Our study population included patients with coronary artery disease and hypertension, rather 
than being restricted to pure aortic stenosis. This is however, generalisable to real world clinical 
practise and reduces the effect of selection bias. CMR assessment of cardiac rotational 
mechanics is sensitive to atrial fibrillation and regional wall motion abnormalities which can 
impair image quality. However, our quantification of strain using myocardial tagging CMR has 
demonstrated good reproducibility (Swoboda et al., 2014).  
 
Image analysis occurred oblivious to patient details which helped to eliminate bias for pre-
operative images. However, post-operative scans inherently appeared different for those with 
and without sternotomy and thus analysis of 6 month images could not truly be blinded. 
 
Our sample size is small with relatively few events carrying a risk of potential statistical over 
fitting. Also, we have reported all-cause mortality rather than cardiac mortality. Thus our findings 
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need to be viewed with caution and validated in larger outcome studies. Finally, we only 
enrolled patients with symptomatic aortic stenosis and further work is required to determine 
whether the prognostic importance of strain assessment can be extended to those who are 
asymptomatic; and thus potentially influence surgical timing.   
 
5.6 Conclusions 
Patients with symptomatic severe AS and preserved LVEF undergoing aortic valve intervention 
have reduced peak circumferential strain and systolic strain rates. At 6m, TAVI and SAVR 
procedures were associated with comparable declines in rotational LV mechanics, with largely 
unchanged strain and strain rates. Pre-operative peak mid LV circumferential strain was 
associated with post-operative total mortality and requires further investigation as to its use as a 
risk stratification tool. 
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Chapter 6. Aortic Regurgitation post-TAVI: a CMR comparison of two 
vendor designs  
6.1 Abstract 
Background: Transcatheter Aortic Valve Replacement (TAVI) is an established treatment for 
patients with symptomatic severe aortic stenosis. Paravalvular aortic regurgitation following 
implantation confers a worse prognosis and can be accurately quantified using CMR. Second 
generation valves have been specifically designed to reduce paravalvular regurgitation and 
improve device implantation success.  
 
Objectives: To compare, using serial CMR, the quantity of aortic regurgitation, following TAVI 
with two different designs: the self-expanding CoreValve (Medtronic, Minneapolis, Minnesota) 
and the mechanically expanded Lotus valve (Boston Scientific, Natick Massachusetts). 
 
Methods:  Fifty-one patients (79.0±7.7 years, 57% male) were recruited and imaged at three 
time points: immediately pre- and post-TAVI, and at 6 months. 
 
Results: Valve Academic Research Consortium defined device success was achieved in 94% of 
the Lotus and 63% of the CoreValve patients (p=0.004), the difference predominantly due to 
differing rates of ‘at least moderate’ aortic regurgitation. The CMR derived aortic regurgitant 
fraction immediately post-TAVI was greater in the CoreValve group (11.7±8.4 vs. 4.3±3.4%, 
p=0.001), with equivalent 6 month values (6.4±5.0 vs. 5.6±5.3% respectively, p=0.623). The 
residual peak pressure gradient immediately following CoreValve implantation was significantly 
lower (14.1±5.6 vs. 25.4±11.6mmHg, p=0.001), with comparable values at 6 months (16.5±9.4 
vs. 19.7±10.5mmHg, p=0.332). CoreValve and Lotus patients were equivalent in the degree of 
LV reverse remodelling observed at 6 months. 
 
Conclusion: In the immediate post-TAVI period, there was significantly less aortic regurgitation 
but a higher residual peak pressure gradient with the Boston Lotus valve compared to the 
Medtronic CoreValve. However at 6 months post-TAVI, both devices had comparable valve 
haemodynamics and extent of LV reverse remodelling. 
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6.2 Introduction  
Transcatheter Aortic Valve Replacement (TAVI) is endorsed by both US (Nishimura et al., 
2014a) and European (Vahanian et al., 2012) guidelines to improve survival and quality of life in 
patients with symptomatic severe aortic stenosis deemed inoperable or too high surgical risk. 
Over 200,000 patients worldwide have received TAVI across ~400 centres. TAVI device design 
continues to evolve in order to improve implantation success rates and clinical outcomes 
(Gooley et al., 2015).  
 
However, paravalvular AR is seen in up to 80% of patients following TAVI, affecting both the 
balloon-expandable and the self-expanding designs (Pibarot et al., 2015). This reflects 
incomplete circumferential apposition between the circular prosthesis and the oval-shaped 
aortic annulus (Sinning et al., 2013) and is often compounded by extensive calcification, under 
expansion of the TAVI prosthesis or malposition (Stahli et al., 2013). 
 
Clinical trials and registry data indicate AR following TAVI is associated with increased mortality 
at short term follow-up (Smith et al., 2011, Ussia et al., 2012, Webb and Wood, 2012). In a 
recent analysis of the PARTNER-IA continued access cohorts, mild AR post-TAVI 
independently predicted an increase in all-cause mortality (HR 1.37) after adjustment of other 
co-morbidities (Kodali et al., 2015). The dimensionless Aortic Regurgitation Index is derived 
from invasive measurement during TAVI implant, and a value of less than 25 has been shown 
to predict 1-year survival (Sinning et al., 2012). There is thus a need to accurately quantify post-
procedure AR in order to assess implantation success and to study new generation valves 
designed to reduce this important complication (Pibarot et al., 2015). 
 
CMR is the reference standard modality for assessing LV mass, volumes and function (Ribeiro 
et al., 2014). In addition, CMR permits full volumetric quantitation of AR that is highly accurate 
and reproducible (Crouch et al., 2015b, Salaun et al., 2015), independent of the number or 
eccentricity of regurgitant jets (Sherif et al., 2011), and unlike echocardiography, is not limited 
by TAVI prosthesis or calcification artefact (Sinning et al., 2013). CMR has lower intra-observer 
and inter-observer variability than echocardiography (Cawley et al., 2013, Altiok et al., 2014) 
and thus is more suited to serial measurements (Merten et al., 2013). Compared with CMR, 
echocardiography underestimates AR following TAVI (Ribeiro et al., 2014, Crouch et al., 2015b, 
Hartlage et al., 2014) and thus CMR offers potentially superior prognostic value in the post-
TAVI patient (Hartlage et al., 2014). 
 
Little is known about how AR evolves over time when compared between different TAVI 
designs, or whether in turn this produces meaningful differences in LV structure and function. 
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The Boston Scientific Lotus valve comprises a unique adaptive seal specifically designed to 
minimise post-TAVI aortic regurgitation (AR) (8), that has proven in the REPRISE I (Meredith et 
al., 2014) and REPRISE II (Meredith Am et al., 2014) studies to be both safe and effective. 
 
The aim of this study was to accurately quantify, using serial CMR, the degree of AR following 
TAVI using two different commercial prosthesis, the extensively trialled Medtronic CoreValve 
(Adams et al., 2014, Tamburino et al., 2011, Linke et al., 2014, Abdel-Wahab et al., 2014, 
Popma et al., 2014) and the novel Boston Scientific Lotus valve, and determine whether a 
particular design had greater predilection for more favourable LV reverse remodelling.  
 
6.3 Methods specific to chapter 6 
6.3.1 Study population 
This study prospectively recruited 59 patients with severe AS who were referred for TAVI at the 
Leeds Teaching Hospitals NHS Trust, UK, between March 2013 and May 2015. Severe AS was 
classified by echocardiography as an aortic valve area of ≤1.0 cm2 or peak velocity >4 m/s. 
Decision for TAVI in all cases was taken by a multidisciplinary heart team in accordance with 
international guidance (Vahanian et al., 2008). Exclusion criteria included any contraindication 
to CMR as well as patients with a known bicuspid aortic valve, aortopathy or previous aortic or 
mitral prostheses.  
 
6.3.2 Transcatheter Aortic Valve Replacement 
TAVI was performed using either a third-generation 18F CoreValve ReValving system (CVR, 
Medtronic, Minneapolis, Minnesota, USA) or an 18F, 20F or 22F Lotus™ Aortic Valve system 
(Boston Scientific Corporation, Natick, MA, USA) employing standard techniques as previously 
described for both vendors (Piazza et al., 2008, Meredith et al., 2012). All patients underwent 
multidetector computed tomography to assist annular sizing and to assess aortic calcification 
prior to TAVI. Percutaneous femoral artery access was the default approach and the AR index, 
derived invasively at the time of TAVI, was determined by ([(Diastolic BP-LVEDP) / Systolic BP] 
x100). For the purposes of analysis, an AR index cut-off of 25 was chosen given previous work 
indicating this threshold holds prognostic importance (Sinning et al., 2012). 
 
6.3.3 CMR Protocol 
For each individual patient, identical pre-, immediately post-TAVI, and 6-month postoperative 
scans were performed at 1.5T (Intera or Ingenia, Phillips Healthcare, Best, Netherlands) (Figure 
6.1). The cardiac imaging of patients immediately post-TAVI required a notice of amendment 
and ethical approval which was duly granted (Appendix 9.2). 
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Figure 6.1 CMR views of TAVI prostheses 
CMR coronal views showing a Medtronic CoreValve (A) and Boston Lotus valve (B). 
 
Details of the CMR pulse sequence acquisition protocol are outlined in the Standard Methods 
chapter (sections 2.4.1 and 2.4.2). 
  
For flow measurements, through-plane velocity encoded (VENC) phase contrast imaging was 
performed perpendicular to the aortic valve jet at the aortic sinotubular junction, at the upper 
margin of the stent holding the TAVI prosthesis (VENC 200–500 cm/s, retrospective gating, 
slice thickness 6 mm, 40 phases, FOV 340 mm). This position for imaging has been previously 
described and validated (Salaun et al., 2015). If significant turbulence or aliasing was seen in 
the velocity image, the acquisition was repeated a few millimetres further from the valve, and/or 
with a higher-velocity window.  
 
6.3.4 CMR Image Analysis 
Image analysis was performed in a blinded fashion, off-line using commercially available 
software (CVI42, Circle Cardiovascular Imaging, Calgary, Alberta, Canada) by two experienced 
observers. Aortic flow was quantified to provide a peak forward flow velocity (m/s), forward flow 
volume (ml), backward flow volume (ml) and regurgitant fraction (%). Images were excluded 
from analysis if artefacts from the TAVI were present on images. Aortic regurgitation was 
classified as regurgitant fraction of none/trivial ≤5%, mild 6-15%, moderate 16-25%, moderate-
severe 26-48%, and severe >48% in line with CMR standard grading criteria (Gelfand et al., 
2006).  
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6.3.5 Statistical Analysis 
Spearman correlation coefficient were calculated to investigate the relationship between aortic 
regurgitant fraction measured by CMR and that derived invasively at time of TAVI implantation.  
Based on published data (Bellenger et al., 2000a), 20 patients per group were required to 
detect a 10ml change in LVEDV or 10g difference in LV mass regression between the two 
treatments (90% power and an alpha error of 0.05); 30 per group would be sufficient to detect a 
clinically meaningful 10% absolute difference in aortic peak forward flow velocity or regurgitant 
fraction (85% power and an alpha error of 0.05). 
 
6.4 Results 
6.4.1 Patient population 
A total of 51 patients (24 Medtronic CoreValve and 27 Boston Lotus) underwent the 
preoperative and immediate post-TAVI CMR scans with 44 of these (19 CoreValve and 25 
Lotus) finally completing 6 month post-TAVI scans. Reasons for non-completion of the CMR 
protocol were varied and depicted in Figure 6.2.  
 
 
Figure 6.2 Study profile  
 
The final analysis population (n=44) was not different to the whole population (n=51) studied 
pre-TAVI (comparable in age (p=0.871), EuroSCORE II (p=0.724) and STS predicted operative 
102 
 
mortality (p=0.736)).The baseline characteristics of this final study population are reported in 
Table 6.1. 
 
Table 6.1 Patient characteristics in those with 6 month follow up 
 CoreValve (n=19) Lotus (n=25) p Value* 
Age (years) 79.6±6.3 78.6±8.7 0.693 
Male, n (%) 12 (63) 14 (56) 0.414 
STS score (%) 3.58±1.9 3.89±2.6 0.669 
BMI (kg/m2) 27.6±4.8 28.7±5.3 0.484 
NYHA, (modal group) 3 3 0.327 
Hypertension, n (%) 9 (47) 8 (32) 0.239 
Diabetes, n (%) 2 (11) 5 (20) 0.441 
Hyperlipidaemia, n (%) 12 (63) 15 (60) 0.659 
Atrial Fibrillation, n (%) 4 (21) 4 (16) 0.609 
Previous MI, n (%) 3 (16) 6 (24) 0.520 
Previous PCI, n (%) 7 (37) 7 (28) 0.458 
Previous CABG, n (%) 5 (26) 5 (20) 0.556 
Previous Stroke, n (%) 3 (16) 6 (24) 0.564 
COPD, n (%) 6 (32) 7 (28) 0.710 
Pulmonary Hypertension, n (%) 6 (32) 10 (40) 0.587 
Peripheral Vascular Disease, n (%) 6 (32) 3 (12) 0.094 
eGFR (ml/min/1.73m2) 61±27 72±19 0.135 
AVA (cm2) 0.61±0.21 0.60±0.18 0.965 
Mean Aortic PG (mmHg) 50±12 55±19 0.292 
AR Regurgitant Fraction (%) 12.5±11.7 11.9±9.6 0.852 
LV EDVI (ml/m2) 98.2±28.6 89.4±34.9 0.379 
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LVEF (%) 56.2±12.8 51.0±19.0 0.306 
LV Mass Index (g/m2) 75±15 69±26 0.357 
Mass : Volume ratio (g/ml) 0.80±0.16 0.73±0.27 0.329 
Values are mean±SD or n (%). *p Value for comparison between procedure types. 
Between groups, patients were comparable for age, gender, symptom class, coronary disease 
and surgical risk score. Similarly, the groups had equivalent baseline left ventricular ejection 
fraction, aortic valve area and mean pressure gradient, and left ventricular mass index. 
 
6.4.2 Procedural data 
All of the Boston Lotus valves were implanted via the femoral artery, as were the majority of 
CoreValves (68%). Fifteen patients (54%) in the Lotus group were treated with smaller Lotus 
devices (23 or 25mm), whereas only 5 (20%) of the CoreValve group received the smaller 
CoreValve prostheses (23 or 26 mm) (p=0.030).  
 
Invasive resting pressure gradients were equivalent between the two groups, in keeping with 
baseline imaging. The implant procedure for a Lotus valve involved significantly longer 
fluoroscopy times, despite a significantly greater proportion of CoreValve TAVI receiving post-
dilatation (0% vs. 28%, p=0.003). Equivalent volumes of contrast were used for each TAVI type 
(Table 6.2).   
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Table 6.2 Catheterisation data for TAVI implant procedures 
 CoreValve (n=24) Lotus (n=27) p Value* 
TAVI size (n(%)) 
Small 
(23 & 26mm CoreValve, 
23 & 25mm Lotus) 
 
Large 
(29 & 31mm CoreValve, 
27mm Lotus) 
 
 
 
23mm (2 (8%)) 
26mm (3 (12%)) 
 
 
29mm (14 (56%)) 
31mm (5 (20%)) 
 
 
23mm (7 (25%)) 
25mm (8 (29%)) 
 
 
27mm (13 (46%)) 
 
 
 
 
0.030 
Femoral route, n (%) 17 (68) 28 (100) 0.003 
Resting PG (mmHg) 51±24 57±27 0.419 
Fluoroscopy time (min) 23±7 28±8 0.017 
Procedure time (min) 152±51 159±43 0.589 
Contrast (ml) 144±49 120±44 0.068 
Pre-dilatation BAV, n (%) 20 (80) 22 (79) 0.899 
Post-dilatation, n (%) 7 (28) 0 (0) 0.003 
 
VARC-defined device success (Leon et al., 2011) was achieved in 94% of the Lotus cohort and 
63% of the CoreValve cohort (p=0.004). The components of this measure were the absence of 
procedural mortality (94% vs. 96%, p=0.177), a mean gradient across the TAVI prosthesis of < 
20mmHg (100% vs. 100%, p=0.999), correct positioning of a single TAVI prosthesis (100% vs. 
96%, p=0.290), and no more than mild aortic regurgitation (100% vs. 63%, p=0.001) in the 
Lotus and CoreValve groups respectively. 
 
The rate of new pacemaker insertion was non-statistically different between the Lotus and 
CoreValve groups (22% vs. 15%, p=0.424). 
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6.4.3 TAVI haemodynamics 
The severity of preoperative aortic valve stenosis was similar between the Lotus and CoreValve 
groups (Table 7.1). Systolic blood pressures (an important measure of LV afterload) remained 
comparable between the CoreValve and Lotus group both immediately (132±23 vs. 
134±22mmHg, p=0.784) and 6 months (141±25 vs. 127±16mmHg respectively, p=0.161) post-
TAVI. Immediately post-TAVI, a significant reduction in peak aortic pressure gradient was 
observed in both Lotus (94.3±28.7 vs. 25.4±11.6mmHg, p<0.001) and CoreValve (88.5±27.4 vs. 
14.1±5.6mmHg, p<0.001) patients of a comparable magnitude (-68.9±27.8 vs. -
74.4±29.0mmHg respectively, p=0.497). However, the residual peak pressure gradient 
immediately following Lotus valve implantation was significantly higher than that following 
CoreValve (25.4±11.6 vs. 14.1±5.6mmHg, p=0.001). At 6 months post-TAVI, the peak pressure 
gradient of the CoreValve remained unchanged from the immediate post-TAVI time point 
(16.5±9.4 vs. 15.0±5.5mmHg respectively, p=0.457) however a significant reduction was 
observed in the Lotus group (25.8±12.1 vs. 19.7±10.5mmHg, p=0.022) (Figure 7.3A). 
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Figure 6.3 Comparison of change over time in valvular and ventricular parameters between Lotus and CoreValve 
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As such, in comparison between CoreValve and Lotus patients, the residual peak pressure 
gradient at 6 months was equivalent (16.5±9.4 vs.19.7±10.5mmHg, p=0.332) (Table 6.3). 
 
Table 6.3 Comparison of LV parameters and aortic valve haemodynamics 
immediately and 6 months post-TAVI from 2 vendors 
 Immediate post-TAVI 6 months post TAVI 
 CoreValve 
(n=24) 
Lotus 
(n=27) 
p Value CoreValve 
(n=19) 
Lotus 
(n=25) 
p Value 
Valvular Function 
Aortic RF, (%) 11.7±8.4 4.3±3.4 0.001 6.4±5.0 5.6±5.3 0.623 
Aortic Peak PG 
(mmHg) 
14.1±5.6 25.4±11.6 0.001 16.5±9.4 19.7±10.5 0.332 
Left Ventricle 
EDVI (ml/m2)  94.7±17.7 91.8±21.0 0.597 87.2±17.8 84.7±19.8 0.664 
LVEF (%)  55.2±11.5 54.3±10.9 0.767 56.4±8.6 54.1±9.3 0.409 
Mass Index (g/m2) 65.8±13.6 69.6±16.2 0.361 56.8±13.2 58.6±11.7 0.646 
LVM/LVEDV (g/ml) 0.71±0.14 0.80±0.30 0.144 0.67±0.17 0.73±0.23 0.337 
 
 
At baseline, the aortic regurgitant fraction comparison between CoreValve and Lotus patients 
was equivalent (12.5±11.7 vs. 11.9±9.6% respectively, p=0.852) highlighting that degenerative 
severe aortic stenosis was the predominant valvular pathology prior to TAVI in both groups. 
Immediately post-TAVI, the aortic regurgitant fraction was statistically greater in the CoreValve 
group (11.7±8.4 vs. 4.3±3.4%, p=0.001). The classification of AR immediately following TAVI in 
the two groups is depicted in Figure 6.4.  
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Figure 6.4 AR classification immediately post-TAVI 
 
There was a significantly higher percentage of patients with mild (p=0.017) and moderate AR 
(p=0.001) following TAVI with CoreValve than Lotus. Between the immediate and 6 month 
scans, the aortic regurgitant fraction in the Lotus group remained unchanged (4.0±3.5 vs. 
5.6±5.3%, p=0.267). However, a significant reduction was observed in the CoreValve patients 
(11.7±7.2 vs. 6.4±5.0%, p=0.002) (Figure 6.3B). As such, comparison between CoreValve and 
Lotus patients at 6 months showed the residual total aortic regurgitant fraction was equivalent 
(6.4±5.0 vs. 5.6±5.3% respectively, p=0.623) (Table 6.3). 
 
6.4.4 LV reverse remodelling  
There were no significant differences in indexed LV end diastolic volume (LVEDV) (p=0.379), 
indexed LV mass (p=0.357), LV ejection fraction (LVEF) (p=0.306) or LV mass:volume ratio 
(p=0.329) between the groups at baseline. A direct comparison of LV characteristics between 
the two groups, immediately and at 6 months post-TAVI, is also summarised in Table 6.3. 
Immediately post-TAVI, there was no change in indexed LVEDV or LVEF in the Lotus group 
(p=0.550 and 0.498) or the CoreValve group (p=0.461 and 0.847, respectively). However, a 
significant reduction in the indexed LV mass occurred following CoreValve TAVI (75.4±15.0 vs. 
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65.8±13.6g/m2, p<0.001) that was not seen following Lotus (70.8±25.0 vs. 69.6±16.2g/m2, 
p=0.811). Compared to baseline, the LVEF and indexed LVEDV values at 6 months were 
unchanged, regardless of the TAVI vendor. However, a significant and comparable regression 
in the indexed LV mass was observed in both TAVI groups (Table 6.4, Figure 6.3C and 6.3D). 
 
Table 6.4 Comparison of aortic valve function and LV reverse remodelling post-
TAVI 
 CoreValve (n=19) Lotus (n=25) p Value† 
 Baseline 6 months Baseline 6 months  
Valvular Function 
Aortic RF, (%) 12.5±11.7 6.4±5.0 11.9±9.6 5.6±5.3* 0.922 
Aortic Peak PG 
(mmHg) 
88.6±27.4 16.5±9.4*** 95.3±28.7 19.7±10.5*** 0.009 
 
Left Ventricle 
EDVI (ml/m2)  98.2±28.6 87.2±17.8 89.4±34.9 84.7±19.8 0.458 
LVEF (%)  56.2±12.8 56.4±8.6 51.0±19.0 54.1±9.3 0.499 
Mass Index (g/m2) 75.4±15.0 56.8±13.2*** 69.2±25.9 58.6±11.7* 0.179 
LVM/LVEDV (g/ml) 0.80±0.16 0.67±0.17** 0.73±0.27 0.73±0.23 0.114 
 
 
6.4.5 Correlation of AR Index with CMR and impact upon LV reverse remodelling  
There was a moderate negative correlation between invasive AR index and CMR aortic 
regurgitant fraction (Spearman’s correlation coefficient = -0.5, N=51, p=0.001) (Figure 7.5).  
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Figure 6.5 Scatter plots demonstrating correlation of invasive and CMR 
quantification of AR 
 
A: All patients, grouped according to their CMR class of AR. 
Line of best fit with 95% confidence intervals shown, indicating a negative correlation. 
 
B: All patients grouped according by vendor of TAVI received. 
Horizontal line indicates AR index of 25. 
 
The mean AR index following Lotus TAVI was non-significantly higher than that following 
CoreValve TAVI (25.0± 6.3 vs. 23.0±8.7, p=0.145), with an equivalent proportion of patients in 
each group with an AR index below 25 (59% Lotus vs. 71% CoreValve, p=0.517) (Figure 7.5). 
 
Analysing the final study population as a whole (n=44), the LV mass:volume ratio did not 
change between the immediate post-TAVI and 6 month scans, in patients with an AR index ≤25 
(0.74±0.27 vs. 0.71±0.21g/ml, p=0.382) unlike those with >25 (0.79±0.18 vs. 0.69±0.21g/ml, 
p=0.003). Furthermore, significantly less LV mass regression was seen between the immediate 
post-TAVI and 6 month scans in patients with an AR index ≤25 when compared with those >25 
(-8.4±11.0 vs. -15.3±9.8 g/m2, p=0.046). 
 
6.5 Discussion 
This is the first study to use CMR to directly and systematically compare two distinct TAVI 
designs for aortic valve haemodynamics and impact on LV reverse remodelling over time. 
 
We have shown in this single-centre non-randomised study that compared with the Boston 
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Lotus, TAVI with the Medtronic CoreValve is associated with a significantly greater quantity of 
aortic regurgitation immediately post-implantation, but with lower residual peak pressure 
gradients. At 6 months post-TAVI, both valves perform equally with respect to aortic valve peak 
pressure gradient and regurgitant fraction, with an equivalent degree of LV mass regression 
observed from baseline. This is consistent with published studies with longer follow-up that 
have demonstrated excellent outcomes with both TAVI designs (Reardon et al., 2015, Meredith 
et al., 2014). 
 
In our study, we observed high rates of procedural success with both CoreValve and Lotus 
TAVI. However, in direct comparison, the VARC-defined primary composite outcome of device 
success was significantly higher in the Lotus group, driven principally by the absence of 
“moderate or more” aortic regurgitation. The Lotus valve has been compared with the 
CoreValve previously using echocardiography (Gooley et al., 2015). However, the 
echocardiographic grading criteria suggested by VARC lacks validation post-TAVI (Lerakis et 
al., 2013). Quantification of regurgitation remains challenging and echo may inherently 
underestimate AR post-TAVI (Ribeiro et al., 2014, Crouch et al., 2015b, Sherif et al., 2011). In a 
recent comparison of 2D echocardiography, 3D echocardiography and CMR, applying VARC 
metrics post-TAVI, the observer variability in determining AR was superior by CMR (Altiok et al., 
2014). This is the first study to our knowledge to assess device success using CMR and 
supports a genuine superiority of the Lotus valve over Medtronic CoreValve. 
 
There is growing evidence suggesting a significant association of post-procedural AR with 
short- and long-term mortality (Kodali et al., 2012, Tamburino et al., 2011, D'Onofrio et al., 
2015). In the PARTNER-IA study, even mild AR following TAVI was associated with increased 
mortality at 2 years (Kodali et al., 2012). In our study, all patients underwent MDCT which is 
crucial for optimal annular sizing and subsequent TAVI function (Oh et al., 2015). This is distinct 
to other studies in which only a minority of TAVI procedures were planned using MDCT (Kodali 
et al., 2015, Linke et al., 2014). We observed a significantly lower quantity of AR following Lotus 
valve implantation compared to CoreValve, which most likely reflects integral differences in 
TAVI prosthesis design rather than device undersizing. 
 
The Lotus valve is mechanically expanded, fully retrievable and repositionable, and carries a 
central radiopaque positioning marker. This allows assessment of TAVI function and 
haemodynamics prior to final deployment, which in part explains the longer fluoroscopy time we 
observed with this device. Furthermore, it has an adaptive seal comprising 
polyurethane/polycarbonate which seals the frame against the native aorto-ventricular interface, 
thus minimising paravalvular AR (Gooley et al., 2013, Meredith et al., 2012). The CoreValve is a 
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self-expanding device with a flared inflow segment designed to anchor the TAVI within the 
native annulus (Gooley et al., 2015). Accurate initial positioning is vital to its placement, 
alongside device oversizing, to optimise annular occlusion. Notably, the rate of post-dilatation in 
the CoreValve group (28%) was comparable to those in other studies using the same 
prosthesis (Adams et al., 2014, Gooley et al., 2015).  
 
Our study used CMR to study the evolution of AR over time. No significant change was seen in 
the Lotus group from post-implant to 6 months, in line with REPRISE I (Meredith et al., 2014) 
and REPRISE II (Meredith Am et al., 2014), both of which used echocardiography for 
surveillance. However, over the same time period, we observed a reduction in quantity of AR 
following CoreValve, and this is consistent with findings reported in a randomised trial (Adams 
et al., 2014) and from a large multicentre registry which showed no further deterioration 
(Tamburino et al., 2011). Furthermore, a recent observation from the multicentre CoreValve US 
pivotal trial indicated over 80% of patients exhibited an improvement of at least 1 grade of 
regurgitation at 1 year, again based on echocardiography (Oh et al., 2015). A recent CMR study 
did suggest a slight increase in AR at 6 months post-TAVI; however this study combined 
measurements of the CoreValve with those of another TAVI design (Merten et al., 2013). Our 
observation of further reduction in AR at 6 months may reflect positive geometric annular 
remodelling (Lerakis et al., 2013), further outward expansion of the bulky CoreValve frame (Oh 
et al., 2015), or occlusion of residual defects over time by fibrous tissue, similar to that 
described from another TAVI design (Bauer et al., 2010, Ewe et al., 2015).  
 
The aortic regurgitation index is a dimensionless measure of haemodynamics following TAVI 
which has shown an inverse correlation with the severity of paravalvular AR. A value ≤ 25 
independently predicts 1-year mortality (Sinning et al., 2012). To our knowledge, this is the first 
study to confirm negative correlation between the invasive AR index and aortic RF measured 
non-invasively by CMR. Furthermore, in patients with an AR index ≤ 25, the LV mass:volume 
ratio remained unchanged at 6 months with significantly less LV mass regression compared to 
those with a higher AR index post-TAVI. A prior CMR study suggested LV mass remained 
unchanged at 6 months in patients with greater than mild AR following TAVI (Merten et al., 
2013) in keeping with our results. Our observation is important given geometric remodelling is 
associated with heart failure and all-cause mortality (Gaasch and Zile, 2011). It is noteworthy 
that the degree of LV mass regression, and concomitant recovery of diastolic function after 
surgical and transcatheter aortic valve replacement, is a positive prognostic indicator (Ali et al., 
2011, Rader et al., 2015), whereas residual hypertrophy after aortic valve replacement is 
thought to be detrimental (Beach et al., 2014). Our CMR study therefore corroborates and may 
explain the worse outcomes previously described in patients with lower AR index post-TAVI. 
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Immediately post-TAVI, we observed a lower residual aortic pressure gradient following 
CoreValve implantation, which was associated with a mean reduction in LV mass of 10 
grams/m2. In contrast, with the Lotus valve there was a mean residual gradient 10mmHg higher, 
and no significant LV mass regression was noted. Whilst this may reflect the significantly higher 
proportion of smaller sized Lotus valves being implanted in our study, our reported values are 
comparable to those reported in REPRISE II at discharge and 30 days (Meredith Am et al., 
2014). Similarly, our CMR measures of residual pressure gradient post-CoreValve implantation 
are consistent with echocardiographic data from prior studies at comparable time points 
(Spethmann et al., 2012, Gooley et al., 2015, Linke et al., 2014). These findings may have 
clinical implications given that early LV mass regression following TAVI is associated with 
improved diastolic function (Vizzardi et al., 2012), lower B-type Natriuretic Peptide levels and 
reduced readmission to hospital for heart failure (Lindman et al., 2014). Therefore whilst 
compared to CoreValve, less immediate aortic regurgitation occurs following Lotus valve 
implantation, a higher residual valve gradient and the absence of immediate LV mass 
regression may be a disadvantage. Further work to validate these findings and directly compare 
the clinical course following these two TAVI designs is thus required. 
 
6.5.1 Clinical Implications  
The evidence base for TAVI implantation is extensive. The potential application in lower-risk 
patients underscores the drive for further improvements in TAVI design to reduce complications, 
with the need to demonstrate prosthesis durability being crucial. It is noteworthy that despite 
superior success according to the VARC criteria for device deployment with the Lotus valve, we 
found comparable haemodynamics and equivalent LV reverse remodelling at 6 months 
following implantation of both prosthesis designs. This is consistent with published studies with 
longer follow-up that have demonstrated excellent outcomes with both TAVI designs (Reardon 
et al., 2015, Meredith et al., 2014). 
 
6.5.2 Limitations 
This was a small single-centre non-randomised comparison. Only patients clinically stable 
enough to participate in the CMR study were included and thus those with more severe AR or 
impaired LV function may have been excluded. Not all patients were able to complete the 6 
month scan, predominantly due to pacemaker implantation or death which may have introduced 
bias; although the final analysed population was not different to the recruited population in 
terms of demographics and comorbidities.  
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VARC-2 criteria includes a measure of Patient-Prosthesis Mismatch; defined as absent when 
the TAVI effective regurgitant orifice area (EOA) is >0.85 cm2/m2 (Kappetein et al., 2013). We 
have assessed TAVI performance by VARC criteria (Leon et al., 2011) as our CMR protocol did 
not include imaging from which TAVI EOA could be ascertained. The VARC criteria are 
nonetheless an accepted end point, forming the basis of a recent randomised clinical trial 
directly comparing two different TAVI systems (Abdel-Wahab et al., 2014). 
 
We used CMR to quantify the total AR seen following TAVI, which is a composite of 
paravalvular and transvalvular regurgitation. Total aortic regurgitation following TAVI has been 
demonstrated as an important marker of mortality (Costopoulos et al., 2013) and central 
transvalvular regurgitation is usually minor and a physiological feature by virtue of prosthesis 
design (Lerakis et al., 2013). Furthermore, VARC-2 criteria advocate a combined measurement 
of “total” aortic regurgitation (AR) reflecting the total regurgitant volume load imposed on the LV 
(Kappetein et al., 2013). 
 
This study utilised a different grading scale for aortic regurgitant fraction to that advocated by 
VARC-2, which is based primarily on data from native valve AR measurements. Our values are 
however entirely consistent with studies focusing on AR specifically after TAVI (Salaun et al., 
2015, Sherif et al., 2011). 
 
6.6 Conclusions 
A significantly lower quantity of aortic regurgitation but higher residual peak pressure gradient 
was seen immediately following Boston Lotus TAVI compared to Medtronic CoreValve 
implantation. However, by 6 months TAVI haemodynamics were comparable and there were 
similar degrees of LV reverse remodelling seen with both valve designs. 
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7. Final Conclusions 
Aortic stenosis is the commonest valvular lesion in the elderly with a prevalence of around 5% 
in those over 75 years. This is anticipated to rise sharply over the next few decades given an 
aging population. For the vast majority the disease remains latent, but the onset of symptoms 
heralds a sinister natural history with a 50% mortality rate at 2 years without intervention. 
 
SAVR has been practised widely for over 50 years with developments in valve technology and 
surgical techniques underscoring the excellent outcomes of modern day. However, the elderly 
still face a mortality risk of 20% at 1 year and thus a notable proportion are deemed prohibitively 
high-risk and managed conservatively (Ruparelia and Prendergast, 2015). The advent of TAVI 
signalled a global shift in approach towards such patients. TAVI has demonstrated clinical 
superiority over medical therapy with results comparable to SAVR in those at high-risk. The 
recently published results from the PARTNER 2 trial have indicated TAVI is non-inferior to 
SAVR with respect to outcomes at 2 years in intermediate-risk patients (Leon et al., 2016).  
Furthermore, shorter hospital stay, lower bleeding rates and dysrhythmia were notable findings, 
particularly given the TAVI-arm of the trial employed a now outdated device. The ongoing UK 
TAVI and SURTAVI trials are also designed to address the role of TAVI in intermediate risk 
patients who are typically younger. Further studies are addressing “off-label” indications for 
TAVI, including its use for AR, bicuspid valves and the treatment of failing surgical 
bioprostheses (termed “valve-in-valve” procedures). 
 
A key recommendation to both European and US guidance is that each individual patient 
should be discussed within a multidisciplinary “Heart Team” to address comprehensively 
patient, procedural and risk factors pertaining to SAVR and TAVI. This typically comprises 
interventional cardiologists, imaging cardiologists, cardiac anaesthetists, cardiothoracic 
surgeons and general physicians. This “Heart Team” needs to appreciate the intense focus on 
the comparative benefits of SAVR and TAVI and tailor a decision on a case by case basis. 
 
Evidence that can guide patient selection and thus clinical practise is fundamental to 
characterising the precise role of TAVI and SAVR in treating the growing problem of 
symptomatic severe aortic stenosis. This thesis advances the comparative effects of SAVR and 
TAVI by contributing original evidence regarding the impact of each intervention upon 
cardiovascular function, assessed using CMR.  
 
The elasticity of the aorta is important to the regulation of coronary blood flow, left ventricular 
function and the compliance of the entire cardiovascular network. This elasticity is sensitive to 
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any factors that can induce histological or functional change in the aortic wall. Importantly, 
arterial stiffness is an independent predictor of cardiovascular risk and mortality in a range of 
conditions, and much work has been directed to modalities of measurement and formulation of 
reference ranges to bring this powerful tool into clinical use (2010). There are two principal 
measures of aortic stiffness; the regional pulse wave velocity which is the velocity at which a 
pressure wave propagates down a vessel, and the local distensibility which is the ability of the 
aorta to expand during systole. There is a strong negative linear relationship between the two 
measures, both of which can accurately and reproducibly made using CMR.  
 
The impact of TAVI and SAVR on aortic pressure gradient and LV performance is well 
documented. However, there has only been limited work assessing aortic stiffness following 
intervention for severe aortic stenosis. These studies have exclusively used echocardiography 
to measure AD and focused on one intervention type. Our work is the first to use CMR 
specifically to analyse simultaneously PWV and AD in a direct comparison between SAVR and 
TAVI. We have demonstrated SAVR but not TAVI is associated with an increase in aortic 
stiffness from baseline at 6 months following intervention. TAVI and SAVR are fundamentally 
different techniques; in particular SAVR disrupts vasa vasorum flow and traumatises aortic wall 
integrity whereas TAVI does not. Animal studies have indicated that ischaemic insult to the 
aortic wall results in histological change and increased stiffness and this is the likely explanation 
of our findings. We were unable to demonstrate any association between any variables of 
cardiothoracic surgery and the decline in measures of aortic stiffness, but interestingly our 
findings do suggest the entire thoracic aorta is affected following SAVR rather than just the focal 
point of clamp contact and surgical incision.  
 
Given the prognostic importance of aortic vascular function our work raises important issues. 
Impairment of aortic elasticity is accompanied by an increase in risk of future cardiovascular 
events. In meta-analysis, an increase in PWV by 1 m/s corresponded to a 15% increase in all-
cause mortality (Vlachopoulos et al., 2010). Similarly, in a healthy population, a decrease in 
aortic distensibility was associated with an increase in cardiac death and non-fatal cardiac 
events by hazard ratios of 1.49 and 1.69 respectively (Maroules et al., 2014). Our comparison 
therefore raises the possibility TAVI confers a MACE advantage over SAVR. This is perhaps 
partly reflected by the favourable results for TAVI in high-risk patients from trial data. In addition, 
our findings support the avoidance of aortic trauma wherever possible and suggest that a direct-
aortic TAVI approach would be more detrimental to aortic vascular function that the traditional 
femoral artery route.  
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Right ventricular function is a major contributor to exercise capacity, holds prognostic 
importance in a range of cardiac conditions and RV failure is an important determinant of 
survival following cardiac surgery (Wenaweser and O'Sullivan, 2012). Previous reports using 
echocardiography have described deterioration in RV function following SAVR but the 
mechanisms for this have been poorly defined. Despite this however, pre-operative risk scoring 
tools do not yet comprise an assessment of RV function. The evaluation of RV performance is 
challenging given its asymmetric and variable shape, thin fee wall, predominant longitudinal 
systolic motion and location behind the sternum. SSFP CMR is the gold standard modality to 
quantify RV dimensions and function; it is reproducible, offers excellent blood-tissue contrast 
and can image in any plane. The findings of this thesis are the first that are statistically 
powered, using CMR, to directly compare the effects of SAVR and TAVI upon RV volumes and 
function. 
 
At baseline, our two groups both had preserved RV systolic function. At 6 months a key finding 
was that SAVR had a significant detrimental impact on RV systolic volume, ejection fraction and 
systolic longitudinal motion (TAPSE) associated with longer surgical cross-clamp times, 
whereas TAVI had no such impact on any RV functional indices. These findings raise some 
pertinent issues. Firstly, it does seem sensible that consideration of RV function should be given 
by the Heart Team MDT when deciding upon an intervention in high-risk patients. Secondly, 
given the deterioration in RV performance 6 months following SAVR, patients with pre-existing 
RV dysfunction and symptomatic severe AS are likely to derive better clinical outcomes with 
TAVI, although this remains to be proven. Furthermore, the reported increase in end-systolic 
volume following SAVR was associated with longer cross-clamp time, and unlikely to be related 
to left heart function or suboptimal protection during cardiopulmonary bypass. Thus, attempts to 
minimise cross-clamp duration may help optimise post-operative recovery, perhaps by 
minimising changes in pulmonary vascular physiology. 
 
Degenerative aortic stenosis exerts a chronic pressure overload upon the LV with elevated end-
diastolic pressures. This results in LV hypertrophy to compensate for increased wall stress as 
per Laplace’s law. There follows the potential for subendocardial ischaemia that can impair 
systolic and diastolic function, even when epicardial coronary vessels are normal. Myocardial 
fibre length changes in the longitudinal, circumferential and radial directions throughout the 
cardiac cycle and each of these changes can be quantified independently using CMR strain 
measurements. Myocardial tissue tagging acquisition is the principal technique employed for 
this purpose. We have used this techniques in this thesis to determine whether circumferential 
strain measurements can predict outcomes following SAVR and TAVI. 
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Chapter 5 of this thesis indicates circumferential strain is associated with survival following 
valve replacement for severe AS. In particular, those with a pre-operative mid-LV 
circumferential strain >-18.7% are at higher risk of mortality, even when index aortic stenosis 
has been relieved with SAVR and TAVI, independent of age, LVEF and surgical risk score. 
CMR strain imaging is hence an advanced technique that may afford crucial insight into the 
progression of aortic valve disease and prognosis. It is recognised that reduced LVEF signals a 
poorer outcome even after intervention (Vaquette et al., 2005) but this is a late change in the 
disease process. Our findings implicate circumferential strain as a marker of LV 
decompensation and survival even when ejection fraction is preserved and thus may have 
important implications again for patient assessment prior to consideration of treatment. Our 
work advocates the use of CMR strain imaging for a more comprehensive examination of LV 
performance in patients with severe symptomatic AS, and further work is needed to confirm 
whether intervening “early” with SAVR or TAVI, based on a measurement circumferential strain, 
can improve clinical outcomes. 
 
Paravalvular aortic regurgitation following TAVI has been a subject of intense scrutiny and study 
in recent years. SAVR involves complete excision of calcified aortic valve leaflets. This does not 
occur during TAVI, with the inherent possibility of paravalvular aortic regurgitation from 
incomplete sealing between native annular calcification and the TAVI prosthesis. Even mild 
regurgitation is often poorly tolerated following SAVR. It is however a common finding following 
TAVI being present in up to 61%of patients (Hamm et al., 2016). Both registry and clinical trial 
data have consistently indicated moderate and severe paravalvular regurgitation following TAVI 
is an independent predictor of early and late survival. This is reflection of the poor 
haemodynamic tolerance of a hypertrophied stiff left ventricle with impaired diastolic function to 
the volume burden of AR and ensuing increase in end-diastolic pressure. The assessment of 
regurgitation following TAVI is challenging using conventional 2D echocardiography; but 
nonetheless is a crucial clinical consideration and part of the VARC recommendations for 
measuring device success. The overall incidence of moderate and severe regurgitation has 
been decreasing of recent. This is in part due to improved delivery devices that allow 
repositioning and optimal deployment of novel TAVI designs with specific features to reduce 
AR.  
  
The use of CMR following TAVI and SAVR to assess both valve and ventricular function has 
been validated (Crouch et al., 2015a) and has proven superiority over echocardiography. We 
used CMR to compare the internationally established self-expanding Medtronic CoreValve with 
a novel TAVI iteration; the mechanically expanded Boston Lotus valve, both acutely following 
implantation and then at 6 months. The Boston Lotus valve is repositionable and can avoid the 
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need for rapid pacing during deployment, with an adaptive seal designed specifically to 
minimise aortic regurgitation. The results presented in this thesis indicate that significantly less 
aortic regurgitation, and thus a higher device success by VARC criteria, is seen immediately 
following implantation of Lotus compared to CoreValve. This is however at the expense of a 
higher pressure gradient and lack of early LV mass regression. At 6 months follow-up, 
comparable degrees of LV reverse remodelling was observed with comparable valvular 
function. The use of CMR in this thesis for such a comparison is unique and informative given it 
is the reference modality for quantifying ventricular volumes, mass and function, and 
outperforms echocardiography in the assessment of AR following TAVI. Invasive measurement 
of AR using the AR index at TAVI implant has been shown to predict mortality; with an index 
value of 25 being the optimal threshold. We have uniquely shown in this thesis that there is 
significantly more mass regression in those patients with higher AR index than those less than 
25. Our work indicates Lotus procedural success is higher than that of CoreValve but 
procedural success does not necessarily herald clinical success. The purpose of novel TAVI 
devices is to afford patients superior health related outcomes and quality of life and it is 
interesting that at 6 months, the two studied valve types were comparable. The active REPRISE 
III trial aims to recruit 1,000 patients form over 60 centres to define whether CoreValve or Lotus 
offers an all-cause mortality advantage. Our findings indicate comparable degrees of cardiac 
response to TAVI by 6 months and thus we might expect no survival benefit to be demonstrated 
at the one year follow-up.  
 
7.1 Future Directions  
The first TAVI implantation was performed by Cribier in 2002 and in the last decade the 
procedure has evolved on a global scale to become a standard credible therapeutic option 
deliverable under only moderate sedation. The fact that over 200,000 procedures have been 
performed worldwide corroborates its success and acceptance. However, it was 1960 when 
Harken reported the first SAVR and this remains the gold standard treatment in patients at low 
or intern mediate risk given its proven safety and efficacy over 50 years of clinical practise. 
 
Two contemporary randomised controlled trials will help shape the future indication of TAVI, 
both with a primary composite end-point of all-cause mortality and disabling stroke at 2 years 
post-TAVI randomised against SAVR. The SURTAVI (Safety and Efficacy Study of the 
Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in 
Intermediate Risk Subjects Who Need Aortic Valve Replacement) trial is designed to investigate 
the safety and efficacy of TAVI in intermediate surgical risk (defined as an STS score 4-10% 
inclusive) with patients being randomised to either SURTAVI or the Medtronic CoreValve. 
SURTAVI aims to recruit 2500 patients from across 75 global sites with a minimum follow-up of 
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24 months. The recently published PARTNER 2 Trial (Placement of AoRTic TraNscathetER 
Valves) enrolled 2,032 intermediate-risk patients (STS 4-8%). TAVI was found to be non-inferior 
to SAVR with respect to outcomes at 2 years, with lower bioprosthetic-valve gradients, risk of 
bleeding and shorter length of hospital stay (Leon et al., 2016). Whilst the evidence to support 
the use of TAVI in younger patients gains prominence, the long-term assessment of TAVI 
durability and performance (i.e. out to 10 years following implantation) remains to be defined. 
 
There is thus an intense international focus on the comparison between TAVI and SAVR. This 
thesis, using CMR specifically to evaluate the impact of these two therapeutic options upon 
cardiovascular function, sheds important light on the subject. There are still however distinct 
areas in which CMR can be used to shape the ongoing debate. 
 
7.1.1 Cerebral Embolism associated with novel TAVI delivery systems 
TAVI has historically raised concerns with an increased risk of cerebrovascular events, typically 
due to embolism intra-operatively or within the first 24 hours. Cerebral MRI has been used to 
detect new ischaemic lesions following TAVI with between 68-84% of patients being reportedly 
affected (Hamm et al., 2016). In the PARTNER trial, a significantly higher rate of stroke was 
observed at 30 days and 1 year following TAVI compared to SAVR. Interestingly, a recent MRI 
study, confirming cerebral microinfarctions are more common after TAVI compared with SAVR, 
indicated there were no negative effects on early (30 days) or medium term (6 months) health-
related quality of life. Aortic atheroma (TAVI) and concomitant coronary artery bypass grafting 
(SAVR) are independent risk factors for cerebral microinfarction (Uddin et al., 2015). Valve 
repositioning and post-TAVI dilatation are associated with higher rates of early stroke post-TAVI 
and thus embolic protection devices, designed to protect the cerebral circulation from 
procedural debris, are currently being trialled. 
 
The Boston Lotus valve is a novel valve that is repositionable and delivered via a large 18F 
sheath. We are currently comparing, using cerebral diffusion-weighted MRI and formal 
neurocognitive assessments at VARC recommended time-points, the impact of the Lotus and 
CoreValve TAVI procedures. As further iterations of TAVI technology continue to emerge, such 
a study is crucial; particularly given their potential extension to increasingly younger candidates.  
 
7.1.2 Balloon Aortic Valvuloplasty 
Prior to the emergence of TAVI, balloon aortic valvuloplasty was offered as an alternative to 
SAVR in those deemed inoperable; accounting for up to 30% of patients in some reports 
(Costopoulos et al., 2015). Balloon valvuloplasty is associated with a notable increase in AVA 
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and reduction in pressure gradients immediately following the procedure. Accordingly, current 
European guidance advocates the use of balloon therapy as a bridge to definitive treatment; 
whether it be SAVR or TAVI as appropriate, or in patients who require urgent non-cardiac 
surgery (class IIb, level of evidence C) (Joint Task Force on the Management of Valvular Heart 
Disease of the European Society of et al., 2012). Reported success rates for bridging from 
balloon aortic valvuloplasty to definitive treatments varies between 26-74%, with SAVR or TAVI 
occurring within a median time of 8 weeks to 7 months (Nwaejike et al., 2015). 
 
The incidence of balloon valvuloplasty is increasing given its inherent association with the TAVI 
procedure, being used both as a pre- and post-dilatation tool to optimise TAVI deployment. 
However, there is an inherent risk of valve material embolization and residual aortic 
regurgitation that is poorly tolerated by a typically stiff ventricle with impaired relaxation. We 
have been studying the impact of balloon valvuloplasty specifically using MRI; with an 
assessment of cerebral sequelae using diffusion-weighted MRI and neurocognitive assessment, 
and of cardiac function using CMR to assess valve performance and LV mass and volumes. We 
aim to compare three groups; those receiving balloon valvuloplasty alone, those with TAVI and 
associated valvuloplasty as part of the implantation procedure, and those receiving direct TAVI 
without any valvuloplasty. This will help characterise the neurological safety profile of the three 
approaches and clarify whether balloon inflatable or valve deployment is more associated with 
embolism. Furthermore, it will allow an assessment of reverse remodelling following ballooning 
which will be noteworthy; particularly as drug-coated balloons become more readily available. 
Balloon valvuloplasty will continue to be an important tool in the future, and such work is thus 
noteworthy, particularly as interventional therapy extends towards younger populations.  
 
7.1.3 The British Society of Cardiovascular Magnetic Resonance “AS700 study” 
CMR offers a unique insight into myocardial tissue characterisation and is gold-standard for the 
assessment of ventricular volumes, mass and function. A number of smaller studies have 
examined the importance of LV ejection fraction, mass, myocardial fibrosis and left atrial size in 
predicting outcomes following TAVI and SAVR. Studies using CMR to predict mortality in 
severe AS and in response to AVR are few and in the response to TAVI completely lacking. 
Currently a large multicentre observational study (comprising groups from Edinburgh, Leeds, 
Leicester, London and Oxford) is under way with the intention of amassing a cohort of patients, 
all of whom have had CMR prior to receiving SAVR or TAVI for severe AS. The intended period 
of follow-up is a minimum of 2 years. Such a study is designed to categorically identify specific 
CMR-derived factors that hold prognostic significance, over and above standard surgical risk 
models, in patients with severe AS undergoing intervention. 
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7.1.4 New Valves 
There has been, and continues to be an impressive emergence of TAVI iterations since the first 
in human implantation by Cribier in 2002 (Figure 7.1). A number of vendors have released new 
(or 2nd generation) products specifically designed to avoid paravalvular leakage, access related 
complication, stroke and improve durability (Blumenstein et al., 2013). Some devices such as 
the Edwards SAPIEN XT (Edwards Lifesciences, Irvine, CA, USA) are balloon expandable, with 
cobalt-chromium stent and thinner struts reducing valve profile and permitting narrower sheath 
delivery whilst still providing the required radial force when deployed. Others, such as the 
Medtronic Engager (Medtronic Inc., Minneapolis, MN, USA) comprise a self-expanding nitinol 
stent with a main frame and support frame mounted together, offering a “predefined” prosthesis 
suitable to individual patient anatomy. The St. Jude Portico prosthesis (St. Jude Medical, CA, 
USA) consists of a bovine and porcine pericardial tissue, again mounted on a nitinol stent that is 
self-expanding. This design holds valve leaflets low in the stent frame with clearance of 
coronary ostia and is thus intended reduce atrio-ventricular block. The proximal stent also 
comprises a tissue cuff designed to preclude para-valvular regurgitation. Each of these valves 
are currently being studied in clinical trials to assess efficacy and complication rates. 
 
 
Figure 7.1 New (second) generation TAVI designs currently being trialled 
 
A. Edwards SAPIEN XTTM. 
B. Medtronic EngagerTM. 
C. St. Jude PorticoTM prosthesis. 
 
CMR offers a comprehensive assessment of TAVI function, able to accurately quantify valvular 
function, regurgitation, reverse remodelling, regression of fibrosis and the detection of 
myocardial injury post procedure, and is thus the ideal imaging modality to compare and 
contrast in detail such emerging technologies. 
123 
 
 
7.1.5 CMR guided TAVI 
Traditionally, the imaging modalities used in the TAVI procedure involve MDCT for annular 
sizing prior to, and X-ray fluoroscopy, angiography and TOE during the procedure. Imaging is 
fundamental to optimal valve positioning across the native aortic valve annulus and to making 
an assessment of TAVI function and potentially life-threatening complications. This affords only 
limited soft-tissue contrast and carries inherent radiation exposure, the need for rapid 
ventricular pacing and nephrotoxic contrast media. Pilot in vivo work has emerged to support 
the use of real-time CMR to guide the TAVI procedure (Kahlert et al., 2012). Real-time CMR 
offers real-time image acquisition without any restriction in scan plane to optimise pinpoint axial 
alignment and TAVI deployment. CMR permits excellent soft-tissue contrast without the need 
for any contrast and thus may hold a survival advantage in the elderly by obviating the risk of 
acute kidney injury following TAVI. Recent work in swine has confirmed the deployment of the 
Medtronic CoreValve via a subclavian approach using a minimally modified delivery system 
guided by real-time CMR is feasible (Miller et al., 2015). Further work will be needed to 
determine whether the potential inherent to CMR can be realised, making it a single 
comprehensive imaging tool to assess anatomy pre-intervention, guide the TAVI procedure, 
and assess valvular function and any complications post-operatively.   
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9.2 Substantial Amendment (addition of immediate post-procedure CMR scan) 
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9.3 Substantial Amendment (extension to recruitment) 
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9.4 Patient Invitation 
 
An information sheet is enclosed which tells you all about a heart research study we are running 
at this hospital. It is called MRI evaluation of Transcatheter and Surgical Aortic Valve 
Implantation.  
 
Please read the information sheet carefully and if you are interested in finding out more about 
the study before your planned admission to hospital then please return the reply slip to us using 
the prepaid envelope. 
 
You may phone us so that the research team can explain the study to you further and answer 
any questions you may have. The numbers you can ring are 0113 39 25909 (Dr Tarique Al 
Musa) or 07733 424 528 (Fiona Richards). Alternatively, once you are admitted to hospital for 
your valve replacement you will have an opportunity to discuss the study with one of the 
researchers. 
 
Please note that you are under no obligation to take part and it will not affect your treatment if 
you decide not to. However we would very much appreciate it if you would let us know. We can 
reimburse any travelling expenses you incur as part of this study and arrange transport as 
needed. Potentially it would only involve one extra visit to the LGI approximately 6 months after 
your TAVI procedure. 
 
Thank you for considering this request. 
 
Yours sincerely 
 
 
Professor JP Greenwood 
Consultant Cardiologist 
Cardiovascular and Diabetes Research 
Leeds General Infirmary 
Leeds 
LS1 3EX 
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9.5 Patient information Leaflet 
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9.6 Consent Form 
 
Patient Study Number: ……………….. Date of Birth: ………………… 
 
Hospital Number: ……………………. Initials: ……………………….. 
 
CONSENT FORM – Version 1.3 November 30 2012 
MRI evaluation of Transcatheter and Surgical Aortic Valve Implantation 
 Name of Researcher: Prof John Greenwood                                                Please initial box 
1. I confirm that I have read and understood the information sheet (version 1.3 
November 30 2012) for the above study and have had the opportunity to ask 
questions. 
 
 
2. I understand that sections of any of my medical notes may be looked at by 
members of the research team and authorised personnel within the Leeds 
Teaching Hospitals NHS Trust and the University of Leeds, where it is relevant to 
the research or to assess that appropriate research standards are being 
maintained within the study. I give permission for these individuals to have 
access to my records. I understand that the information about me will be held in 
the strictest confidence and that my results will not be available to a third party. 
 
 
3. I give my consent for my General Practitioner to be informed of my participation in 
the study. 
 
 
4. I understand that images collected will be stored on a computer system, and, 
after my name and address have been removed, may be available to researchers 
at other institutions 
 
 
5. I understand that my participation is voluntary; and that I am free to withdraw at 
anytime, without giving any reason, without my medical care or legal rights being 
affected. 
 
 
6. I agree to take part in the study and that the general results of the study will be 
made available to medical community most likely through publication in a 
reputable medical journal 
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7. If I were to lose capacity, I understand that data already collected will be kept and 
used for the purposes of the study. 
 
 
 
Signature.............................................................. 
 
 
Name (block capitals)..........................................Date………………………………………. 
 
 
Signature of witness............................................. 
 
 
Name (block capitals)..........................................Date………………………………………. 
 
